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PROTEINS AS MARKERS OF TSE INFECTION IN SHEEP BLOOD 
Joanne Martin 
 
Transmissible spongiform encephalopathies (TSEs) are a group of fatal infectious 
neurodegenerative diseases affecting both humans and agricultural animals.  TSE 
transmission via blood transfusion has been demonstrated experimentally in rodent, 
primate and sheep models.  Additionally, in humans, four variant Creutzfeld-Jakob 
disease (vCJD) cases have been reported which probably resulted from infected blood 
transfusions.  Although TSEs can be transmitted via blood transfusion, little is known 
about which blood cells are involved in the replication of the TSE agent and how 
infectivity is spread throughout the body prior to neuroinvasion.  There are no currently 
validated diagnostic tests for TSE infection in blood. 
  Detection of PK-resistant PrP
Sc has been extensively used as a biochemical marker for 
TSE infectivity.  However, when this project was started it was not known if PK-
resistant PrP
Sc was present in TSE-infected sheep blood in sufficient quantities to 
explain the infectivity levels shown by bioassay.  Following the development of an 
optimised Western blot method, this project has demonstrated that the pattern of protein 
detected with novel anti-PrP monoclonal antibodies is very different from the 
conventional triple banded pattern of PK-resistant PrP
Sc.  High molecular weight bands 
were apparent in phosphotungstic acid (NaPTA) concentrated scrapie-infected and 
uninfected blood and may represent a novel form of blood-specific PrP.  PK-resistant 
PrP
Sc is not therefore a suitable marker for TSE infection in blood.  
  Other proteins in TSE infected blood were also investigated.  Using a proteomics 
approach three protein markers, lactate dehydrogenase, elongation factor 1 and annexin 
1 had altered expression patterns in scrapie infected blood.  These proteins, in addition 
to the novel forms of PrP found in blood, may provide new information on the 
mechanisms of pathogenesis in scrapie-infected sheep and might prove to be useful 
molecular indicators of diagnostic value.  
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PE     Phycoerythrin 
Pint 1    Protein interactor 1 
PK     Proteinase K 
PMCA   Protein Misfolding Cyclic Amplification 
PMSF   Phenylmethylsulphonyl Fluoride 
PNGase F   Peptide-N-Glycosidase F 
POM     Polyoxometalates 
PrP     Prion Protein 
PrP
C     Cellular Form Of PrP 
Prnp 
0/0   PrP Null Mice 
PrP
Sc     Disease Associated Form Of PrP 
P 27-30    PK Resistant Form Of PrP 
Q-TOF-MS  Quadrupole Time-of-Flight mass spectrometry 
RAG-1   Recombinase Activating Gene   xviii
RNA     Ribonucleic Acid 
rPrP     Recombinant PrP 
RT     Room Temperature 
sc        Subcutaneous  
SCID  Severe Combined Immunodeficient Mice 
sCJD     Sporadic Creutzfeldt-Jakob Disease 
ScMNB   Scrapie-Infected Mouse Neuroblastoma-Derived Cells 
ScN2a   Scrapie-Infected Neuroblastoma N2a 
SDS     Sodium Dodecyl Sulphate 
SDS-PAGE  Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
sec PrP   Secreted PrP 
SMB     Scrapie-Infected Mouse Brain Cells 
SMB-PS   Scrapie-Infected Mouse Brain Pentosan Sulphate Cells 
SOD     Superoxide Dismutase 
SSBP/1   Scrapie Sheep Brain Pool 1 
STI1     Stress Inducible Protein 1 
TNF-α   Tumour Necrosis Factor 
Tris-HCL   Tris-Hydrochloric Acid 
TME     Transmissible Mink Encephalopathy 
TSEs     Transmissible Spongiform Encephalopathies 
vCJD  Variant Creutzfeldt-Jakob Disease 
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1.1.  Transmissible spongiform encephalopathies 
 
Transmissible spongiform encephalopathies (TSEs) or prion diseases are fatal 
infectious neurodegenerative diseases of humans and animals. They have long 
incubation times with clinical signs taking months, years or even decades to develop, 
followed by a short clinical phase, usually measured in months.  These diseases are 
biologically unique, as they are believed by some to be transmitted by an infectious 
agent comprised only of protein, with no nucleic acid component (Prusiner, 1982). 
Clinically, these diseases present with motor disturbances and behavioural changes. 
There is currently no effective treatment or cure and a definitive diagnosis is only 
possible after death upon histopathological examination of the brain.  The major 
pathological changes seen are neuronal loss, vacuolation (spongiform change), 
proliferation and branching of glial cells, astrocytic proliferation and accumulation of 
the prion protein PrP
Sc, which can form amyloid plaques (Prusiner, 1998). 
 
The prototypic TSE is scrapie, a naturally occurring disease affecting sheep and goats, 
first identified over 200 years ago and now endemic in many countries.  An increasing 
number of animal and human TSEs have since been recognised (Table 1.1).  In humans 
the most common TSE is Creutzfeldt-Jakob disease (CJD) of which three forms have 
been recognised: sporadic, acquired and inherited/familial (Collinge, 2001).  Although 
these disorders are rare, interest has increased in recent years with the emergence of 
bovine spongiform encephalopathy (BSE) which affects cattle (Wells et al., 1987).  It is 
believed that consumption of meat infected with BSE has led to the appearance of a 
new variant form of Creutzfeldt-Jakob disease (vCJD) (Will et al., 1996).  This first 
emerged in the UK, and identification of this new variant form and the risk it poses to 
humans has renewed interest in TSE research. 
  
Clinical signs of TSEs differ depending on the species and reflect progressive 
neurological dysfunction. In sheep symptoms include excitability, rubbing/scratching 
(pruritus) and ataxia.  Animals also may show weight loss, hindlimb weakness, and in 
some cases develop impaired vision (Hadlow et al., 1982). 
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Disease  Host  Year first described 
Scrapie  Sheep and goats  1750 
Creutzfeldt-Jakob disease 
(CJD) sporadic, familial, 
and iatrogenic forms 
Humans 1920 
Gerstmann-Straussler-
Scheinker syndrome 
(GSS) 
Humans 1928 
Kuru Humans  1957 
Transmissible mink 
encephalopathy (TME) 
Mink 1965 
Chronic wasting disease 
(CWD) 
Whitetail deer, mule deer 
and elk 
1967 
Fatal familial insomnia 
(FFI) 
Humans 1986 
Bovine spongiform 
encephalopathy (BSE) 
Cattle 1987 
Feline spongiform 
encephalopathy (FSE) 
Domestic cats  1990 
Exotic ungulate 
encephalopathy 
Oryx, nyala and greater 
kudu 
1990 
New variant CJD (vCJD)  Humans  1996 
 
Table 1.1:  TSE diseases of animals and humans. 
 
 
1.1.1.  The prion protein (PrP) 
 
The prion protein was identified in 1982, being the major component in the infectious 
fraction of scrapie-infected hamster brains (Prusiner, 1982).  PrP consists of 
approximately 250 amino acids and exists in two alternate forms; a normal cellular 
form (PrP
c) and a disease-associated form (PrP
Sc).  PrP
c is a 30-35 kDa glycoprotein 
with two N-glycosylation sites and is attached to the outside of the cell membrane by a 
glycosylphosphatidylinositol (GPI) anchor at amino acid 231 (Hope, 1993; Stahl et al., 
1987).  The normal and pathological forms of prion protein have identical amino acid 
sequences and differ only in their folded tertiary structure and biochemical properties. 
PrP
C is non-infectious and exists as a monomer, consisting of 43 % α-helix and 3 % β-
sheet (Pan et al., 1993).  It is found in many tissues and cell types where it is rapidly 
turned over and has a half life of approximately 6 hours (Anderson et al., 1992).  PrP
C 4  
is also sensitive to digestion with PK (Meyer et al., 1986).  PrP
Sc is the infection 
associated variant of the protein and forms aggregates and amyloid fibrils which bind to 
histological dyes such as Congo red, giving a green birefringence when viewed under 
polarized light (Divry, 1927).  Abnormal PrP consists of 34 % α-helix and 43 % β-sheet 
(Pan  et al., 1993).  PrP
Sc turn over is slower and has a half life of years while 
accumulation occurs in TSE-infected brain.  Unlike PrP
C, PrP
Sc is partially resistant to 
treatment with proteinase K (PK) leaving a 27-30 KDa protein fragment.  The two 
conformers also have differing solubilities in detergents and guanidinium hydrochloride 
(Safar et al., 1998).  Table 1.2 summarises the structural and biochemical differences 
between PrP
C and PrP
Sc. 
 
PrP
C  PrP
Sc
Normal, cellular form  Disease-associated form 
43 % α-helical 34  %  α-helical 
3 % β-sheet 43  %  β-sheet 
Monomeric   Forms aggregates/ amyloid fibrils 
Soluble in mild detergents  Insoluble in mild detergents 
PK sensitive   Partially PK resistant 
Non-infectious Infectious 
Present in many tissues and cells  Accumulates in CNS and lymphoid tissue 
  
Table 1.2: Structural and biochemical differences between PrP
C and PrP
Sc 
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1.1.2.  Animal TSEs 
 
Scrapie is a disease of sheep and goats that has been known in Europe for over 200 
years (McGowan, 1922) and is present worldwide, with the exception of New Zealand 
and Australia.  Scrapie has been reported in the majority of sheep breeds, and resistance 
or susceptibility to scrapie infection has been shown to be associated with several 
polymorphic codons in the sheep prion protein (PrP) gene. In particular, an arginine at 
amino acid codon 171 is associated with scrapie resistance and a valine at amino acid 
codon 136 is associated with scrapie susceptibility (Hunter, 1997). 
 
BSE first emerged in UK cattle in 1986 (Wells et al., 1987) and rapidly evolved into a 
major epidemic with more than 180,000 cases confirmed.  Contaminated protein feed 
supplements prepared from rendered ruminant carcasses were found to be the most 
likely source of infection (Wilesmith et al., 1988).  The rendering process of abattoir 
waste was altered during the 1970s which is thought to have led to a less efficient 
system for inactivating scrapie-infected sheep offal.  An alternative hypothesis is that 
BSE resulted from recycling of rare sporadic BSE cases, as cattle were also rendered to 
produce cattle feed.  Following the emergence of BSE, many new species developed 
spongiform encephalopathies, including nyala (Jeffrey and Wells, 1988) greater kudu 
(Cunningham et al., 1993, Kirkwood et al., 1992) oryx (Kirkwood et al., 1990) eland 
(Fleetwood and Furley, 1990) cheetah (Peet and Curran, 1992) puma (Willoughby et 
al., 1992) and the domestic cat (Pearson et al., 1992).  Several of these cases have been 
confirmed to be caused by a BSE-like prion strain and contaminated feed is suspected 
(Bruce et al., 1994, Fraser et al., 1988).  In 1988 the ruminant feed ban was introduced 
and since then the number of BSE-infected cattle in the UK has declined, although 
cases have since been reported in other countries, with significant epidemics reported in 
Switzerland (Doherr et al., 1999) Ireland, France and Portugal. 
 
Chronic wasting disease (CWD) is a TSE of North American cervid ruminants 
(Williams and Young, 1980).  CWD has been present at low levels in free-ranging 
mule deer, white-tailed deer and Rocky Mountain elk in Wyoming, Nebraska and 
Colorado for over 30 years.  CWD also occurs in farm-raised animals.   The number of 6  
clinically diagnosed CWD infected animals has increased (Knight, 2002) and cases are 
being identified in new locations in America and Canada.  This may be due to 
improved diagnostic techniques and an increased awareness of TSE diseases.   
Alternatively, this may be attributed to the increase in the movement of animals since 
the expansion of the elk industry, (which raises animals for meat, the commercial value 
of their antlers, or game parks) in the 1990s.  It is not known if CWD can be 
transmitted to other species, including humans who hunt and eat these animals. 
 
Transmissible mink encephalopathy (TME) (Marsh and Kimberlin, 1975) was at first 
recognised as a food-borne disease of ranch-raised mink in the USA.  Infrequent 
epidemics have since occurred. 
 
Active surveillance of TSEs in ruminants has allowed for identification of a number of 
unusual isolates in cattle, sheep and goats.  An unusual presentation of scrapie in sheep 
was first recognised and described in Norway in 1998 (Nor98) (Benestad et al., 2003).  
In this novel scrapie type, PrP
Sc, although never present at high levels, was found to be 
more abundant in the cerebellum and the cortex than in the brain stem, in contrast with 
classicial scrapie or ovine BSE.  Also Western blot analyses showed a complex 
electrophoretic pattern, including an unusual band of low apparent molecular mass (10-
12 kDa) while in classical scrapie PrP
Sc is detected as three bands between 18 and 30 
kDa corresponding to the un-, mono, and di-glycosylated PrP
Sc forms (Gavier-Widen et 
al., 2004).  A number of Nor98 isolates have been identified in sheep with genotypes of 
the prion gene associated with resistance to classical scrapie or BSE (Buschmann et al., 
2004).  The possibility that these cases were not genuine TSEs was ruled out following 
studies where atypical isolates were transmitted successfully to transgenic mice (Le 
Dur et al., 2005).  The origin of such atypical scrapie cases is unclear, as is their 
potential transmissibility within the affected species and to other species.   
 
Until 2004, BSE in cattle was considered to be a disease with unique features, in 
relation with its origin as a food borne epidemic.  However, evidence of a second cattle 
TSE was reported in March 2004 (Casalone et al., 2004).  During a routine screening 
program of cattle in Italy, pathological differences (such as the nature and distribution 7  
of brain lesions) to classical BSE were observed.  This led to the term bovine 
amyloidotic spongiform encephalopathy (BASE).  The molecular signature of BASE is 
not characteristic of classical BSE, but shows similarities to a subtype of human 
sporadic CJD (sCJD).  Molecular characterisation of PrP
Sc shows a lower apparent 
molecular mass of unglycosylated PrP
Sc, although the most striking difference is that of 
strongly decreased levels of diglycosylated PrP
Sc, which is prominent in typical BSE 
(Casalone et al., 2004).  The origin of such atypical BSE cases remains unknown, and it 
is unclear whether BASE is a sporadic form of cattle TSE or is linked to human 
sporadic TSE.  Interestingly, in transmission studies where transgenic mice expressing 
human PrP are inoculated with BSE material, the glycoform pattern on gels is 
consistent with sporadic CJD (sCJD) (Collinge et al., 1996).   
 
In some atypical BSE cases, the unglycosylated PrP
Sc band has a higher molecular 
mass relative to that observed in classical BSE.  Such cases are referred to as H-type 
BSE.  Recently, the first case of BSE in the UK showing an H-type molecular profile 
was documented (Terry et al., 2007).       
 
1.1.3.  Human TSEs 
 
Creutzfeldt-Jakob disease (CJD) was first identified in 1921 (Jakob, 1921).  CJD can be 
divided into three forms; sporadic, inherited and acquired.  The majority of CJD cases 
(85 %) are sporadic, and occur in all countries with a random case distribution and an 
annual incidence of one per million (Masters and Richardson, 1978).  Around 15 % of 
CJD cases are inherited, and are associated with coding mutations in the prion protein 
gene, of which over 20 distinct types are recognised (Masters and Richardson, 1978; 
Masters et al., 1981; Goldfarb et al., 1991).  Acquired disease includes iatrogenic CJD 
which occurs through accidental exposure to TSE agent through medical procedures 
such as surgical operations, dura mater implants, corneal transplants, blood transfusion 
and human pituitary-derived growth hormone.   
 
Fatal familial insomnia (FFI) (Lugaresi et al., 1986) is a very rare, autosomal dominant 
inherited disorder.  FFI is associated with a dual mutation in the PrP gene, where an 8  
aspartic acid to asparagine mutation occurs at PrP amino acid codon 178, and 
methionine is present at PrP amino acid codon 129. 
 
Kuru is seen only among the Fore Highlanders of Papua New Guinea (Gajdusek and 
Zigas, 1957).  The Fore tribe reportedly honoured the dead by eating their brains, and it 
is thought that affected individuals acquired kuru through this ritual cannibalism.  Kuru 
became a major cause of death, especially in women and children who consumed the 
brains during these rituals and the recycling of the infectious agent in this isolated 
population caused an epidemic.  Cannibalism ceased in the 1950s and kuru has 
virtually disappeared (Collinge, 2001). 
 
Gerstmann-Straussler syndrome (GSS) (Gerstmann et al., 1936) is a rare, autosomal 
dominant disorder.  Initially GSS was associated with a proline to leucine mutation at 
PrP amino acid codon 102 (Doh-ura et al., 1989) however GSS is now known to be 
associated with several different mutations in the PrP encoding gene (Hsiao et al., 
1989, 1991, and 1992; Goldfarb et al., 1992).  
 
In 1995, a novel human prion disease characterised by florid plaques and early age at 
onset (Wills et al., 1986) called variant CJD (vCJD) appeared in the UK.  This disease 
has been shown to be caused by a TSE agent with identical strain characteristics to that 
isolated from BSE-infected cattle (Bruce et al., 1997) and probably occurred as a result 
of dietary exposure to BSE contaminated meat.  A large proportion of the population in 
the UK were exposed to BSE, as by 1995 almost one million BSE-infected carcasses 
had entered the food chain.  At the time of writing (June 2008) 164 definite cases of 
vCJD (of which 3 remain alive and are classed as probable cases) have been reported in 
the UK, 23 cases in France and 18 elsewhere in the world (www.cjd.ed.ac.uk).  
Although the number of vCJD cases per year has fallen, it is unclear if numbers will 
remain small.  Mathematical models have been developed to predict numbers of future 
cases (Ghani et al., 2000) but early models do not take into account levels of 
asymptomatic infection, secondary transmissions from human to human, or whether 
BSE has entered the sheep population.  Mathematical modelling has indicated that 
vCJD could become a self-sustaining disease in the UK population via secondary 9  
transmission by blood transfusion or surgical instruments (Clarke and Ghani, 2005).  
However, a more recent study suggests that a self sustaining epidemic although 
possible, is unlikely due to the interventions made by the UK Department of Health to 
prevent vCJD spread via secondary transmissions (Clarke et al., 2007).   The National 
Blood Service (NBS), for example, have put in place a number of control measures, 
such as leucodepletion, to reduce the risk of vCJD transmission by blood products.  
These factors may influence the number of future vCJD cases (Ferguson et al., 2002).  
A study in 1994 of 13,000 appendix and tonsil samples revealed that PrP
Sc (assumed to 
be associated with vCJD as in other human TSE diseases PrP
Sc is not detected in 
lymphoid tissues) was found in three of the samples, indicating that as many as 4000 
individuals may be infected (Hilton et al., 2004).  However, statistical evidence 
acquired by the National CJD surveillance unit in Edinburgh, UK suggests that the 
epidemic may have reached its peak (www.cjd.ed.ac.uk) .   I t  i s  p o s s i b l e  t h a t  a  
significant number of people are asymptomatic carriers of disease which may account 
for the differences seen in these estimates.   
 
Asante and colleagues (2002) showed in transgenic mouse experiments that individuals 
homozygous for methionine at PrP amino acid codon 129, may be at risk through 
iatrogenic vCJD spread via surgical procedures or blood transfusion (Asante et al., 
2002).  Until 2004 all recorded vCJD cases had occurred in people homozygous for 
methionine, however an elderly patient, heterozygous at PrP amino acid codon 129 
who died from unrelated causes five years after receiving an infected blood transfusion 
from an asymptomatic donor, had PrP
Sc deposits in the lymphoid tissues following post 
mortem examination (Peden et al., 2004).  Additionally, two of the tonsil/appendix 
samples that were positive for PrP
Sc in Hiltons study were genotyped as homozygous 
for valine at PrP amino acid codon 129 (Ironside, 2006) and a possible clinical case of 
vCJD in an individual homozygous for valine has also been reported (Mead et al., 
2007).  Transgenic mouse lines have recently been produced that express human PrP 
with the codon 129 homozygous for methionine (MM), heterozygous for methionine 
and valine (MV) and homozygous for valine (VV).  All individuals, irrespective of 
codon-129 genotype, were susceptible to vCJD infection (Bishop et al., 2006). These 
studies suggest that susceptibility to vCJD is not confined to the methionine 10   
homozygous PrP genotype.  The nature of the transmissible agent following 
transmission from human to human via blood has also been studied using the transgenic 
mouse lines that express human PrP.  Brain material from the first case of blood 
transfusion associated vCJD (reported by Llewelyn et al., 2004) was inoculated into 
wild-type and transgenic mice.  The agent was transmitted with the same efficiency in 
both murine models, suggesting that there is no increased virulence of the agent 
following human to human transmission of blood transfusion associated vCJD (Bishop 
et al., 2008). 
 
1.2.  Nature of the infectious agent 
    
In the absence of a specific TSE agent directed immune response and/or inflammatory 
cell infiltrate in the brain, it was thought that the infectious agent was a slow virus. 
However ionizing and UV irradiation experiments that normally destroy nucleic acids, 
performed on mouse brain homogenates showed that the agent was resistant to such 
treatment (Alper et al., 1966; Alper et al., 1967; Latarjet et al., 1970). This then 
excluded viruses and gave rise to an alterative hypothesis, that the agent could be a 
small piece of nucleic acid surrounded by a protein coat- a virino (Kimberlin, 1982).  
Several different approaches have been taken to try to identify a scrapie-specific 
nucleic acid.  Numerous procedures that hydrolyse or modify nucleic acid without 
altering protein have been employed but none reported a reduction in the titer of TSE 
agent (Diener et al., 1982; Prusiner, 1991).  Additionally, molecular cloning and 
differential hybridization studies could not identify an agent-specific polynucleotide 
(Aiken  et al., 1990).  More recently, in case a nucleic acid molecule had been 
overlooked, techniques increasing overall sensitivity of electrophoretic separations 
were applied to purified brain fractions (highly enriched for agent infectivity) from 
scrapie-infected hamsters.  However, no TSE agent-specific polynucleotide was 
identified (Safar et al., 2005).      In over 30 years of research no specific nucleic acid 
has been found associated with a TSE infectious particle.  
 
Griffith (1967) suggested that a protein, which could replicate in the body, may be 
responsible for TSE disease progression. This was supported in experiments which 11   
showed that scrapie infectivity could be reduced by procedures that hydrolyze or 
modify proteins (Diener et al., 1982).  Prusiner and colleagues then isolated an unusual 
protease- resistant protein (PrP
Sc) in the brains of scrapie-infected hamsters that was not 
present in healthy animals.  Using biochemical and immunological methods they 
showed that PrP
Sc  and infectivity copurified.   These experiments led to Prusiner 
coining the term “prion” (derived from proteinaceous and infectious) for the infectious 
particle (Bolton et al., 1982). The “protein-only” hypothesis proposes that the prion is a 
conformational isoform of the normal host protein PrP
c and is exclusively the causative 
agent of TSE disease.  
 
Primary support for the protein-only hypothesis is based on the finding that PrP 
knockout mice (Prnp
º/º) appear completely protected against scrapie disease and fail to 
propagate infectious agent (Bueler et al., 1993). If murine PrP transgenes are re-
introduced into these mice susceptibility is restored (Fischer et al., 1996).   
Additionally, procedures that inactivate PrP
Sc markedly reduce or eliminate infectivity 
(Prusiner et al., 1993) and transgenic mice overexpressing the PrP gene spontaneously 
develop neuropathological and clinical features of TSEs (Hsiao et al., 1990).    
 
Further evidence supporting the protein-only hypothesis emerged after it was 
discovered that the pathological protein catalyzes the cell-free conversion of PrP
c into 
PrP
Sc (Kocisko et al., 1994). In these experiments purified PrP
c was mixed with 
stoichiometeric amounts of purified PrP
Sc, producing a low yield of newly formed 
PrP
Sc.  More recently a new in vitro conversion system has been developed where large 
quantities of PrP
c are transformed using minute amounts of PrP
Sc. This system called 
protein misfolding cyclic amplification (PMCA) supports the idea that PrP
Sc replication 
may be a cyclical process with newly produced PrP
Sc triggering further misfolding to 
maintain abnormal protein propagation (Saborio et al., 2001; Castilla et al., 2005).   
PrP
Sc generated in a PMCA reaction was recently shown to be infectious following 
inoculation into hamsters, where animals developed a disease with scrapie 
characteristics (Castilla et al., 2005).  In these experiments, the source of the PrP
C 
substrate was not purified but from whole brain homogenate from healthy hamsters, so 12   
the possibility that other molecules may be involved in agent infectivity cannot be ruled 
out. 
 
Experiments where PrP
Sc  is synthesized in vitro and shown that it can, by itself, 
produce an infectious disease in healthy animals are required to finally prove the 
“protein-only” hypothesis.  Successful efforts in yeast (Sparrer et al., 2000) have been 
achieved and more recently “synthetic prions” consisting of part mouse PrP were 
generated in Escherichia coli and then polymerized into misfolded fibrils akin to PrP
Sc.  
Following injection into the brains of mice (transgenic mice overexpressing PrP), 
neurodegenerative disease was triggered that could be transmitted to other animals 
(Legname  et al., 2004, 2005).  However, the “synthetic prions” were not given to 
normal mice and to guarantee that lab contamination didn't influence the infections, 
other labs would have to replicate the experiments.  Therefore these studies don’t 
conclusively prove the “protein-only” hypothesis.   
 
There are characteristics of TSEs that challenge the “protein-only” hypothesis. For 
instance, scrapie and other TSEs occur in multiple strains, which have markedly 
different incubation times, clinical features and neuropathology when passaged in 
laboratory rodents (Bruce et al., 1991).  In other infectious micro-organisms, different 
strains arise as a result of mutations or polymorphisms in the genetic makeup of the 
agent.  To explain this for an agent composed exclusively of protein it has been 
proposed that PrP
Sc has slightly different conformation states that replicate faithfully at 
the expense of the host PrP
c (Prusiner, 1998; Safar et al., 1998).  In cell-free conversion 
assays where PrP
C is incubated with PrP
Sc from two different hamster TSE strains 
(called hyper or drowsy) PrP
C appears to fold and exhibit the biochemical properties of 
the PrP
Sc in each respective strain (Bessen et al., 1995).  The conformational stability of 
PrP
Sc molecules can be studied using guanidine hydrochloride (GdnHCL) and different 
TSE strains have been distinguished based on the concentration of GdnHCL required to 
denature different conformations of PrP
Sc (Safar et  al., 1998; Peretz et al., 2001).   
Using this technique, more recent studies also show that distinct TSE strains can be 
discriminated by their distinct conformers of PrP
Sc  (Khalili-Shirazi  et al., 2005; 
Thackray et al., 2007).  13   
There are also reports of TSE transmission to rodents where protease resistant prion 
protein is undetectable (Lasmezas et al., 1997; Manson et al., 1999; Barron et al., 
2001).  Supporters of the “protein-only” hypothesis suggest that protease resistance 
does not necessarily equate with infectivity (Safar et al., 1998).   Also, TSE infectivity 
can be associated with a wide range of PrP
Sc aggregates (Caughey et al., 1997) and it 
may be that detection methods for disease-associated PrP are currently unable to detect 
the infectious form of the PrP.  
 
Some researchers believe that TSE diseases are caused by slow acting viruses although 
this idea is not well supported.  In a recent study, infection with a slow-acting 
Creutzfeldt Jakob strain was shown to protect mouse cells from infection with a faster 
one and this may point to an immune defence reaction and thus a virus (Nishida et al., 
2005).  Dickinson proposed another explanation which he termed “the scrapie 
replication-site hypothesis” to explain a similar phenomenon of strain interference.   
Although hypothetical, he suggested that the agent can only replicate in a limited 
number of sites in peripheral tissues and if these are occupied by a slowly replicating 
strain, a faster strain could be blocked (Dickinson and Outram, 1979).   
 
There is also evidence for virus-like particles in TSEs.  Such particles were first 
described in experimental mouse scrapie in 1968 (David-Ferreira  et al., 1968) in 
natural sheep scrapie in 1971 (Bignami and Parry, 1971) and more recently in primate 
and human CJD brain samples (Liberski et al., 2004).  Interestingly, recent studies of 
neuroblastoma cells infected with the 22L strain of scrapie produced intracellular 25-
nm virus-like particles very similar to the ones described in 1968 (Manuelidis et al., 
2007).   
 
Sheep pathogenesis studies also question whether prion protein alone causes disease.  
Using surgically modified sheep, Jeffery and co-workers loaded a small area of the gut 
with scrapie-infected brain homogenate.  They observed that PrP
Sc was taken up in villi 
and passed into the lymph.  Interestingly it was not taken up by the Peyer’s patches, 
where amplification of the TSE agent is thought to take place.  It is possible that the 
PrP
Sc may have been amplified in other lymphoid tissues for instance the mesenteric 14   
lymph nodes, although this result may also imply that the PrP
Sc alone does not cause 
the infection (Jeffery et al., 2006).  In the same study, the researchers pre-digested a 
mixture containing high levels of PrP
Sc with standard stomach contents, and injected 
the resultant mixture into the gut.  Western blot analysis indicated that only a very 
small amount of PrP
Sc had survived.  In the natural environment, grazing sheep are not 
naturally exposed to highly infective brain material, but are more likely to pick up 
small amounts of PrP
Sc from discarded placental tissue, or faecal/urinary contamination 
of pasture.  It is possible therefore that sheep in the field may be exposed to very little 
abnormal prion protein in the gut as the stomach would dispose of the small amount 
ingested.  This suggests that infectious molecules other than PrP
Sc may be involved in 
disease pathogenesis.  This study however, does not rule out the possibility that PrP
Sc 
could cause disease if absorbed in sufficient enough amounts or if the animals were 
exposed to small doses in the environment cumulatively over time.  It may also be 
possible that PrP
Sc may be absorbed higher in the gut, before the abnormal proteins are 
digested, for instance in the mouth.       
 
Finally, although no nucleic acid consistently associated with a TSE molecule has been 
identified, there is evidence to suggest that nucleic acids may help catalyze the 
conversion of PrP
c into PrP
Sc.  Deleault and colleagues (2003) looked at the effect of 
nucleic acids on the propagation of PrP
Sc in brain homogenates.  They found that PK 
resistant protein was amplified sixfold after mixing infected and normal brain 
homogenates.  When the homogenates were depleted of single-stranded RNA, no 
amplification was detected.  In contrast when exogenous RNA (extracted from 
uninfected hamster or mouse tissue) was added PrP
Sc amplification was boosted 
twenty-four fold (Deleault et al., 2003).  These results suggest that single-stranded 
RNA is required for PrP
Sc  amplification, although do not necessarily disprove the 
“protein-only” hypothesis.  The authors also showed that active RNA was present in 
extracts of normal mammalian tissue indicating that these molecules are not specific to 
TSE infections.  Also RNA may be a host-cell co-factor needed for the conversion of 
PrP
C rather than a component of the infectious agent.  Other molecules such as 
glycosaminoglycans (GAGs) and GAG-containing proteoglycans have also been shown 
to stimulate prion conversion in vitro and may be candidate co-factors in the prion 15   
protein conversion process (Wong et al., 2001).  Additionally, biochemical analysis of 
purified PrP
Sc preparations have provided no evidence that a nucleic acid component is 
an essential part of the infectious unit (Meyer et al., 1991).     
 
In conclusion, there is evidence that both supports and challenges the “protein-only” 
hypothesis and although PrP
Sc is commonly used as a disease specific marker of TSE 
infection, the precise nature of the infectious agent remains ill-defined.  
 
1.3.  The structure of the prion protein (PrP) 
 
The structure of the ubiquitous cellular form of the PrP protein consists of a flexible N-
terminal tail at amino acids 23-90 and a globular C-terminal domain (amino acids 90-
250) with a structure made of three α-helices and a short β-sheet (Pan et al., 1993).  
PrP
C also has an intramolecular disulfide bond (Cys179-Cys214) which provides 
structural stability to the C-terminus of the protein (Bosques et al., 2003), an alanine 
rich (AGAAAAGAVVGGVG) hydrophobic region between amino acid 113-128, and a 
series of 5 or more repeats of an eight amino acid sequence (PHGGGWGQ), known as 
the octapeptide repeat region (Figure 1.1).  Studies using synthetic peptides 
corresponding to this sequence showed the octapeptide repeat region to be a substrate 
of the proteolytic PK enzyme (Georgieva et al., 2004).   The generation of transgenic 
mice expressing an anchorless, secreted version of PrP
C, has shown that membrane 
anchoring is a crucial prerequisite for agent toxicity resulting in clinical TSE (Chesebro 
et al., 2005).    
 
Due to low abundance, natural PrP
C can not be used to apply nuclear magnetic 
resonance (NMR) spectroscopy or x-ray analysis to determine the exact three-
dimensional structure.  Structural analysis of PrP
Sc has also proved challenging due to 
the insoluble, non-crystalline nature of this protein.  However, the structure of refolded 
recombinant PrP (rPrP) in solution is known from spectroscopic studies and with high 
resolutions from NMR analysis (Zahn et al., 2000; Riek et al., 1997; James et al., 
1997).  Because rPrP is soluble, monomeric and α-helical in structure it is thought to be 
representative of PrP
C, and x-ray crystal structures of rPrP have been published (Knaus 16   
et al., 2001; Haire et al., 2004; Eghiaion et al., 2004).  A final description of the 
structure of PrP
Sc has yet to be made, although hypothetical models exist.  Wille and 
colleagues (2002) were able to prepare two-dimensional crystalline-like arrays of 
PrP
Sc-like molecules of N-terminally truncated PrP (PrP
27-30) and a miniprion 
composed of amino acids 23-88 and 141-176 (PrP106), both from Syrian hamsters.  
This model takes into account both electron microscopic and spectroscopic data as well 
as the intermolecular stabilization of the PrP
Sc structure (Wille et al., 2002). 
 
 
 
KKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGTWGQPHGGGWGQPHGGSWG
QPHGGSWGQPHGGGWGQGGGTHNQWNKPSKPKTNLKHVAGAAAAGAVVGGLG
GYMLGSAMSRPHILFGSDYEDRYYRENMYRYPHQVYYRPVDQYSNQNNFVHDCV
NITIKQHTVTTTTKGENFTETDIKMMERVVEQMCVTQYQRESQAYYQRRRS
80                        90                     100             110                  120
130                   140                    150                 160                  170
180                190                 200                   210 220                   230
30                     40                       50               60                        70
Octapeptide repeats        Hydrophobic region          β-sheets          N-linked glycosylation
GPI-anchor addition
KKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGTWGQPHGGGWGQPHGGSWG
QPHGGSWGQPHGGGWGQGGGTHNQWNKPSKPKTNLKHVAGAAAAGAVVGGLG
GYMLGSAMSRPHILFGSDYEDRYYRENMYRYPHQVYYRPVDQYSNQNNFVHDCV
NITIKQHTVTTTTKGENFTETDIKMMERVVEQMCVTQYQRESQAYYQRRRS
80                        90                     100             110                  120
130                   140                    150                 160                  170
180                190                 200                   210 220                   230
30                     40                       50               60                        70
KKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGTWGQPHGGGWGQPHGGSWG
QPHGGSWGQPHGGGWGQGGGTHNQWNKPSKPKTNLKHVAGAAAAGAVVGGLG
GYMLGSAMSRPHILFGSDYEDRYYRENMYRYPHQVYYRPVDQYSNQNNFVHDCV
NITIKQHTVTTTTKGENFTETDIKMMERVVEQMCVTQYQRESQAYYQRRRS
80                        90                     100             110                  120
130                   140                    150                 160                  170
180                190                 200                   210 220                   230
30                     40                       50               60                        70
Octapeptide repeats        Hydrophobic region          β-sheets          N-linked glycosylation
GPI-anchor addition  
 
 
Figure 1.1:  Primary amino acid sequence of PrP.  Sheep PrP sequence from amino acids 
23-230 without the N -terminal and C-terminal signal peptides.  The features of PrP are 
highlighted in colour. 
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1.3.1.  Biosynthesis of PrP
C 
 
Like other membrane proteins, PrP
C is synthesized in the rough endoplasmic reticulum 
(ER).  Two signal peptides are present in the molecule, one at the N-terminus which is 
cleaved during biosynthesis in the ER and the other at the C-terminus which is replaced 
with a GPI anchor (Stahl et al., 1987).  The GPI anchor may play a role in stabilising 
the conformation of PrP
C to prevent conversion to PrP
Sc (Eberl et al., 2004; Hicks et 
al., 2006).  Two glycosylation sites are also mapped to the C-terminus and the 
formation of a disulfide bond occurs between two cysteine residues at amino acid 
codons 179 and 214 (Endo et al., 1989).  PrP
C trafficking through the Golgi complex 
occurs before the mature protein is transported to the cell surface.  On the cell surface, 
PrP
C  is continuously recycled between the plasma membrane and endocytic 
compartments (Harris et al., 2003).  PrP
C is enriched in membrane rafts both at the 
transgolgi network, plasma membrane and in interconnecting chains of endocytic 
caveolae-like domains (Vey et al., 1996; Peters et al., 2003).  Whilst still on the cell 
surface, PrP
C leaves its raft environment to cross the non-raft membrane and then enter 
coated pits where it is endocytosed.  Endocytosed PrP
C-containing caveolae are not 
directed to the ER and Golgi complex, but return to the surface (Sunyach et al., 2003). 
Recent evidence from neuronal cell studies also suggest that cholesterol is essential for 
the transport of PrP
C  to the cell surface.  Treatment with the cholesterol inhibitor 
mevinolin appears to reduce the amount of cell surface PrP
C, resulting in PrP
C 
accumulation in the Golgi complex (Gilch et al., 2006).  Cycling of PrP
C between the 
plasma membrane and endocytic compartments is though to occur via a clathrin-
dependent mechanism, and it appears that the N-terminal domain of PrP
C is essential 
for endocytosis via clathrin-coated pits (Shyng et al., 1994; Sunyach et al., 2003; 
Taylor and Hooper, 2006).   
 
The prion protein can adopt multiple membrane topologies including a fully secreted 
form (
SecPrP) and two transmembrane forms (
ntmPrP and 
ctmPrP) (Hegde et al., 1998; 
Hedge et al., 1999).  These forms span the lipid bilayer once via a highly conversed 
hydrophobic region in the centre of the molecule (amino acids 111-134), with either the 
N or C terminus, respectively on the extracytoplasmic side of the membrane.  It has 18   
been shown that these species are generated in small amounts (less than 10 % of total 
PrP) as part of the normal biosynthesis of wild type PrP in the ER.   
 
1.3.2.  The function of PrP
C 
 
The function of PrP
c remains unclear and the first observations of PrP
c gene-ablated 
mice (Prnp
0/0) surprisingly suggested that the animals without the protein develop 
normally and do not show major behavioural abnormalities (Bueler et al., 1992).   
However, since then several minor differences were noticed in some strains of PrP
c null 
mice when compared to their wild-type controls.  For instance, defects in synaptic 
function were observed (Collinge et al., 1994), increased vulnerability of neurones to 
oxidative stress (Brown et al., 1997), reduced Cu
2+/Zn
2+ dependent superoxide 
dismutase (SOD) activity (Brown et al., 1999) and changes in membrane localisation of 
nitric oxide synthase (Ovadia et al., 1996).  It is possible that a loss of PrP
C may 
contribute to neurodegeneration, as all of these features are associated with neuronal 
cell damage and death, and are observed in scrapie-infected animals. Based on these 
observations, several different roles for PrP
c in the central nervous system have been 
suggested, ranging from regulation of oxidative stress in neurones to influencing 
neurotransmission (Brown and Besinger. 1998; Collinge et al., 1994).  PrP
C may also 
play a role in neurogenesis (Kanaani et al., 2005), differentiation of neural precursor 
cells (Steele et al., 2006) and release of the neurotransmitter acetylcholine at 
neuromuscular junctions (Re et al., 2006).  
 
It is well known that the prion protein binds copper in vivo (Brown et al., 1997).  The 
N-terminal domain of PrP
C contains octapeptide repeat motifs encompassing five Cu
2+ 
ion binding sites.  PrP
C may have a functional role in copper metabolism.  It may be a 
principal copper-binding protein in brain membrane fractions and could control the 
activity of other membrane-associated copper binding proteins.  It has been shown that 
the octapeptide repeat region of the prion protein is involved in copper reduction from 
Cu
2+ to Cu
+ (Miura et al., 2005).  Prion protein expression alters copper uptake into 
cells and enhances copper incorporation into SOD (Brown et al., 1999; Brown et al., 
2001).  More recently, copper-bound prion peptide fragments have been shown to 19   
catalyse the formation of superoxide (Kawano, 2006) causing irreversible damage.   
However, in contrast to these findings, two other studies suggest that recombinant PrP 
(Hutter et al., 2003) and cellular PrP
C in vivo (Sakudo et al., 2008) may not possess any 
SOD-like activity.     
 
PrP
C interacts with various macromolecules at the cell membrane, in endocytic 
compartments and in the secretory pathway.  Identification of PrP
C ligands may aid in 
establishing biological functions in the cell.  PrP
C has been shown to interact with the 
transmembrane protein laminin receptor precursor (Rieger et al., 1997).  Laminin 
mediates internalisation of PrP
C and directs the complex through clathrin coated pits 
(Gauczynski et al., 2001).  Additionally, PrP
C has also been reported as a high affinity 
receptor for laminin (Graner et al., 2000).  The interaction of these two proteins may be 
important in cell signalling pathways.  Other specific PrP
C ligands include stress 
inducible protein 1 (STI1) which promotes neuroprotection of retinal neurones (Zanata 
et al., 2002), the adapter protein Grb2 and the prion interactor Pint1 (Petrakis and 
Sklavladis, 2006).   PrP
C may also interact with hemin (iron protoporphyrin IX) which 
plays a role in hemin homeostasis.  Hemin is a component of haemoglobin, a molecule 
essential for oxygen transport in red blood cells (Lee et al., 2007).  
 
PrP
C may also have a specific role in the immune system.  It is expressed on 
haematopoietic stem cells and may be important for their self-renewal (Zhang et al., 
2006).  Based on work in PrP null mice or cells derived from them, PrP
C has also been 
proposed to down-regulate phagocytosis by macrophages (De Almeida et al., 2005).  
Additionally, PrP
C may play a role in T cell activation and proliferation (Bainbridge 
and Walker, 2005) and could induce signalling cascades in monocytes (Krebs et al., 
2006).   
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1.3.3.  Models of PrP
C/PrP
Sc conversion 
A key molecular event in TSE diseases is the conversion of PrP
c to PrP
Sc, however the 
exact mechanism is unknown. Prusiner et al (1982) have suggested that the interaction 
between exogenously introduced PrP
Sc and endogenous PrP
c may induce refolding of 
the native molecule, inducing a structural change from alpha helix to beta-sheet (Figure 
1.2, A). Alternatively, in the nucleation-polymerisation model it has been suggested 
that unstable monomeric PrP
Sc molecules could slowly form an infectious stable seed. 
After further PrP
Sc recruitment, the oligomeric seed fragments into several infectious 
seeds which incorporate and convert PrP
c (Xiong et al., 2001; Griffith, 1967) (Figure 
1.2, B).  It has recently been reported that smaller PrP
Sc-containing aggregates with 
masses equivalent to 14-28 PrP molecules may be more toxic than larger amyloid 
fibrils (Silveira et al., 2005).  It has also been considered that there may be an 
intermediate step in which another protein or molecule (often termed protein X) acts as 
a molecular chaperone and interacts with PrP
Sc to facilitate conversion (Saborio et al., 
1999) (Figure 1.2, C).  Evidence also suggests that nucleic acids may be host-cell co-
factors needed for conversion of PrP
C (Deleault et al., 2003).  
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Figure 1.2:  Models of PrP
Sc replication.  (A) In the heterodimer model PrP
Sc exists as a 
monomer that binds to PrP
C, forming a heterodimer and catalysing the conversion of PrP
C to 
PrP
Sc.  The homodimer then splits to give two PrP
Sc seeds for further conversion of PrP
C.  (B) 
In the nucleated polymerisation model the conversion of PrP
C to PrP
Sc is reversible and PrP
Sc is 
stabilised by aggregation.  In the noncatalytic model the monomer of PrP
C may interchange 
between the two conformations, with the β-form stabilised by binding to preformed PrP
Sc.  In 
the catalytic model the α to β conformational change takes place on binding to PrP
S .  (C) There 
may be an intermediate step in which another protein or molecule (often termed protein X) acts 
as a molecular chaperone and interacts with PrP
Sc to facilitate conversion of PrP
C to PrP
Sc. 22   
1.4.  Sheep PrP genetics 
 
Studies of natural and experimental scrapie confirm the importance of 3 polymorphic 
codons in the sheep PrP gene 136, 154 and 171, that are associated with either 
resistance and susceptibility to TSE infection following experimental challenge with  
isolates of scrapie (e.g  scrapie sheep brain pool 1 or  SSBP/1) and BSE (see table 1.3 
Hunter 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.3: The three most important disease-related polymorphisms of the sheep PrP 
gene.  Taken from Hunter (1997). 
 
The current commonly accepted designation for sheep genotypes is a 3 letter code for 
the amino acids at 136, 154 and 171 for each allele in turn, for instance VRQ or ARR. 
Polymorphisms of the PrP gene were found to be associated with differences in 
susceptibility and length of incubation period in sheep with natural scrapie and 
experimentally infected animals (Goldmann et al., 1994; Clouscard et al., 1995). Sheep 
genotypes with VRQ and ARQ are linked to a higher susceptibility to scrapie, whereas 
those with AHQ and ARR alleles are linked with increased resistance to scrapie.   
Scrapie susceptibility is also influenced by sheep breed. In Suffolk sheep the genotype 
Codon              Amino acid alternatives                    Single-letter 
code 
136  Valine                                                         V 
                         Alanine                                                        A 
 
154                   Arginine                                                      R 
                                     Histidine                                                     H 
 
171                   Arginine                                                     R 
                                     Glutamine                                                  Q               
                          Histidine                                                   H 23   
ARQ/ARQ is susceptible to natural scrapie, whereas in some flocks of Cheviots this 
genotype is relatively resistant (Hunter 1997).  
 
In sheep, PrP genotype can influence the disease pathogenesis. Sheep with the 
genotype VRQ/ARR are relatively resistant to natural scrapie, and in the occasional 
cases that occur, minimal PrP
Sc deposits are found in their lymphoid tissues 
(Andreoletti et al., 2000). In contrast, highly susceptible VRQ/VRQ animals exposed to 
natural scrapie show PrP
Sc deposition in the tonsils one year before the onset of clinical 
disease (Schreuder et al., 1998).  Therefore disease resistance associated with the 
VRQ/ARR genotype may result from the lack of lymphoid involvement in the 
peripheral pathogenesis of scrapie in these sheep.  
1.5.  Peripheral pathogenesis 
1.5.1.  Initial infection routes 
Although the initial route of TSE infection is unclear, there is evidence in sheep to 
suggest that disease can be acquired orally (Hadlow et al., 1982; Andreoletti et al., 
2000).  Maternal or vertical transmission from mother to lamb is highly suspected, 
although contamination of foetuses in utero has not been shown.  PrP
C is present in 
human and ruminant milk (Franscini et al., 2006), and recently transmission of scrapie 
infectivity was reported using milk from sheep infected with classical scrapie (Konold 
et al., 2008).  Scrapie and mastitis infection may lead to accumulation of 
PrP
Sc/infectivity in inflamed ectopic lymphoid follicles of mammary glands, also 
indicating that milk may play a role in direct transmission (Ligios et al., 2005).     
 
Rodent studies indicate that skin scarification is an effective means of scrapie 
transmission (Taylor et al., 1996) and it may be that natural scrapie in sheep could be 
transmitted through skin lesions in the mouth (Bartz et al., 2003).  Additionally, traces 
of scrapie infectivity have been reported in the salivary glands of scrapie-infected goats 
(Hadlow et al., 1974) and more recently detection of abnormal PrP was observed in 
salivary glands of clinical scrapie sheep.  Transmission of CWD via saliva has also 
been demonstrated.   (Mathiason et al., 2006; Vascellari et al., 2007).   24   
Infected faeces and urine have been suggested as a potential source of contamination 
and transmission of TSE disease in the environment.  In murine models PrP
Sc is 
apparent in stools after oral ingestion of TSE agent (Maluquer de Motes et al., 2008) 
and PMCA amplification methods have demonstrated that PrP
Sc is present in the urine 
of some scrapie-infected hamsters during the clinical stage of disease (Murayama et al., 
2007).  Also, in hamster models, TSE transmission has been shown via inoculation of 
scrapie-infected urine into healthy animals (Kariv-Inbal et al., 2006).  Additionally, 
animals suffering from inflammatory kidney disorders appear to accumulate TSE 
infectivity in urine, highlighting that general health may be important in disease 
pathogenesis (Seeger et al., 2005).  TSE agents can persist in the environment for a 
number of years in soil, which may also be a source of infection for sheep grazing on 
pastures where infected sheep have been kept before (Seidel et al., 2007).  Evidence 
also suggests animals may eat TSE infected discarded placental tissues (Pattison et al., 
1972, 1974) which accumulate abnormal prion protein (Andreoletti et al.,  2002).    
Although not formally demonstrated other possible sources of infection may include 
open wounds, ectoparasites, and colostrum.  
1.5.2.  Infectious agent uptake 
Once ingested, TSE agents must replicate and reach the central nervous system (CNS).  
Research using rodent models suggest that ingested infectious particles (following 
either experimental intragastric or oral exposure to scrapie) initially gain entry to gut–
associated lymphoid tissues (GALT) in the small intestinal mucosa (Kimberlin and 
Walker, 1989). This has also been demonstrated in sheep naturally exposed to scrapie 
(Hadlow et al., 1982; Andreoletti et al., 2000). GALT consists of highly organized 
Peyer’s patches present in the mucosa of the small intestine. At the surface of Peyer’s 
patches are specialised M cells which are able to transport proteins and pathogens from 
the gut lumen through the cytoplasm to the basal surface (Heppner et al., 2001). It is 
possible that the scrapie agent could be taken up in the same way.  TSE agents could 
also pass across the gut epithelium independently of M-cell transport.  Evidence 
suggests that digestive enzymes break down the infectious agent into smaller molecules 
which form complexes with other proteins such as ferritin.  Particles are then 
endocytosed in vesicular structures by a ferritin dependent mechanism (Mishra et al., 25   
2004).  Alternatively, TSE agents may be directly taken up by dendritic cells (DCs).   
DCs open up the tight junctions between epithelial cells and the captured antigen by 
inserting dendritic processes into the gut lumen.  This process has yet to be 
demonstrated with TSE agents, but has been shown using microbial cells (Rescigno et 
al., 2001).  Possible spread of scrapie infectivity from the gut to the nervous system 
following oral inoculation is illustrated in Figure 1.3. 
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Figure 1.3:  Possible spread of scrapie infectivity from the gut to the nervous system 
following oral inoculation.  Figure 1.3 is adapted from Mabbott and Bruce, (2001).  Key:  
FAE, follicle-associated epithelium, FDC, follicular dendritic cell, DC, dendritic cell, ENS, 
enteric nervous system, dotted line, route of infection.  Following ingestion PrP
Sc is detected 
within Peyer’s patches upon FDCs, within macrophages, within M cells and within ganglia of 
the ENS.  Infectious agent may also be broken down into smaller molecules which form 
complexes with other proteins such as ferritin.  These observations suggest that following 
uptake of scrapie infectivity from the gut lumen, infectivity accumulates upon FDCs in Peyer’s 
patches and spreads via the ENS to the central nervous system.      
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Some TSE agents replicate in lymphoid tissues before neuroinvasion occurs.  In sheep, 
research has shown the early appearance of scrapie agent in tonsil, retropharyngeal and 
mesenteric lymph nodes and intestine (Hadlow et al., 1982).   Mice fed with scrapie or 
BSE agent show initial PrP
Sc deposition in Peyer’s patches and mesenteric lymph nodes 
prior to infection of other lymphoid tissues, including the spleen (Maignien et al., 
1999).  Splenectomized mice (whether the spleen was removed surgically or 
genetically induced) were shown to have increased disease incubation periods when 
compared to mice with intact spleens after intra-peritoneal (i/p) inoculation (Fraser and 
Dickinson., 1970, 1978). Additionally, severe combined immunodeficient (SCID) mice 
which lack B and T lymphocytes are relatively resistant to experimental infection with 
scrapie (Fraser et  al., 1996; Lasmezas et  al., 1996).  Susceptibility was restored 
following allogenic bone marrow transplantation from normal mice (Fraser et  al., 
1996).  Exposing animals to ionising radiation does not appear to delay neuroinvasion 
(Fraser and Farquhar, 1987).  Such treatment destroys all rapidly dividing cells, 
including bone marrow precursors of most of the cells that populate the immune 
system. However, it does not destroy follicular dendritic cells (FDCs).  As 
neuroinvasion is not impaired by the effects of radiation this indicates that FDCs and 
other cells of the immune system may play an important role in TSE pathogenesis.   
 
1.5.3.  Follicular dendritic cells, macrophages, T cells, B cells and dendritic cells 
 
Follicular dendritic cells (FDCs) are present within Peyers patches and all germinal 
centres (GCs) including those of the spleen, lymph nodes and tonsil (Montrasio et al., 
2000).  FDCs are thought to be derived from stromal precursor cells, and are non-
phagocytic and non-migratory (Maeda et al., 1995).  The majority of studies 
investigating the role of FDCs in TSE agent uptake have been carried out using rodent 
models.  However, in sheep, PrP
Sc is also found on FDCs in addition to other cell types 
in lymphoid nodules in the gut (van Keulen et al., 2002).  Mouse studies show early 
TSE agent accumulation on FDCs in the Peyer’s patches and immature isolated 
lymphoid follicles of the intestine (Glaysher and Mabbott, 2007).  Chimeric mouse 
models show that FDCs themselves express PrP
c rather than acquiring it from other 
PrP-expressing cells.  In these models PrP
C can be expressed on FDCs, but not 28   
lymphocytes and vice versa (Blattler et al., 1997; Klein et al., 1998; Brown et al., 
1999).  When chimeric mice are challenged with the ME7 scrapie stain, high levels of 
infectivity are observed in the spleen only in the presence of PrP-expressing FDCs, 
highlighting again that it is in these cells that early accumulation and replication of TSE 
agents occurs.  Additionally, when FDCs are eliminated by disrupting cytokine 
signalling pathways required to maintain FDCs in their differentiated state, infectious 
agent does not accumulate in the spleen or lymph nodes and neuroinvasion is delayed 
after scrapie inoculation (Mabbott et al., 2000, Prinz et al., 2002).   
 
Transgenic mice with specific immune system defects show that B cells also play a role 
in disease pathogenesis, as B cell deficient or knockout mice are also relatively 
resistant to scrapie (Frigg et al., 1999; Weissmann et al., 1994). It appears that PrP
c 
expression on B lymphocytes is not required for neuroinvasion (Klein et al., 1998) 
suggesting that rather than being targets for infection their role in pathogenesis may be 
indirect. B lymphocytes secrete the cytokines lymphotoxin α/β (LTα/β) and tumour 
necrosis factor (TNF-α) which are essential for the formation and maturation of FDC 
networks in GCs.  Knockout mice with defective TNFα or LTα/β and/or their receptors 
lack mature FDCs and are less susceptible to disease when challenged with scrapie 
(Mabbott et al., 2000; Montrasio et al., 2000).  The same effect is achieved when FDCs 
are temporarily depleted by blocking the LTβ pathway with an inhibitor (Mohan et al., 
2004).  Therefore, the importance of B cells in pathogenesis may be due to their role in 
maintenance of FDC networks.  They may also deliver infectious agent to FDCs or 
even transfer infection from FDCs to other cell types (Raeber et al., 2001). 
 
FDCs are immobile, so it is unclear how infection first reaches these cells and is 
transported to other tissues. It may be that FDCs directly trap cell-free PrP
Sc or other 
molecules associated with the agent in complement-bound complexes (Klein et al., 
2001; Mabbot et al., 2001). In mice, once an antigen enters the body it is bound by 
antibody and complement components such as C3 fragments (C3b, C3d, C1q).  FDCs 
express the complement receptors CR1 (CD35) and CR2 (CD21) which are important 
for trapping immune complexes via activated C3 fragments. C3 knockout mice show 
impaired PrP
Sc accumulation as do mice with transient C3 depletion, indicating that 29   
such fragments may bind the infectious agent to FDCs (Klein et al., 2001; Mabbott et 
al., 2001).  Two distinct pathways are involved in C3 activation.  C1q can interact with 
antibody bound to antigen or can interact directly in an antibody-independent manner 
to cell surface molecules on pathogens.  This is termed the classical pathway.  In 
contrast, the alternative pathway is completely antibody-independent, and is initiated 
by direct binding of C3 to a range of pathogen cell surface components.  Recently both 
recombinant PrP and PrP
Sc from diseased mouse brain has been shown to directly 
activate and fix complement via the classical but not the alterative pathway (Mitchell et 
al., 2007).     
 
TSE agents could also be transferred to FDCs via mobile cells such as migratory bone 
marrow derived dendritic cells (DCs) which specifically migrate to lymphoid tissues 
once activated by tissue injury or infection.  Human DCs express PrP
c (Burthem et al., 
2001) and these cells are associated with PrP
Sc in intestinal lymph following 
experimental oral infection of rats (Huang et al., 2002). Other groups have shown that 
the neurotoxic prion protein fragment PrP106-126 is a chemoattractant for monocyte-
derived DCs. These experiments were performed in vitro however and as yet there is no 
evidence that this PrP fragment is generated in vivo (Kaneider et al., 2003). It has also 
been demonstrated that DCs from scrapie-infected mice induce disease when injected 
intravenously into RAG-1
0/0 mice (recombinase activating gene null mice, deficient in 
B and T cells).   The recipient mice developed scrapie without accumulation of agent in 
the spleen, which suggests that DCs alone may be able to mediate neuroinvasion 
without the involvement of other components of the lymphoid system (Aucouturier et 
al., 2001).  Recently transgenic mice deficient in CD11c
+ DCs showed a lack of scrapie 
accumulation in the GALT and spleen following oral scrapie challenge.  Additionally, 
CD11c
+ DC depletion increased resistance to oral scrapie challenge, indicating that 
migratory CD11c
+ DCs may play a role in TSE agent transfer from the gut lumen to the 
GALT which precedes neuroinvasion (Raymond et al., 2007).  DCs have also been 
shown to express complement receptors (Castellano et al., 2004) and it is conceivable 
that DCs may utilize the complement system in the targeting and transport of TSE 
agents although this has not formally been demonstrated.  
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PrP
Sc has also been detected in GC macrophages suggesting that these cells may take up 
PrP
Sc from FDCs (Jeffrey et al., 2000).  Macrophages may help clear infection by 
digesting or phagocytosing infectious agent (Beringue et al., 2000).  Competition may 
then occur between destruction of infectivity by macrophages and accumulation by 
FDCs. 
T lymphocytes are not thought to be involved in scrapie pathogenesis.  Thymectomy 
has no effect on the disease incubation period after peripheral scrapie infection of mice 
(McFarlin  et al., 1971; Fraser and Dickinson, 1978).  Since this first observation, 
additional studies from Klein and colleagues have shown that T cell deficiencies in 
mice (CD4 
-/-, CD8 
-/-, TCRα 
-/-) have no effect on the accumulation of TSE agent in the 
spleen or on disease susceptibility (Klein et al., 1997, 1998).     
1.5.4.  Neuroinvasion 
 
Before the onset of clinical signs, infection spreads from the lymphoid tissues to the 
CNS.  As lymphocytes recirculate between lymphoid tissues and blood it is possible 
that infectivity and/or PrP
Sc may be spread to the CNS via blood.  Also TSE infectivity 
has been demonstrated during the preclinical and clinical stages of incubation in the 
blood of sheep infected with scrapie and BSE (Houston et al., 2000; Hunter et al., 
2002).  Additionally, low levels of infectivity are detected in blood in mouse TSE 
models (Brown et al., 1998, 1999).  Studies by Blattler and colleagues suggest however 
that neuroinvasion does not occur via blood.  In these experiments neurografts (PrP
+) 
were introduced into PrP null mice.  Following intracerebral inoculation with scrapie, 
the graft but not the surrounding tissue showed scrapie pathology.  However, when 
animals were inoculated with scrapie agent via the intravenous route, the grafts were 
not infected (Blattler et al., 1997).  This is a highly artificial situation and it is not clear 
if it relates to natural infection or not.  It is not surprising that the grafts become 
infected following intracerebral inoculation with scrapie and it is possible that 
infectivity following intravenous inoculation may reach the blood brain barrier but not 
necessarily the graft site, which would prevent the graft becoming infected.  Other 
evidence suggesting that neuroinvasion does not occur via blood, is presented in 
immunohistochemical studies which show that disease pathology appears to begin in 31   
areas of the brain such as the dorsal nucleus of the vagus nerve that are not associated 
with blood vessels (Jeffrey et al., 2001).      
 
In contrast, more recent evidence suggests that infectivity and/or PrP
Sc may be spread 
to the CNS via blood.  Experiments in sheep show that factors such as the breed of 
sheep, PrP genotype, TSE source and the route of infection appear to have no effect on 
the location of PrP
Sc deposition in the brain, which was the same as if infection had 
been acquired orally (Siso et al., in press).  PrP
Sc was found in capillary rich areas near 
the base of the brain that lack the usual blood-brain barrier.   It is possible that 
infection, when present in the blood, may be transferred to the brain via such 
capillaries, thus representing an alternative pathway of neuroinvasion (Siso et al., in 
press).   
 
Studies in sheep suggest that the enteric nervous system, at the level of the duodenum 
and ileum are the first neural tissues to be involved in neuroinvasion (van Keulen et al., 
2000; van Keulen et al., 2002).  Recent evidence suggests that it is the somatostatin-
expressing enteric neurones, with fibre projections near Peyer’s patches that are early 
targets (Schneider et al., 2008).  From the enteric nervous system, infectivity and/or 
PrP
Sc may travel along sympathetic nerves (Chiocchetti et al., 2008) via the celiac-
mesenteric ganglion to the spinal cord, or along parasympathetic neuronal pathways 
directly to the brain stem.  Experiments in rodents have also shown that the sympathetic 
and parasympathetic branches of the autonomic nervous system may be involved in 
neuroinvasion (Kimberlin and Walker, 1989; McBride and Beekes, 1999). Infection 
may spread from FDCs directly or via other cell types to the vagus nerve which 
terminates in the ganglia of the enteric nervous system or from splanchnic nerve 
endings in lymphoid tissues such as the spleen and then be transported to the CNS 
along nerve fibres (Kimberlin and Walker, 1989; Baldauf et al., 1997; McBride and 
Beekes, 1999; van Keulen et al., 2000). The distance between FDCs and nerve endings 
may influence the rate of agent transfer to the nervous system, such that neuroinvasion 
could occur more rapidly from sites where FDCs are closely associated with nerve 
fibres (Prinz et al., 2003). 
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1.5.5.  Summary 
 
The mechanisms which underpin TSE agent accumulation and replication in lymphoid 
tissue and neuroinvasion may vary depending on factors including the strain of agent, 
the infectious dose, host species and route of infection.  The general health of the 
animal may also be important, as it has been shown that animals suffering 
inflammatory conditions such as nephritis and pancreatitis appear to accumulate TSE 
agent in organs that are not normally affected in healthy mice (Heikenwalder et al., 
2005).  PrP
Sc is also present in ovine mammary glands, if animals are suffering from 
both scrapie and mastitis (Ligios et al., 2005).  PrP genotype may also influence the 
distribution of infectious agent, with infectivity being replicated more efficiently in the 
periphery of susceptible sheep and less frequently in animals with resistant genotypes 
(Ersdal et al., 2005; Jeffrey et al., 2006).     
 
1.6.   Role of blood in pathogenesis 
 
1.6.1.  Evidence of infectivity in blood 
 
Lymphocytes recirculate between lymphoid tissues and blood and in scrapie-infected 
animals it is possible that infectivity is spread in this manner, although it is not believed 
significant for neuroinvasion (Blattler et al., 1997).  Scrapie and experimental BSE can 
be transmitted between sheep by transfusion of whole blood and buffy coat (Hunter et 
al., 2002; Houston et al., 2000).  Experimental rodent TSE models have demonstrated 
low levels of infectivity in blood during preclinical and clinical stages of disease 
(Brown et al., 1998, 1999; Cervenakova et al., 2003).  Taylor and co-workers found 
only a small proportion (four from a total group of forty eight) of healthy mice showed 
clinical signs of disease after intracerebral (i/c) inoculation with plasma infected with 
experimental BSE (Taylor et al., 2000).  Transmission of infection may be limited by 
effects such as the species barrier (which occurs due to the difficulty to infect animals 
e.g mice with infectious agent from animals of a different species e.g cattle).   
Additionally, only small volumes of plasma can be assayed by i/c inoculation.  Other 
rodent studies have shown that TSE infected whole blood does not cause infection 33   
following transmission to healthy rodents (Eklund et al., 1967).  It is possible that 
levels of infectivity in blood may be low and larger volumes are required to transmit 
disease.   
 
More recently, infectivity in blood has been demonstrated in sheep and primate models 
(Houston et al., 2000; Hunter et al., 2002; Bons et al., 2002) after transfusion of TSE 
infected whole blood and buffy coat.  Additionally, CWD transmission has been shown 
via blood transfusion in white tailed deer fawns (Mathiason et al., 2006).  Blood from 
scrapie-infected sheep without accumulation of abnormal PrP in lymphoid tissues can 
also transmit infection and cause disease in healthy animals.  This highlights the fact 
that animals early in the incubation period can transmit disease via blood (Siso et al., 
2006).   In humans four vCJD cases have also been reported which probably resulted 
from an infected blood transfusion (Llewelyn et al., 2004; Peden et al., 2004; Wroe et 
al., 2006; Health Protection Agency., 2007).  The first case was identified in December 
2003, where one recipient developed symptoms of vCJD six and a half years after 
receiving a transfusion of red blood cells donated by an individual three and a half 
years before the donor developed vCJD.  The recipient was homozygous for 
methionine at PrP amino acid codon 129 (Llewelyn et al., 2004).  Until 2004 all 
recorded vCJD cases had occurred in people homozygous for methionine, however a 
preclinical vCJD case was reported in a PrP codon 129 heterozygous 
(methionine/valine) patient, who died of a non-neurological disorder five years after 
receiving blood from a donor who developed vCJD eighteen months after donation.  
Although no pathological features of vCJD were seen, post mortem investigations 
revealed that PrP
Sc was present in the spleen and a cervical lymph node, but was absent 
in the brain  (Peden et al., 2004).  In 2006, the third case of vCJD infection associated 
with blood transfusion was reported (Wroe et al., 2006).  The recipient developed 
symptoms of vCJD six years and died eight years, eight months after receiving blood 
from a donor who developed vCJD about twenty months after the blood was donated.  
The recipient was also homozygous for methionine at PrP amino acid codon 129 
(Health Protection Agency., 2007).  At the time of writing (August 2008) a fourth case 
of vCJD transmitted via blood transfusion has been reported.  In this latest case, the 
recipient developed symptoms of vCJD eight and a half years after receiving blood 34   
from a donor who died of vCJD about seventeen months after this blood was donated.  
The donor in this latest case also donated the vCJD-implicated blood that was 
transfused to the third case patient (Health Protection Agency., 2007).  All the four 
blood transfusion transmissions of vCJD occurred following transfusion of 
nonleukodepleted red blood cells collected between 1996 and 1999 (Health Protection 
Agency., 2007).  It is still unclear though which blood components carry infection. 
 
Table 1.4 summarises studies showing TSE transmission via blood or blood 
components. 
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Table 1.4: Summary of the studies showing TSE transmission via blood and blood components.  This table has been adapted from 
Brown, 2005. Key: BSE, bovine spongiform encephalopathy; CJD, Creutzfeldt-Jakob disease; CWD, chronic wasting disease; GSS, 
Gerstmann-Straussler-Scheinker syndrome; vCJD, variant Creutzfeldt-Jakob disease; i.c, intra-cerebral; i.p, intra-peritoneal; i.v., intra-
venous; i.m, intra-muscular; s.c, subcutaneous.  
 
Donor Animal  Assay 
Animal 
Inoculum Route  Of 
Inoculation 
Positive/total 
donors 
Reference  
Scrapie 
(natural) 
Goat 
Sheep 
Sheep 
Sheep 
 
 
Mouse 
Mouse 
Sheep 
Sheep 
 
 
Blood clot/serum 
Blood clot/serum 
Whole blood/buffy coat 
Whole blood/buffy coat 
 
 
i.c. 
i.c. 
i.v. 
i.v. 
 
 
0/3 
0/18 
4/21 
9/21 
 
 
Hadlow et al., 1980 
Hadlow et al., 1982 
Hunter  et al., 2002 
Houston et al., 2008 
(follow up to the Hunter 
study in 2002) 
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Table 1.4: Summary of the studies showing TSE transmission via blood and blood components.  This table has been adapted from 
Brown, 2005. Key: BSE, bovine spongiform encephalopathy; CJD, Creutzfeldt-Jakob disease; CWD, chronic wasting disease; GSS, 
Gerstmann-Straussler-Scheinker syndrome; vCJD, variant Creutzfeldt-Jakob disease; i.c, intra-cerebral; i.p, intra-peritoneal; i.v., intra-
venous; i.m, intra-muscular; s.c, subcutaneous.  
 
Donor Animal  Assay 
Animal 
Inoculum Route  Of 
Inoculation 
Positive/total 
donors 
Reference  
CJD 
(experimental) 
Guinea pig 
Mouse 
Mouse 
Mouse 
 
 
Guinea pig 
Mouse 
Mouse 
Mouse 
 
 
Buffy coat 
Buffy coat 
All components 
All components 
 
 
i.c., s.c., i.m., i.p. 
i.p. 
i.c. 
i.c. 
 
 
10/28 
4/7 
 
22/235 
 
 
Manuelidis, 1978 
Kuroda, 1983 
Brown et al., 1998 
Brown et al., 1999 
CWD 
(natural) 
Deer Whole  blood  i.v.  3/3  Mathiason  et al., 2006 
vCJD 
(experimental) 
Mouse Buffy  coat 
 
Plasma 
i.c. 
i.v. 
i.c. 
i.v. 
 
2/2 
2/2 
2/2 
2/2 
Cervenakova et al., 2003 37   
Table 1.4: Summary of the studies showing TSE transmission via blood and blood components.  This table has been adapted from 
Brown, 2005. Key: BSE, bovine spongiform encephalopathy; CJD, Creutzfeldt-Jakob disease; CWD, chronic wasting disease; GSS, 
Gerstmann-Straussler-Scheinker syndrome; vCJD, variant Creutzfeldt-Jakob disease; i.c, intra-cerebral; i.p, intra-peritoneal; i.v., intra-
venous; i.m, intra-muscular; s.c, subcutaneous.  
Donor Animal  Assay 
Animal 
Inoculum Route  Of 
Inoculation 
Positive/total 
donors 
Reference  
Scrapie 
(experimental) 
Goat 
 
Sheep 
Mouse 
Mouse 
Rat 
Mouse 
Goat 
Hamster 
Hamster 
Hamster 
 
 
 
Goat 
 
Mouse 
Mouse 
Mouse 
Rat 
Mouse 
Mouse 
Hamster 
Hamster 
Hamster 
 
 
 
Whole blood 
 
Serum 
Whole blood 
Serum 
Serum 
Whole blood 
Blood clot 
Whole blood 
Blood extract 
Blood extract 
 
 
 
i.c. 
 
i.c. 
i.c. 
i.c. 
i.c. 
i.c. 
i.c or s.c. 
i.c. 
i.c. 
i.c. 
 
 
 
0/14 
 
1/1 
0/39 
1/1 
1/1 
3/13 
0/20 
0/9 
5/5 
10/11 
 
 
 
Pattison and Millson 
1962 
Gibbs et al., 1965 
Eklund et al., 1967 
Clarke and Haig, 1967 
Clarke and Haig,1967 
Dickinson et al., 1969 
Hadlow, 1974 
Diringer, 1984 
Diringer, 1984 
Casaccia et al., 1989 
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Table 1.4: Summary of the studies showing TSE transmission via blood and blood components.  This table has been adapted from 
Brown, 2005. Key: BSE, bovine spongiform encephalopathy; CJD, Creutzfeldt-Jakob disease; CWD, chronic wasting disease; GSS, 
Gerstmann-Straussler-Scheinker syndrome; vCJD, variant Creutzfeldt-Jakob disease; i.c, intra-cerebral; i.p, intra-peritoneal; i.v., intra-
venous; i.m, intra-muscular; s.c, subcutaneous.  
Donor Animal  Assay 
Animal 
Inoculum Route  Of 
Inoculation 
Positive/total 
donors 
Reference  
BSE 
(experimental) 
Mouse 
Cow 
Sheep 
Sheep 
 
 
Primate 
(Microcebus 
murinus) 
 
 
Mouse 
Mouse 
Sheep 
Sheep 
 
 
Primate 
(Microcebus 
murinus) 
 
 
Plasma 
Buffy coat 
Whole blood/buffy coat 
Whole blood/buffy coat 
 
 
Buffy coat 
 
 
i.c. 
i.c. and i.p. 
i.v. 
i.v. 
 
 
i.c. 
 
 
 
4/48 
0/11 
2/17 
5/22 
 
 
1/1 
 
 
Taylor et al., 2000 
Wells et al., 2000 
Hunter et al., 2002 
Houston et al., 2008 
(follow up to the Hunter 
study in 2002) 
Bons et al., 2002 
BSE (natural) 
Cow 
 
Mouse 
 
Blood clot/serum/buffy coat 
 
i.c. and i.p. 
 
0/4 
 
Fraser et al., 1994 
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Table 1.4: Summary of the studies showing TSE transmission via blood and blood components.  This table has been adapted from 
Brown, 2005. Key: BSE, bovine spongiform encephalopathy; CJD, Creutzfeldt-Jakob disease; CWD, chronic wasting disease; GSS, 
Gerstmann-Straussler-Scheinker syndrome; vCJD, variant Creutzfeldt-Jakob disease; i.c, intra-cerebral; i.p, intra-peritoneal; i.v., intra-
venous; i.m, intra-muscular; s.c, subcutaneous.  
Donor Animal  Assay 
Animal 
Inoculum Route  Of 
Inoculation 
Positive/total 
donors 
Reference  
Mink 
encephalopathy 
(experimental) 
Mink 
Mink 
 
 
 
Mink 
Mink 
 
 
 
Serum 
Whole blood or components 
 
 
 
i.c. 
i.c. 
 
 
 
0/1 
0/8 
 
 
 
Marsh et al., 1969 
Marsh et al., 1973 
GSS 
(experimental) 
Mouse 
Mouse 
Mouse 
 
 
Mouse 
Mouse 
Mouse 
 
 
 
Buffy coat 
Buffy coat/plasma 
Buffy coat/plasma 
 
 
i.p. 
i.c. 
i.v. 
 
 
4/7 
5/5 
2/2 
 
 
Kuroda, 1983 
Brown et al., 1999 
Brown et al., 1999 40   
 
1.6.2.  Distribution of infectivity in blood  
 
Evidence suggests that the highest levels of infectivity are found in the buffy coat 
fraction of blood.  In one study, blood from mice infected with either a human-derived 
strain of GSS (Gerstmann-Straussler-Scheinker) disease or vCJD contained around 20-
30 infectious units of agent infectivity per ml of buffy coat (containing platelets and 
leukocytes or white blood cells) while erythrocytes showed no infectivity 
(Cervenakova et al., 2003). Brown et al (1998) carried out experiments where scrapie-
infected hamster brain homogenate was “spiked” into normal human blood and found 
that the highest levels were also in the buffy coat fraction with slightly lower levels in 
plasma. In follow up work these researchers used the same GSS model described by 
Cervenakova and co-workers to demonstrate that endogenous infectivity could be 
transmitted  via the intravenous route, although larger volumes (seven times more 
plasma and five times more buffy coat) of plasma and buffy coat were needed to 
transmit disease by the intravenous route than by the intracerebral route, suggesting that 
transmission by the intravenous route is more inefficient (Brown et al., 1999). BSE 
infectivity was also transmitted via buffy coat after the primate species Microcebus 
murinus was inoculated intracerebrally (Bons et al., 2002).  However, in a purified 
platelet population from a hamster model little infectivity was found (Holada et al., 
2002).  In sheep models, TSE infectivity is also found in the buffy coat fraction of 
blood (Houston et al., 2000; Hunter et al., 2002) and recent evidence suggest it is 
mainly linked to the monocyte subset of leukocytes (Andreoletti et al., 2007). This 
suggests that infection may be associated mainly with leukocytes in addition to plasma, 
and is the basis for blood transfusion services using leucodepletion as a precaution to 
prevent the spread of vCJD via blood in humans.  
 
The significant levels of TSE infectivity observed in plasma may be associated with 
exosomes.  Exosomes were first reported from culture of sheep reticulocytes 
(Johnstone et al., 1987).  They are small membrane vesicles formed by invagination of 
the membrane of multi-vesicular bodies (MVBs) (Stoorvogel et al., 2002).  Exosome 
secretion into the extracellular environment occurs upon fusion of MVBs with the cell 41   
membrane and was suggested to be a mechanism of releasing unnecessary proteins 
during the maturation of reticulocytes (Johnstone et al., 1987).  Exosomes have been 
shown to be associated with FDCs (Denzer et al., 2000), urine (Pisitkun et al., 2004), 
malignant tumour effusions (Andre et al., 2002), blood (Caby et al., 2005) and platelets 
(Robertson et al., 2006).  In addition to removing unwanted cellular proteins, a role for 
exosomes has been described in the intercellular trafficking of human 
immunodeficiency virus (HIV-1) infectivity (Wiley et al., 2006) suggesting exosomes 
may play a role in distributing pathogens in the body.  Endogenous PrP
C is associated 
with exosomes from epididymal fluid (Gatti et al., 2002), platelets (Robertson et al., 
2006), primary cultured cortical neurones (Faure et al., 2006) and ovine cerebral spinal 
fluid (Vella et al., 2008).  Recently, several groups have shown that PrP
Sc is associated 
with exosomes released from non-neuronal and neuronal cells in culture (Fevrier et al., 
2004; Vella et al., 2007).  The exosomes released from TSE-infected neuronal cells 
were efficient initiators of PrP
Sc propagation in uninfected recipient cells and to non-
neuronal cells.  Additionally, neuronal cells were susceptible to infection by non-
neuronal cell derived exosome PrP
Sc (Vella et al., 2007).  This provides evidence that 
exosomes may play a role in PrP
Sc spread via blood.     
 
Soluble, oligomeric forms of PrP could also be present in blood (Kayed et al., 2003) 
and leucodepletion only removes 42 % of infectivity (Gregori et al., 2004).  The 
effectiveness of this measure has recently been increased to 72 % by passing 
leucoreduced blood through filters containing resin designed to remove TSE infectivity 
(Gregori  et al., 2006).  These experiment provide further evidence for soluble 
infectivity in blood  
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1.6.3.  PrP
Sc detection in blood 
 
The detection of proteinase K resistant PrP
Sc is used as a biochemical marker for the 
presence of infectivity.  So far, most attempts to detect PrP
Sc  in blood have been 
unsuccessful. Methods used to date include immunohistochemistry (IHC) (Herrmann et 
al., 2002), immunocapillary electrophoresis (Schmerr et al., 1999) and Western blotting 
(Wadsworth  et al., 2001).  Immunocapillary electrophoresis (ICE) uses labelled 
synthetic peptides in a competitive binding assay. This test has been used to detect 
abnormal prions in scrapie infected sheep blood and elk blood infected with chronic 
wasting disease but with limited success. As a result this test has not been validated as a 
diagnostic method.  An attempt has been made to adapt immunohistochemical methods 
to detect PrP
Sc in blood, specifically in sheep peripheral blood leukocytes (PBLs). By 
titrating PBLs with dissociated retropharyngeal lymph node cells known to express 
PrP
Sc,
 the researchers demonstrated that a minimum of 0.000205% or 60 PrP
Sc positive 
cells could be detected in 3x10
6 PBLs (Herrmann et al., 2002). However, they failed to 
show any positive staining for PrP
Sc  in PBL isolated from scrapie-affected sheep. 
Wadsworth et al (2001) developed a highly sensitive Western blot, but failed to detect 
PrP
Sc in the buffy coat fraction from a single vCJD case.  These workers estimated that 
if PrP
Sc was present in the 150µl buffy coat sample, then the concentration in blood 
would be 30,000 times less than the maximum detection limit found in brain.  
 
One possible explanation for the difficulty in detecting PrP
Sc in blood is that infectivity 
is in a form in blood which is dissimilar to that which is detected in brain.   
Experimental rodent models show that the detection of PrP
Sc does not always correlate 
with infectivity (Manson et al., 1999; Barron et al., 2001).  It may be in blood that titres 
of infectivity are present in the absence of detectable PK-resistant PrP
Sc. Sensitive 
methods for PrP
Sc detection that have been applied to blood have so far produced 
negative results suggesting that if PK-resistant PrP
Sc is present it is so in very small 
amounts. It is possible that not all disease-associated PrP
Sc in blood is PK-resistant.  
Evidence suggests that PK sensitive forms of PrP
Sc do exist and therefore will not be 
detected by current methods which rely on treatment with PK (Tremblay et al., 2004).  43   
Blood infectivity also appears reduced following PK treatment (Yakovleva et al., 
2004).  
 
 Recently PK resistant PrP
Sc has been detected in the blood of sick hamsters (infected 
with the 263K scrapie strain) by means of the protein misfolding cyclic amplification 
(PMCA) technology (Saborio et al., 2001).  By incubating infected buffy coat fractions 
with uninfected hamster brain homogenate, in a cyclical process the minute amounts of 
PrP
Sc in the buffy coat convert the larger quantities of PrP
C in the uninfected brain into 
more of the misfolded form of the protein, thus amplifying the quantity of PrP
Sc in the 
blood.  This method is very sensitive and has been used to detect PrP
Sc in the blood of 
both clinical and preclinical animals although the technology has yet to detect abnormal 
prion protein in species other than the hamster 263K model (Castilla et al., 2005; Saá et 
al., 2006).  Currently, PMCA technology is not generally available, is expensive and 
requires a high level of skill.  Additionally, this technology has only recently been 
developed and was not available at the beginning of this project.  Therefore PMCA was 
not pursed as a method for PrP
Sc detection in blood.  Western blotting is a widely 
available method which can be very sensitive for detection of PrP
Sc (Lee et al., 2000) 
and was therefore developed in this project for detection of abnormal prion protein in 
blood.           
 
1.6.4.  Distribution
 of cellular PrP in blood 
 
In the absence of a reliable method for detection of PrP
Sc in blood, the distribution of 
PrP
C expression on cellular blood components has been used to define potential targets 
for infection.  This is despite the fact that the function of PrP
C in blood is unknown.  
Comparisons of healthy animals of different species (hamster, mouse, human, sheep 
and cattle) have revealed differences in the expression and distribution of PrP
c on blood 
cells (Barclay et al., 2002; Holada and Vostal, 2000).  In humans, the highest PrP
c 
expression levels were seen on platelets and PBMCs and lower levels were detected on 
neutrophils and erythrocytes (Barclay et al., 2002; Herrmann et al., 2001).  PrP mRNA 
and cell surface PrP
C have been found in peripheral blood mononuclear cells (PBMCs) 
of normal and scrapie-infected sheep. The PrP was found to be proteinase K sensitive 44   
(Herrmann et al., 2001). Using FACS analysis, Barclay et al. (2002) also showed PrP
c 
expression on PBMC but were unable to detect PrP
c on the cell surface of platelets, 
erythrocytes and granulocytes prepared from uninfected sheep blood. However, using 
Western blot analysis, it has been shown that sheep platelets do express PrP
c  internally 
rather than on the surface (Halliday et al., 2005).  This difference in observation is 
likely due to the way in which the samples were prepared in Western blot assays 
(where cells were lysed) representing intracellular PrP
c, whereas FACS analysis 
represents PrP expression only on the cell surface.   
 
In sheep PrP
C is expressed on all major subsets of PBMCs, with the highest levels on 
the CD21
+ subset of B cells.  In some scrapie-infected animals PrP
C expression on 
CD21
+ B cells appears dramatically up-regulated (Halliday et al., 2005; Eaton et al., 
2007).  CD21 
+ B cells have been highlighted as being important in preclinical disease 
in deer calves orally infected with CWD.   Using confocal microscopy the authors 
demonstrated that PrP
Sc appeared to co-localise on membranes associated with FDCs 
and CD21 expressing B lymphocytes (Sigurdson et al., 2002).   CD21 
+ B cells may 
also play a role in scrapie pathogenesis in mice peripherally inoculated with scrapie 
(Frigg et al., 1999; Mabbott et al., 2001) which suggests these cells may be potential 
carriers of the infection.    
 
Variation of cellular PrP levels in blood may occur depending on the TSE disease as 
PrP
c concentration differs in variant and sporadic CJD cases after detection using 
FACS and DELFIA techniques (dissociation enhanced lanthanide fluoroimmunoassay, 
Fagge et al., 2005).     Levels of PrP
C in blood were reduced in vCJD cases.  This may 
be because in vCJD replication of PrP
Sc occurs in the periphery before neuroinvasion 
and whole blood PrP
C may be converted to PrP
Sc as part of the replication process 
involved in disease pathogenesis.  Reduction of PrP
C in whole blood was not seen in 
sporadic CJD cases and this may be due to PrP
Sc being largely confined to the central 
nervous system and replication of PrP
Sc in the periphery before neuroinvasion is not a 
feature of this disease.   
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Variation of PrP
C levels in blood may also occur depending on the PrP genotype of the 
animal.  PrP
C was highly expressed on PBMC subsets of scrapie-susceptible 
VRQ/VRQ sheep, whereas lower levels were observed in scrapie-resistant (ARR/ARR) 
animals (Halliday et al., 2005).  Surprisingly, although hamsters PBMCs do not express 
PrP
c, they are associated with infectivity (Holada et al., 2002). This may imply that 
PrP
C expression is not an absolute requirement for susceptibility to infection. In this 
case, hamster PBMCs may act as carriers, passing the infection to other cell types, 
without replicating the infectious agent themselves. 
 
1.6.5.  Protein markers of disease other than PrP
Sc  
 
A major goal in TSE research is the development of methods which are sensitive 
enough to detect infection and/or PrP
Sc in blood.   However, if PrP
Sc can not be 
detected in blood, it is possible that other molecules may be identified as surrogate 
markers for TSE infection.  In blood, TSE associated biochemical changes in 
metabolites and hormones have been described.  TSE infected hamsters show elevated 
levels of plasma noradrenalin after comparison with control animals (Pollera et al., 
2007).  Moorby and co-workers (2000) sampled blood from 47 healthy and BSE-
infected dairy cows over a 28 week period, and observed increased levels of plasma β-
hydroxybutyrate in diseased animals.  In a follow up study, increased concentrations of 
lactic acid and amino acids were observed in pre-clinical and clinical BSE-infected 
animals (Moorby et al., 2002).   However, changes in metabolite concentrations can be 
attributed to other conditions such as ketosis (Lindner, 1959). 
 
Other novel molecular biomarkers in blood have also been described.  Miele et al., 
(2001) found that transcription of the gene encoding erythroid differentiation related 
factor (EDRF) now known as erythroid-associated factor (ERAF) was down-regulated 
in TSE infected mice.  However, ERAF transcription in healthy individuals was found 
to occur with a high degree of variation which questions the suitability of using ERAF 
as a marker for TSE disease.   Alternatively PrP
Sc binding proteins could be sought such 
as plasminogen which has been shown to discriminate between PrP
Sc  and PrP
C, 
selectively binding to the PK-resistant form of the protein (Fischer et al., 2000).   If  46   
PrP
Sc can not be detected in blood, other markers for TSE infection may form the basis 
of TSE diagnostic tests. 
 
1.7.  Methods of detecting and measuring PrP
c/PrP
Sc 
 
Whilst the detection of proteinase K resistant PrP
Sc is used as a biochemical marker for 
the presence of infectivity, the only available method which formally demonstrates 
infectivity is the bioassay. Here the infectious agent or a particular strain is inoculated 
into another animal (usually mice) to see if the animals develop the same disease and 
the strain characteristics are maintained in primary and secondary passages. These 
assays are limited by effects such as the species barrier and can also take many months 
or years to obtain results. The development of transgenic mice lines is providing ways 
to overcome such limitations (Scott et al., 1997; Yokoyama et al., 2007).  
 
1.7.1.  Immunohistochemistry 
 
Traditional methods used to confirm TSE infection include detection of PrP
Sc using 
immunohistochemistry (IHC). These techniques help give an idea of disease 
pathogenesis and their main advantage is that they allow identification of the cellular 
location of PrP
Sc in tissues. Using such methods infection can often be detected before 
neuroinvasion or the onset of clinical signs (Schreuder et al., 1998). IHC is one of the 
most sensitive methods of detection for PrP
Sc (Grassi, 2002).  PrP
Sc  can be 
distinguished
 from PrP
c by PK treating the tissue section (although PK treatment is not 
used in all methods) and using an antibody that recognises an epitope beyond the PK 
cleavage point. However IHC is not a rapid method and the amount of PrP
Sc deposited 
in tissues cannot be reliably measured. 
 
1.7.2.  Western blotting  
  
Western blotting for detection of PrP
Sc  relies on proteinase K digestion to distinguish 
the abnormal protein from PrP
C. Extracts of PrP
Sc from infected tissues are treated with 
proteinase K, run on an SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel 47   
electrophoresis) gel, transferred to nitrocellulose membrane and then probed using 
specific antibodies to detect undigested PrP (Bolton et al., 1982). After digestion with 
proteinase K, PrP
Sc gives a distinct pattern on Western blots where three distinct bands 
can be identified and resolve between 27-30 kDa.  Hence, the PK resistant core of PrP
Sc 
is called p27-30.  The three distinct bands represent differential glycosylation as PrP 
has two sites at which carbohydrates can be attached. The diglycosylated form exists 
when both sites are occupied, monoglycosylated forms occur when either one of the 
two sites are occupied, and unglycosylated forms occur when no sites are occupied 
(Collinge et al., 1996).   
 
Efforts made to enhance Western blot sensitivity include concentrating PrP
Sc  by 
precipitation with sodium phosphotungstic acid (NaPTA). In a recent study adopting 
this step sensitivity was increased up to three-fold, allowing for the identification of 
extraneural abnormal PrP in spleen and muscle from sporadic CJD victims (Glatzel et 
al., 2003). Despite these advances, PrP
Sc has not to date been detected in blood by 
Western blot.  However this method can be very sensitive for PrP
Sc detection (Lee et 
al., 2000) and is a relatively rapid method compared to the bioassay.  
 
1.7.3.  Sandwich immunoassays 
 
More recently, immunoassays have been developed using the sandwich principle in 
which monoclonal antibodies are used for antigen (PrP) capture and detection e.g. an 
enzyme-linked immunosorbent assay (ELISA, Korth et al., 1999), dissociation-
enhanced lanthanide fluorescence immunoassay (DELFIA, Barnard et al., 2000) or 
conformation-dependent immunoassay (CDI, Safar et al., 1998; McCutcheon et al., 
2005). In ELISAs an enzymatic reaction measures PrP, whereas in DELFIA systems 
the detection is based on formation of a fluorescent chelate (Safar et al., 1998). 
DELFIA and CDI use denaturation with guanidinium hydrochloride, rather than PK-
resistance to distinguish between cellular and disease associated PrP. The basis of the 
CDI is that the detector antibody recognises an epitope that is always exposed in PrP
c, 
but only becomes exposed in PrP
Sc following denaturation. As a result of this PrP
Sc can 48   
be identified and measured by comparing antibody binding to denatured and native 
forms of the prion protein.  
 
1.7.4.  PrP
Sc specific antibodies 
 
One main focus in TSE research is the development of monoclonal antibodies that can 
specifically bind to PrP
Sc and not PrP
c. However despite early reports it has proved 
difficult to discriminate between the two isoforms using antibodies (Korth et al., 1999).  
Antibodies directed against tyrosine-tyrosine-arginine (YYR) motifs have been 
reported as being capable of selectively detecting PrP
Sc (Paramithiotis et al., 2003). 
However, YYR motifs are not unique to pathological prion proteins. Antibodies 
binding epitopes comprising residues 96-104 and 133-158 of cellular PrP have been 
shown to inhibit conversion of PrP
c to PrP
Sc.  Moroncini and co-workers grafted PrP 
sequence motifs corresponding to these regions into a recipient antibody scaffold.  This 
resulted in the production of motif-grafted antibodies specific for disease-associated 
PrP (Moroncini et al., 2004).  PrP
Sc specific antibodies (which are not generally 
available) are tested by methods not dependent on PK digestion or denaturation of the 
protein such as immunoprecipitation.  If conformational antibodies can be produced the 
sensitivity of methods may be increased and more direct assays for PrP
Sc detection may 
emerge. 
 
1.7.5.  Cell lines 
 
Cultured cells persistently infected with scrapie offer a convenient system to study the 
biogenesis of the prion protein isoforms (Taraboulos et al., 1990).  Only a few cell lines 
have been established in vitro that continuously produce low levels of PrP
Sc. These 
include the scrapie-infected mouse neuroblastoma-derived  ScMNB and ScN2a cells 
(Race et al., 1987; Butler et al., 1988) and the HaB line, derived from the culture of a 
Syrian hamster brain (Taraboulos et al., 1990).  The SMB cell line is also well 
established (Clarke and Haig, 1970, 1971; Birkett et al., 2001).  Methods utilising such 
models have enabled the development of highly sensitive cell-based infectivity assays 
comparable to mouse bioassays (Klohn et al., 2003). In such assays uninfected 49   
susceptible cell lines can be incubated with TSE infected brain and the transmission of 
infectious agent to the cells measured.  Infected cells can be quantified by visualizing 
single PrP
Sc positive cells by an ELISA based method.  Alternatively, infected cells can 
be cultured and the number of PrP
Sc positive colonies determined using cell blotting 
techniques.  The infectivity titres measured in tissue culture and in the mouse are 
similar and if the method can be applied to more than one mouse scrapie strain, cellular 
components, in addition to tissue homogenates, could be used to assess the sensitivity 
of other methods (for instance Western blots) (Klohn et al., 2003).  
 
1.8.  Progress of TSE diagnostic tools 
 
Accurate pre-mortem tests using IHC on lymphoid tissues (tonsil, 3
rd eyelid and rectal 
mucosa) exist, although such tests do not always have the required sensitivity for 
detection (Gonzalez et al., 2008).  Therefore, a definitive TSE diagnosis can only be 
made post-mortem.  Following the BSE epidemic in the UK in the 1980s, the European 
Commission implemented a system to evaluate and validate biochemical tests that 
could rapidly detect infected animals.  Currently, five post-mortem BSE detection tests 
have been approved, which all rely on immunodetection of PrP
Sc in brain tissue.  The 
principle behind each test, the advantages and disadvantages and the detection limits of 
each are outlined in table 1.5. 
 
Based on estimated sensitivities (table 1.5) the ability of these current tests to detect 
individuals during pre-clinical stages of infection is unlikely.  Although all these 
current tests detect PrP
Sc in the brain, they do not have the required sensitivity of 
detection for use with other tissues or fluids, including blood.    
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Technique Principle  Detection  limit Advantages  Disadvantages 
Prionics-Check Western 
test 
Gel electrophoresis and 
Western blot 
5-20 pmol  Good reproducibility, low 
rate of false-positives  
Low throughput, low 
sensitivity  
Enfer test  Simple ELISA  1-10 pmol  Rapid and simple  Potential for false-
positives 
CEA/Biorad test  Sandwich ELISA using 
two different antibodies 
0.5-2 pmol  High sensitivity  Longer and more 
laborious, potential for 
false-positives 
Prionics-Check LIA test  Sandwich ELISA using 
two different antibodies 
1-5 pmol  Rapid, automated, simple  Variability depending on 
sample preparation, 
potential for false-
positives  
Conformational-
dependent immunoassay 
(CDI) 
Differential antibody 
binding to native and 
denatured PrP
Sc 
0.5-5 pmol  Independent of protease 
digestion, high sensitivity 
Complicated and involves 
more steps than other 
tests 
IDEXX BSE-Scrapie EIA  Seprion-capture 
technology applied to a 
microtiter plate format. 
Detects classical scrapie 
brain diluted 1:4000 
A single test kit can be 
used to test cattle, sheep, 
goat samples. 
Relatively expensive. 
Prionics –Check LIA  ELISA based  -  Suitable for processing 
sample volumes of 
several hundred assays or 
more per day. 
Low sensitivity. 
 
Table 1.5:  Summary of the tests currently approved for post-mortem detection of PrP
Sc in cattle brain.  This table has been taken 
from Soto, 2004.  The detection limits are based on the estimates reported in previous publications, (Brown et al., 2001; Ingrosso et al., 
2002).51   
 
Technique Principle  Detection  limit Advantages  Disadvantages 
Prionics-Check Prio-Strip  Lateral flow technology  -  Cost effective. Unique 8-
strip format. 
Low sensitivity. 
 
 
 
HerdChek BSE Test BSE  No PK digestion and uses 
an aggregate specific 
capture ligand on a 
dextran polymer of PrPSc 
which after denaturation 
is detected using an anti-
PrP antibody. 
-  New technology with 
potential for greater 
sensitivity. 
Relatively expensive. 
 
 
Table 1.5:  Summary of the tests currently approved for post-mortem detection of PrP
Sc in cattle brain.  This table has been taken 
from Soto, 2004.  The detection limits are based on the estimates reported in previous publications, (Brown et al., 2001; Ingrosso et al., 
2002).52   
 
1.8.1.  Current status of TSE blood tests 
 
Infectivity studies in rodents show that high concentrations of infectivity reside in the 
buffy coat fraction of blood, where a level of 5-10 infectious units (IU) ml
-1 can be 
present during the incubation period and up to 100 IU ml
-1 at the onset of clinical signs 
(Brown et al., 1998; Brown, 2001; Cervenakova et al., 2003; Holada et al., 2002).  
Levels of infectivity in plasma and red cells are estimated to be a least 5-10 times lower 
than in buffy coat (Brown et al., 1998).  This means that blood tests using PrP
Sc as a 
marker for infectivity would have to detect the protein in the femtomolar concentration 
range.  The detection tests currently available are still approximately 2-4 orders of 
magnitude away from reaching the sensitivities required for clinical and pre-clinical 
blood detection (table 1.5).  However, recently many companies and research groups 
have used novel strategies to try to overcome this problem.   
 
1.8.2.  Specific ligands 
 
Ligands that are able to bind specificity to PrP
Sc could be used to concentrate abnormal 
PrP by immunoprecipitation techniques.  Such ligands include plasminogen (Fischer et 
al., 2000), RNA (Weiss et al., 1997), the 15B3 antibody produced by Prionics (Korth et 
al., 1997) and the Seprion ligand developed by Microsens Biotechnologies (Oliver et 
al., 2006).  PrP
Sc concentration using specific ligands could be combined with an 
ELISA-based immunoassay or Western blotting to increase overall sensitivity of these 
methods.  However, not all ligands may be suitable for TSE diagnosis, for example it 
has been reported that plasminogen has a high affinity for PrP
C (Shaked et al., 2002; 
Kornblatt et al., 2003) and therefore may not bind specifically to PrP
Sc.    
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1.8.3.  AS-ELISA 
 
Aggregate specific ELISAs, termed AS-ELISAs, are immunoassays where the same 
monoclonal antibody is used for capture and detection, and which have been developed 
to detect polymerised PrP (Pan et al., 2005).  Overall sensitivity is increased using a 
combination of signal amplification (fluorescence) and amplification of PrP
Sc using a 
simplified PMCA like procedure.  AS-ELISA methods have enabled detection of PrP
Sc 
aggregates in clinical plasma from mice or deer infected with scrapie or CWD (Chang 
et al., 2007).  However, to allow licensing as a diagnostic/screening test, these methods 
need to be successfully applied to pre-clinical blood samples to establish if the 
necessary levels of sensitivity and specificity can be achieved.     
 
1.8.4.  Conformationally sensitive peptides 
 
Recently, fluorescence labelled palindromic PrP peptides have been developed and 
used to detect misfolded prion protein in clinical TSE-infected plasma.  In this 
approach, when the labelled peptide is in contact with PrP
Sc, it undergoes a large coil to 
a  β-sheet conformational change which largely modifies the properties of the 
fluorescent label.  Fluorescence is then measured which allows for discrimination 
between TSE infected and uninfected animals (Pan et al., 2007).  Similar to AS-ELISA, 
further testing is required on pre-clinical samples to assess suitability as an effective 
TSE diagnostic test.    
 
1.8.5  Other approaches 
 
Several other techniques may be used to increase the sensitivity of PrP
Sc for detection 
in blood.  These include the use of NaPTA to concentrate PrP prior to Western blotting 
(described in Chapter 3) and PMCA technology which has be used to detect PrP
Sc in 
pre-clinical blood samples (Castilla et al., 2005; Saá et al., 2006).  Additionally, more 
complicated methods requiring a high level of skill to measure and interpret results 
have also been described such as fourier-transformed infrared spectroscopy (FTIR) 
(Lasch et al., 2003). 54   
1.8.6.  Summary 
 
Although current diagnostic tests do not have the required sensitivity to be applied to 
blood samples, some of the newer strategies remain promising for the early detection of 
pre-clinical TSE-infected individuals.  Blood diagnostic tests are of particular 
importance for ensuring the safety of blood transfusion in countries that have 
experienced large BSE epidemics (UK and Western Europe).  Therefore, the 
development of a TSE blood test remains a major goal in the field of TSE research.  In 
order to achieve this goal, further knowledge of the mechanisms of TSE disease 
pathogenesis is required.  For instance, it is not yet known which blood cells may be 
involved in replication and spread of the TSE agent within the body prior to 
neuroinvasion.  If the blood cells that contribute to spread of infection can be identified, 
these findings may aid in the development of pre-mortem blood diagnostic tests.     
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1.9.  Thesis Aims 
 
TSE transmission via  blood transfusion has been demonstrated experimentally in 
rodent, primate and sheep models.  More concerning however, is the reporting of four 
human vCJD cases occurring as a result of infected blood transfusions.  Despite a 
wealth of research within this area, little is known about which cells are involved in the 
replication of the TSE agent and once “infected”, how infectivity is spread throughout 
the body prior to neuroinvasion.   
 
Detection of PK-resistant PrP
Sc is used as a biochemical marker for the presence of 
infectivity.  The aim of this thesis was to use PrP
Sc as a marker for TSE infection in 
blood, and to determine which blood cells may be responsible for harbouring/ 
spreading infection throughout the body.  The difficulty here lies with the fact that 
conventional forms of PK-resistant PrP
Sc may not be detectable in blood and also that if 
they are, then levels may be very low (against a high background of PrP
C).   
 
Preliminary aims were to give a definitive answer to the question of whether 
conventional PK-resistant PrP
Sc is present in TSE-infected sheep blood in sufficient 
quantities to explain the infectivity levels shown by bioassay.  It was first therefore 
necessary to develop and optimise a sensitive Western blot immunoassay for 
conventional PK-resistant PrP
Sc using scrapie-infected sheep brain homogenates. 
 
Secondary aims were to apply this immunoassay to blood cell subsets.  By determining 
which cells are associated with infectivity and/or PrP
Sc it may be that underlying 
mechanisms of pathogenesis would be revealed.  Of course, it may be the case that 
PrP
Sc is simply not a suitable marker for TSE infection, as evidence would suggest that 
this protein doesn’t always correlate with TSE infection.  Therefore, another aim of the 
project was to investigate the role of other protein markers in TSE pathogenesis within 
the blood system. 
 
By taking these combined approaches, it is hoped that the nature of conventional PK-
resistant PrP
Sc in blood may be better characterised, and it will be determined whether 56   
conventional PrP
Sc correlates with infectivity.  Additionally, mechanisms of TSE 
disease pathogenesis may be revealed, particularly which blood cells contribute to 
spread of infection within the body.  Finally, such findings may aid in the development 
of pre-mortem blood diagnostic tests and the effectiveness of control measures 
currently used by the National Blood Service to safeguard the UK blood supply could 
also be assessed.          
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Chapter 2 
Materials And Methods 
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2.1.  Materials 
 
2.1.1.  Animal tissues 
 
Brains from Cheviot sheep (genotype VRQ/VRQ) infected with natural scrapie, 
SSBP/1 scrapie or uninfected (controls) were obtained from Dr F. Houston (Glasgow 
University).  Mouse brains infected with 139 A scrapie strain were obtained from R. 
Hennion (IAH, Compton).  All brain samples were stored at – 80 ºC. 
  
Starting blood volumes of 50 ml from sixteen different uninfected and fourteen 
different clinical SSBP/1 infected Cheviot sheep (genotypes VRQ/VRQ, VRQ/ARR) 
were obtained from Dr F. Houston (Glasgow University). A 50 ml sample of pre-
clinical BSE infected blood from one Cheviot sheep (ARQ/ARQ) was also obtained 
from Dr S. McCutcheon (Roslin Institute).  Control animals were inoculated with 2 ml 
of normal 10% (w/v) sheep brain homogenate (1 ml injected subcutaneously into each 
medial thigh).  Experimentally infected sheep were inoculated subcutaneously with 2 
ml scrapie sheep brain pool 1 (SSBP/1) 10% (w/v) brain homogenate in the same way.  
BSE infected sheep were orally inoculated with 5 g (w/v) of bovine BSE brain.   
 
The 50 ml samples of uninfected and SSBP/1 scrapie infected blood were collected in 
Falcon tubes containing 60 mM ethylenediaminetetraacetic acid (EDTA).  The 50 ml 
sample of pre-clinical BSE infected blood was obtained at 10-11 months post challenge 
and collected from a bag containing 12 % (w/v) citrate phosphate dextrose (CPD-1) 
anticoagulant.  All blood samples were used immediately or stored at – 80 º C or – 20 º 
C. The number of buffy coat or PBMC cells obtained from 50 ml of blood fluctuated 
between different sheep but ranged from between 1 x 10
6 to 1 x 10
8 cells.  All animals 
were housed in accordance with Home Office guidelines, and were killed after the 
development of clinical signs of scrapie. 
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2.1.2.  Antibodies 
 
The panel of novel PrP specific monoclonal antibodies described in this thesis were 
generously donated by Dr S. McCutcheon (Roslin Institute) (paper in preparation).   
Further information on antibodies, including the immunogen they were raised against, 
dilutions used and suppliers are tabulated in Appendix 1. 
 
2.1.3.  Chemical reagents 
 
All chemicals were analytical grade and supplied by Sigma Aldrich Co. UK; BDH Ltd 
UK; Gibco, UK; Invitrogen, UK; Amersham Biosciences UK; GE Healthcare, UK, 
except where stated. 
 
2.1.4.  Enzymes 
 
Porcine trypsin containing 0.02 % (w/v) EDTA and proteinase K (PK) enzymes were 
obtained from Sigma Aldrich Co. UK.  Porcine trypsin was also obtained from 
Promega, USA.  Benzonase (Benzon nuclease, purity 1) was obtained from Merck, 
Germany and deoxyribonuclease (DNase) type I from Sigma Aldrich Co. UK.   
 
2.1.5.  Magnetic beads 
 
Magnetic beads conjugated to immunoglobulin isotype-specific rat anti-mouse 
antibodies (Miltenyi Biotech, USA) were used to sort leucocyte cell populations.   
 
2.1.6.  Monoclonal antibody purification 
 
BC6 antibody was obtained from Dr S. McCutcheon (Roslin Institute) or purified as 
below.  BC6 culture fluid was centrifuged at 1000 g for 5 min and adjusted to pH 8.0 
by the addition of one tenth volume of neutralisation buffer (see section 2.2.6).  A 
HiTrap protein G column was pre-equilibrated with wash buffer (see section 2.2.6) 
before loading with neutralised BC6 culture fluid.  The column was washed with 50 ml   60
wash buffer and purified antibody was eluted with 7- 10 ml elution buffer (see section 
2.2.6).  Purified antibody was neutralised by the addition of one tenth volume of 
neutralisation buffer.  After determining concentration using a Beckman DU 650 
spectrophotometer, purified antibody was dialysed overnight in PBS (see section 2.2.3) 
using pre-prepared dialysis tubing with a 15,000 molecular weight cut off. PBS was 
changed twice after which purified antibody was stored at a concentration of 1 µg/ml at 
4 º C.   
 
2.1.7.  Recombinant protein 
 
Full length ARR genotype α-conformation recombinant ovine PrP (residues 25-233) at 
a concentration of 0.82 µg/ml was kindly provided by Dr A.C. Gill (Roslin Institute) 
for use in BC6 antibody blocking studies.  BC6 (1 µg/ml) was incubated with 830 µl of 
full length ARR alpha recombinant ovine PrP protein (0.82 µg/ml) for 1 hr with 
agitation.  After further incubation for 1 hr in antibody binding buffer (used in Western 
blotting, section 2.2.15) this mixture was added to nitrocellulose immobilon-P transfer 
membranes (Millpore, USA) containing protein from uninfected PBMCs and brain with 
and without NaPTA precipitation.  Membranes were incubated overnight before 
Western blotting as described in chapter 2, section 2.3.5.5. 
 
2.1.8.  Scrapie mouse brain (SMB) cell lines 
 
The SMBs15 (scrapie-infected) and SMB-PS (cured of infection with pentosan 
sulphate) cell lines (Clarke and Haig, 1970) were obtained from the TSE Resource 
Centre at IAH, Compton.  All cells were cultured at 37 º C, used immediately or stored 
in liquid nitrogen or – 20 º C.    
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2.2.  Solutions, buffers and media 
 
All solutions were made using sterile double distilled Milli-Q water, except where 
stated otherwise. 
 
2.2.1.  Coomassie staining solutions (for mass spectrometry) 
 
Coomassie fixative: 45 % (v/v) methanol, 1 % (v/v) glacial acetic acid. 
 
 Coomassie stain:  34 % (v/v) methanol, 17 % (w/v) ammonium sulphate, 0.5 % (v/v) 
glacial acetic acid, 0.1 % (w/v) coomassie brilliant blue R250. 
 
2.2.2.  Coomassie staining solutions (for 1-D SDS-PAGE) 
 
Coomassie stain: 40 % (v/v) methanol, 10 % (v/v) glacial acetic acid, 0.1 % (w/v)  
coomassie brilliant blue R250. 
 
Destain:  20 % (v/v) methanol, 5 % (v/v) glacial acetic acid. 
 
2.2.3.  Fluorescence activated cell sorting (FACS) solutions and buffers  
 
FACS fixative: 1 % (w/v) paraformaldehyde in phosphate buffered saline (PBS). 
 
PBS: 80 mM disodium hydrogen orthophosphate, 26 mM potassium chloride, 14 mM 
monopotassium phosphate, 1.4 mM sodium chloride.  
 
FACS wash buffer: 1 % (w/v) bovine serum albumin (BSA) 0.1 % (w/v) sodium azide 
in PBS. 
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2.2.4.  Lysis buffers 
 
Ammonium chloride lysis buffer: 155 mM ammonium chloride, 10 mM potassium 
hydrogen carbonate, 0.1 mM EDTA in PBS. Adjust to pH 7.2 with 1M sodium 
hydroxide.   
 
Brain lysis buffer: 1 % (v/v) Igepal, 1 % (w/v) sodium-deoxycholic monohydrate. 
 
Cell lysis buffer: 100 mM sodium chloride, 10 mM Tris-HCL pH 7.8, 10 mM EDTA, 
0.5 % (v/v) igepal, 0.5 % (v/v) sodium deoxycholate, 1 complete EDTA-free protease 
inhibitor tablet (Roche, UK) for each 50 ml cell lysis buffer.   
 
2.2.5.  Magnetic activated cell sorting (MACS) buffers 
 
MACS wash buffer:  1 % (w/v) BSA in PBS. 
 
2.2.6.  Monoclonal antibody purification buffers 
 
Elution buffer: 0.75 % (w/v) glycine.  Adjust to pH 2.3 with 1 M HCL. 
 
Neutralisation buffer: 12.13 % (w/v) Tris (free base). Adjust to pH 8 with 1 M HCL. 
 
Wash buffer: 1.2 % (w/v) Tris (free base).  Adjust to pH 8 with 1 M HCL.  
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2.2.7.  Protein digestion and peptide extraction buffers  
 
Digestion buffer 1: 50 mM ammonium bicarbonate, 5 mM calcium chloride, 0.013 % 
(w/v) porcine trypsin (Promega, USA). 
 
Digestion buffer 2: 50 mM ammonium bicarbonate, 5 mM calcium chloride. 
 
Reduction buffer 1: 100 mM ammonium bicarbonate, 10 mM dithiothreitol. 
 
Reduction buffer 2:  100 mM ammonium bicarbonate, 55 mM iodoacetamide. 
 
2.2.8.  Sodium phosphotungstic acid (NaPTA) buffers 
 
Benzonase/DNase buffer: 1 mM magnesium chloride, 50 units/ml benzonase, 0.5 % 
(w/v) DNase in PBS. 
 
  Magnesium chloride buffer: 1 mM magnesium chloride, 50 units/ml Benzonase in 
PBS. 
 
Sodium N-lauroylsarcosinate buffer : 4 % (v/v) sodium N-lauroylsarcosinate in PBS. 
 
NaPTA  stock buffer: 170 mM magnesium chloride, 4 % (w/v) NaPTA in PBS. 
 
NaPTA wash buffer 1: 12.5 mM EDTA, 0.1 % (v/v) sarcosyl in PBS. 
 
NaPTA wash buffer 2: 0.1 % (v/v) sarcosyl in PBS. 
 
 
 
 
   64
 
2.2.9.  Sodium dodecyl sulphate – polyacrylamide gel electrophoresis buffers  
(1D SDS-PAGE) 
 
NuPAGE running buffer (20 X): 50 mM Tris-HCL pH 8.3, 0.5 mM glycine, 0.1 % 
(w/v) SDS. 
 
NuPAGE sample buffer (4 X):  8 M urea, 65 mM Tris-HCL pH 6.8, 5 % (w/v) SDS, 5 
% (v/v) glycerol, 5 % (v/v) β – mercaptoethanol, 0.01 % (w/v) bromophenol blue. 
 
2.2.10.  Sodium dodecyl sulphate – polyacrylamide gel electrophoresis solutions 
and buffers (2D SDS-PAGE) 
 
Agarose sealing solution: 192 mM glycine, 25 mM Tris base, 0.1 % (w/v) SDS. 
 
DeStreak rehydration buffer: Manufactured by GE Healthcare but contains optimized 
concentrations of urea, thiourea, 3-[(3-cholamidopropyl) dimethylammonio]  - 1 - 
propanesulfonate (CHAPS) and DeStreak Reagent. 
 
SDS equilibration buffer: 6 M urea, 75 mM Tris-HCL pH 8.8, 29.3 % (w/v) glycerol, 2 
% (w/v) SDS, 0.002 % (w/v) bromophenol blue.  
 
Running buffer (10 X): 1.92 M glycine, 250 mM Tris base, 1 % (w/v) SDS. 
 
Sample preparation solution: 7 M urea, 2 M thiourea, 30 mM Tris-HCL pH 8.5, 4 % 
(w/v) CHAPS, one complete EDTA-free protease inhibitor tablet (Roche, UK). 
 
Wash buffer: 30 mM Tris-HCL pH 8.5. 
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2.2.11.  Silver staining solutions (1D PAGE) 
 
Fixative: 50 % (v/v) ethanol, 10 % (v/v) glacial acetic acid. 
 
Pre - sensitising: 5 % (v/v) ethanol, 1 % (v/v) glacial acetic acid. 
 
Sensitising: 0.02 % sodium thiosulphate pentahydrate. 
 
Silver reaction: 0.2 % (w/v) silver nitrate, 0.029 % (w/v) formaldehyde (Fluka, 
Switzerland). 
 
Developing:  6 % (w/v) sodium carbonate, 0.029 % (w/v) formaldehyde (Fluka, 
Switzerland).  
 
Stopping: 5 % (v/v) glacial acetic acid. 
 
2.2.12.  Silver staining solutions (2D PAGE) 
 
Fixative: 30 % (v/v) ethanol, 10 % glacial acetic acid. 
 
Sensitising:  30 % (v/v) ethanol, 0.5 % (v/v) glutaraldehyde, 0.2 % (w/v) sodium 
thiosulphate, 8.8 % (w/v) sodium acetate. 
 
Silver reaction: 0.25 % (w/v) silver nitrate, 0.058 % (w/v) formaldehyde (Fluka, 
Switzerland). 
 
Developing:  2.5 % (w/v) sodium carbonate, 0.12 % (w/v) formaldehyde (Fluka, 
Switzerland). 
 
Stopping: 1.46 % (w/v) EDTA sodium salt. 
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2.2.13.  Scrapie mouse brain (SMB) cell culture solutions 
 
SMBs15 and SMB-PS cell growth media: Medium 199 with Earle’s salts, 10 mM L-
glutamine, 10 % (v/v) newborn calf serum, 5 % (v/v) foetal calf serum (PAA 
laboratories, UK) 0.1 % (w/v) streptomycin, 0.1 % (w/v) penicillin. 
 
Trypsin/EDTA Solution: 0.05 % (w/v) porcine  trypsin, 0.02 % (w/v) EDTA. Made in 
PBS. 
 
Freezing media: 90 % (v/v) foetal calf serum (PAA laboratories, UK) 10 % (v/v) 
dimethylsulphoxide (DMSO). 
 
2.2.14.  SYPRO
® orange staining solutions 
 
Fixative: 40 % (v/v) ethanol, 2 % (v/v) glacial acetic acid, 0.0005 % (w/v) SDS. 
 
Pre-stain wash: 2 % (v/v) glacial acetic acid, 0.0005 % (w/v) SDS. 
 
SYPRO
® orange reaction: 0.05 % (w/v) SYPRO
® orange (Molecular probes, UK). 
 
2.2.15.  Western blotting buffers 
 
Antibody binding buffer: 0.5 % (w/v) dried skimmed milk (Marvel, Premier Brands, 
UK) in PBS-Tween. 
 
Blocking buffer: 5 % (w/v) Marvel in PBS-Tween. 
 
PBS-Tween:  0.05 % (v/v) Tween-20 in PBS. 
 
Transfer buffer (1 X): 25 mM Bicine, 25 mM Bis-Tris, 1 mM EDTA, 20 % (v/v) 
methanol.   67
2.3.  Methods 
 
All steps were performed at room temperature unless otherwise stated. 
 
2.3.1.  Brain tissue methods 
 
2.3.1.1.  Brain homogenisation 
 
Scrapie-infected and uninfected half brains were chopped into small pieces and 
homogenised in phosphate buffered saline (PBS) (see section 2.2.3) (20 % w/v) using 
an electronic homogeniser (Camlab, UK).  Uninfected brain homogenates were pooled, 
aliquotted into 5 ml volumes and stored at – 80 º C.  Scrapie brain homogenates were 
aliquotted into 1 ml volumes (without pooling) and stored at – 80 º C.   
 
2.3.1.2.  Serial dilutions of brain homogenate 
 
Brain homogenate pellets containing 200 mg wet brain tissue were diluted in PBS (see 
section 2.2.3) to give wet tissue equivalents of 2500 µg, 1250 µg, 625 µg, 313 µg, 156 
µg, 78 µg, 19 µg, 9 µg, and 4.5 µg.  For Western blotting of this standard dilution 
series see Appendix 2.  
 
To prepare scrapie brain spikes (where small volumes of infected brain homogenate are 
diluted into larger volumes of uninfected brain homogenate) 20 % (w/v) scrapie brain 
homogenate was spiked into a 200 µl final volume, using 10 % (w/v) normal brain 
homogenate as diluent, to give final concentrations of 10 %, 1 %, 0.1 %, 0.01 % and 
0.001 % scrapie brain.  The respective wet tissue equivalents were 20 mg (10 %), 2 mg 
(1 %), 0.2 mg (0.1 %), 0.02 mg (0.01 %) and 0.002 mg (0.001 %).  In each case the 
total amount of wet tissue (scrapie brain spike and normal brain homogenate combined) 
was made to 20 mg in a volume of 200 µl. Scrapie brain spikes described above were 
added to 300 µl 10 % uninfected brain homogenate (30 mg wet tissue) giving in each 
case a total sample volume of 500µl containing 50 mg total wet tissue. After sonication 
samples were proteinase K (PK) digested, sodium phosphotungstic acid (NaPTA)   68
precipitated and analysed by Western blotting after sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE).  
 
2.3.1.3.  Storage conditions of brain homogenate 
 
Brain homogenates were stored at – 80 º C or – 20 º C unless otherwise stated.  The 
efficiency of storing brain homogenates under these conditions was tested by Western 
blotting as shown in Appendix 3. 
 
2.3.2.  Preparation of scrapie mouse brain (SMB) cells 
 
2.3.2.1.  SMB cell culture 
 
SMBs15 and SMB-PS cells were grown in T75 flasks (Costar,UK) in SMB cell growth 
media (see section 2.2.13) under 5 % (v/v) CO2 in air, 95 % relative humidity at 37 º C 
until 70 % confluent.  To remove cells from flasks 2 ml of trypsin/EDTA solution (see 
section 2.2.13) was added for 3-5 min before the addition of 10 ml of SMB cell growth 
media.  Cells were centrifuged for 5 min at 100 g, counted and seeded at a density of 
1.2 x 10
4 cells/cm
2.   
 
2.3.2.2.  SMB cell thawing and freezing 
 
Freezing SMBs15 and SMB-PS cells: Cells grown to 70 % confluency were removed 
from T75 flasks (Costar, UK) after incubation with 2 ml of trypsin/EDTA solution (see 
section 2.2.13).  After centrifugation for 5 min at 100 g, cells were resuspended in 2 ml 
freezing media (see section 2.2.13) transferred to 2 cryovials and frozen for 24 h at – 80 
º C, followed by storage in liquid nitrogen.  
 
Thawing SMBs15 and SMB-PS cells: Cells were thawed by submerging the cryovials 
in a 37 º C water bath for 3 min.  Cells were then added to 12 ml of pre-warmed SMB 
cell growth media (see section 2.2.13).  After centrifugation at 100 g for 5 min, cells   69
resuspended in 5 ml SMB cell growth media were seeded into a single T75 flask 
containing 15 ml SMB cell growth media. 
 
2.3.3.  Preparation of leukocytes 
 
2.3.3.1.  Buffy coat isolation from blood 
 
Blood (50 ml) was centrifuged for 15 min, 500 g at 4 º C.  Three distinct layers form 
corresponding to plasma, buffy coat interface and red cells.  Buffy coat at the gradient 
interface was collected by gentle pipetting.  To remove contaminating red cells from 
the buffy coat fraction 50 ml of ammonium chloride lysis buffer (see section 2.2.4) was 
added for 10 min at RT, followed by centrifugation at 300 g for 10 min at 4 º C.  Buffy 
coat cells (mainly leucocytes including mononuclear cells and granulocytes) were 
washed twice by resuspending in 50 ml PBS (see section 2.2.3) and centrifugation for 5 
min, 300 g at 4 º C.  Cell pellets at a concentration of 1 x 10
8 or 1 x 10
7 cells were 
frozen at – 80 º C after snap freezing in liquid nitrogen.   
 
2.3.3.2.  Peripheral blood mononuclear cell (PBMC) isolation from whole blood 
 
Whole blood was diluted with an equal volume of PBS (see section 2.2.3) underlaid 
with Histopaque (density 1.083 g ml 
-1) and centrifuged (with no brake) at 1000 g for 
30 min.  PBMCs, at the gradient interface, were collected, incubated in ammonium 
chloride lysis buffer (see section 2.2.4) for 10 min, to lyse contaminating red cells and 
centrifuged at 300 g for 10 min at 4 º C.  PBMCs were washed three times in 50 ml 
PBS by centrifugation at 100 g for 30 min.  PBMC pellets were stored at – 80 º C. 
 
2.3.3.3.  Cell counting 
 
After positioning a clean coverslip on a haemocytometer (Neubauer, Germany) 50 µl of 
cell suspension (in PBS) was pipetted into the haemocytometer chamber.  If the 
concentration of cells covered approximately 50 % microscope field (at 40x 
magnification) the cells were counted, if not the sample was centrifuged for 5 min at   70
300 g and resuspended in a more appropriate volume. Once cells were well distributed 
all those in squares within the 1 mm
2 ruled area in the centre of the chamber were 
counted.  Cells touching or lying on the top and right boundary lines were not counted. 
Cells touching or lying on the bottom or left boundary lines were included in the 
counts.  
 
Cell viability/ trypan blue staining:  Before counting 50 µl of cell suspension (in PBS) 
was added to 50 µl undiluted trypan blue to assess cell viability.   
After 2 separate counts cell suspensions were centrifuged for 5 min at 300 g, cell 
pellets frozen at – 80 º C or – 20 º C, or used immediately for SDS-PAGE analysis after 
cell lysis.  
 
2.3.3.4.  Leukocyte cell sorting 
 
Cells (5 x 10
7 – 3 x 10
8) were incubated in primary antibody (tabulated in Appendix 1) 
diluted in magnetic activated cell sorting (MACS) wash buffer (see section 2.2.5) (2 
ml) for 10 min.  Cells were washed once in MACS wash buffer before centrifugation at 
100 g for 5 min.   Cell pellets were then resuspended in 20 µl of immunoglobulin 
isotype-specific rat anti-mouse antibodies conjugated with magnetic beads (Miltenyi 
Biotec, USA) per 10
7 cells for an additional 10 min.  After washing as above, cells were 
separated using a magnetic cell sorter with MACS mini columns and a MACS mini 
separator (MACS Magnetic Cell Sorting Systems; Miltenyi Biotec, USA).  Prior to cell 
sorting, MACS mini columns were washed with 3 ml MACS wash buffer.  Cells were 
then passed through the column, washed three times with 3 ml MACS wash buffer, 
before the column was removed from the MACS mini separator and cells eluted into 5 
ml of MACS wash buffer.    Unlabelled and labelled cells were counted, centrifuged at 
100 g for 5 min and cell pellets were frozen at – 80 °C.   
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2.3.3.5.  Flow cytometry staining and acquisition 
 
Cells (1 x 10
5 – 1 x 10
6 per well) were transferred to 96 well U-shaped plates and 
incubated in primary antibody diluted in fluorescence activated cell sorting (FACS) 
wash buffer (see section 2.2.3) (25 µl) for 10 min.  Information on antibodies and 
working dilutions are tabulated in Appendix 1.  Following incubation, cells were 
washed three times in FACS wash buffer, with a centrifugation step of 2 min at 100 g 
after each wash.  Cells were incubated for 10 min with isotype-specific secondary 
antibodies, then washed twice as above.    Cells were resuspended in 100 µl FACS 
fixative (see section 2.2.3) and stored overnight at 4 ° C before analysis.  Samples were 
analysed as described by Barclay et al., (2002) on a flow cytometer (FACSCalibur; 
Becton Dickinson) using CELLQuest software (Becton Dickinson).  Software used for 
analysis was FACS Express version 3.  For each sample studied a minimum of 10,000 
events was acquired by appropriate gating based on light-scattering characteristics 
and/or expression of cell specific markers.    
 
2.3.3.6.  Leukocyte freezing and thawing 
 
Freezing leukocytes:  Buffy coat cells at a concentration of 1 x 10
8 cells / ml or   1 x 
10
7 cells / ml, PBMCs and T cells at a concentration of 1 x 10
7 cells / ml, and B cells at 
a concentration of 1 x 10
6 cells /ml were resuspended in 1 ml of freezing media (see 
section 2.2.13) before storage at – 80 º C for 24 hr in cryovials (Nalgene, UK).   
Cryovials were transferred to liquid nitrogen for long term storage.  Cell pellets at a 
concentration of 1 x 10
8,
 1 x 10
7 and 1 x 10
6 were also frozen at – 80 º C or – 20 º C. 
 
Thawing leukocytes: Cells were thawed by submerging the cryovials in a 37 º C water 
bath for 3 min.   
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2.3.4.  Sample preparation for protein analysis on Western blots 
 
2.3.4.1.  Lysis of brain homogenates    
 
Brain homogenates (10 and 20 %) (w/v) were incubated with an equal volume of brain 
lysis buffer (see section 2.2.4) for 10 min at 37 º C.  After centrifugation at 1500 g for 5 
min supernatant was transferred to a new eppendorf tube and stored at – 20 º C. 
 
2.3.4.2.  Lysis of cells 
 
Leukocytes:  Cell pellets at a concentration of 1 x 10
8, 1 x 10
7 and 1 x 10
6 cells were 
incubated with an equal volume of pre-chilled cell lysis buffer (see section 2.2.4) (with 
or without an EDTA-free protease inhibitor tablet, Roche, UK) for 5 min at 4 º C.  
After centrifugation at 100 g for 5 min, supernatants were analysed immediately by 
SDS-PAGE after PK digestion and NaPTA precipitation or stored at – 20 º C. 
 
SMBs15 and SMB-PS cells:   Cells growing in 60 mm culture plates (Corning, UK) 
were rinsed twice with ice cold PBS (see section 2.2.3) scraped from the plate in 1 ml 
of pre-chilled cell lysis buffer (see section 2.2.4) and centrifuged at 100 g for 5 min at 4 
º C.  Supernatants were frozen at – 80 º C or treated with PK, NaPTA precipitated and 
analysed by SDS-PAGE.  
 
2.3.4.3.  Proteinase K (PK) treatment of brain homogenates 
 
Brain homogenates (10 and 20 %) (w/v) were lysed as described in 2.3.4.1.  PK was 
added to a final concentration of 50 µg/ml and samples incubated for 1 hr 15 min at 37 
º C with constant agitation.  The reaction was stopped by the addition of 1 mg/ml 
phenylmethylsulphonyl fluoride (PMSF).  Samples were snap frozen in liquid nitrogen 
before storage at – 20 º C.    
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2.3.4.4.  PK treatment of cell lysates  
 
Cells were lysed as described in 2.3.4.2.    Leukocyte cell lysates were digested with a 
final concentration of 50 µg/ml PK, while 20, 50 or 75 µg/ml PK was added to SMB 
cell lysates.  Samples were incubated and stored as described for brain homogenates in 
2.3.4.3. 
 
2.3.4.5.  Sodium phosphotungstic acid (NaPTA) precipitation of brain homogenate 
: Method 1  
 
Methods for NaPTA precipitation were adapted from Wadsworth et al. (2001) and 
McCutcheon  et al. (2005).  10 % (w/v) brain homogenates were incubated with 
magnesium chloride buffer (see section 2.2.8) for 30 min at 37 º C with constant 
agitation.  An equal volume of sodium N-lauroylsarcosinate buffer (see section 2.2.8) 
was added and samples incubated as above for a further 10 min.  NaPTA stock buffer 
(see section 2.2.8) (pre-warmed to 37 º C) was added to give a final concentration of 
0.3 % (w/v) NaPTA.  Samples were incubated overnight with constant shaking at 37 º 
C.  Samples were centrifuged for 30 min at 15 800 g.  The pellet was resuspended in 
200 µl of NaPTA wash buffer 1 (see section 2.2.8) before centrifugation at 15 800 g for 
30 min.  The pellet was washed in 200 µl of NaPTA wash buffer 2 (see section 2.2.8) 
before centrifugation as above for 15 min.  After sonication (Mixsonics Ultrasonic 
Processor XL, USA) in a final volume of 20 µl wash buffer 2 samples were snap frozen 
in liquid nitrogen before storage at – 20 º C.    
 
2.3.4.6.  NaPTA precipitation of brain homogenate : Method 2  
 
Brain homogenates (10 %) (w/v) were incubated with 500 µl of pre-chilled brain lysis 
buffer (see section 2.2.4) for 5 min at 4 º C.  Gross cellular debris was removed by 
centrifugation at 500 g for 5 min at 4 º C, and the supernatant transferred to a new 
eppendorf tube.  Samples were incubated in NaPTA stock buffer (see section 2.2.8) at a 
final concentration of 0.3 % (w/v) NaPTA, overnight at 37 º C with agitation.  After 
centrifugation for 30 min at 15 800 g, the pellet was resuspended by sonication in a   74
final volume of 100 µl PBS (see section 2.2.3).  Samples were snap frozen in liquid 
nitrogen before storage at – 20 º C.    
 
2.3.4.7.  NaPTA precipitation of leukocytes and SMB cell lysates : Method 1 
 
Leukocyte and SMB cell lysates were resuspended in 500 µl pre-chilled cell lysis 
buffer (see section 2.2.4) and incubated in Benzonase/DNase buffer (see section 2.2.8) 
for 30 min at 37 º C with agitation.  Lysates were then NaPTA precipitated as described 
for brain homogenates in 2.3.4.5. 
 
2.3.4.8.  NaPTA precipitation of leukocyte cell lysates : Method 2 
 
Leukocyte cell lysates were NaPTA precipitated as described for brain homogenates in 
2.3.4.6. 
 
2.3.5.  Protein analysis by SDS-PAGE and Western blotting 
 
2.3.5.1.  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
(1D) 
 
SDS-PAGE is a technique used to separate proteins according to their molecular 
weight.  Sodium dodecyl sulphate (SDS) is used to denature protein, and binds to 
polypeptides producing an even negative charge on the protein.  Under the influence of 
an electric field and bound to SDS, proteins resolve through the gel.  Large proteins 
resolve slowly, while smaller proteins resolve more quickly.  Marker proteins of known 
molecular weight are also resolved in order to determine the molecular weights of 
unknown proteins within the test sample. 
    
SDS-PAGE was carried out according to the method of Laemmli (1970) using pre-cast 
gels and the Novex X-Cell SureLock
TM Mini-cell (Invitrogen).  10 % and 4-12 %, 1 
mm thick, 15 and 10 well, Bis-Tris gels were assembled in the gel rig according to the 
manufacturer’s instructions and 1 X NuPAGE running buffer (see section 2.2.9) placed   75
in the buffer chambers.  Protein samples were heated in an equal volume of 2 X 
NuPAGE sample buffer (see section 2.2.9) at 100 º C for 10 min.  Samples were 
centrifuged for 1 min at 15 800 g, before being loaded into wells.  6 µl of Kaleidoscope 
prestained molecular weight standards (Bio-Rad) were loaded alongside samples.  Gels 
were electrophoresed at 200 V, 130 mA for 45 min – 1 hr, until the dye front reached 
the bottom of the gel.  Gels were removed from plates and analysed either by 
Commassie staining, silver staining or Western blotting. 
 
2.3.5.2.  Coomassie staining 
 
Following SDS-PAGE gels were placed in Coomassie stain (see section 2.2.2) for 2 hr 
or overnight with gentle agitation.  Coomassie stain was removed and replaced with 
destain (see section 2.2.2).  Gels were destained with gentle agitation, replacing the 
destain 3-4 times, until protein bands could be visualised.  Gels were scanned using a 
Umax Powerlook III scanner (Amersham Pharmacia Biotech) then stored at 4 º C in 
distilled water.  
 
Coomassie staining for mass spectrometry: Gels were incubated for 1 hr in coomassie 
fixative (see section 2.2.1) with gentle agitation.  Coomassie fixative was removed and 
gels incubated in Coomassie stain (see section 2.2.1) overnight with gentle agitation.  
Coomassie stain was removed and gels were incubated in distilled water, replacing the 
water eight times until protein bands could be visualised.  Protein bands were excised 
from gels using disposable sterile scalpel blades (Swann-Morton, UK) and stored at 4 º 
C in distilled water. 
 
2.3.5.3.  Silver staining (1D PAGE) 
 
Immediately after SDS-PAGE, gels were removed from plates and immersed in 
fixative (see section 2.2.11) overnight with gentle agitation.  Fixative was removed and 
pre-sensitising solution (see section 2.2.11) added for 30 min with gentle agitation.  
Following three, 15 min washes with distilled water, sensitising solution (see section 
2.2.11) was added and gels incubated for 1 min with gentle agitation.  A further three,   76
30 sec washes with distilled water were carried out, before incubation in silver reaction 
solution (see section 2.2.11) for 1 hr with gentle agitation.  After two, 30 sec washes in 
distilled water, developing solution (see section 2.2.11) was added for approximately 5-
15 min, after which gels were transferred into stop solution (see section 2.2.11).  Gels 
were scanned using a Umax Powerlook III scanner (Amersham Pharmacia Biotech) 
then stored at 4 º C in distilled water.  
 
2.3.5.4.  SYPRO
® orange staining 
 
After electrophoresis and removal from plates, gels were incubated overnight in 
fixative (see section 2.2.14) with gentle agitation.  Fixative was removed and three 
washes for 1 hr each in pre-stain wash (see section 2.2.14) were carried out with gentle 
agitation.  After washing gels were incubated in SYPRO
® orange reaction solution (see 
section 2.2.14) for 4 hr, with gentle agitation, in the dark.  Gels were scanned using a 
Typhoon Trio Imager laser scanner (GE Healthcare, UK) then stored at 4 º C in 
distilled water.  
 
2.3.5.5.  Western blotting 
 
Immediately after SDS-PAGE proteins were transferred on to nitrocellulose 
immobilon-P transfer membrane (Millipore, USA) that had been methanol activated 
and equilibrated in transfer buffer (see section 2.2.15) by the use of a Transfer X-Cell II 
blot module (Invitrogen) at 430 V, 170 mA for 2 hr.  Following transfer the surface of 
the membrane was blocked with blocking buffer (see section 2.2.15) for 1 hr with 
gentle agitation.  The blocked membrane was incubated with primary antibody, diluted 
in antibody binding buffer (see section 2.2.15) overnight at 4 º C.  For information on 
antibodies used and dilutions see Appendix 1.  Following eight, 5 min washes in PBS-
tween (see section 2.2.15) the membrane was incubated with secondary antibody 
conjugated to horse radish peroxidase (HRP) diluted in antibody binding buffer, for 1 
hr with gentle agitation.  The membrane was washed as described above, and the bound 
HRP conjugate visualised using SuperSignal West Pico chemiluminescent reagents 
(Pierce, UK) according to the manufacturer’s instructions.  Briefly equal volumes of   77
West Pico enhancer and peroxide solutions were mixed and added to the membrane for 
1 min.  The solution was drained from the membrane and the membrane wrapped in 
clear plastic food wrap and exposed to Hyperfilm (Amersham Pharmacia Biotech, UK). 
Film was developed using the Xograph Automatic Compact X4 processor. 
 
2.3.6.  Two-dimensional (2D) PAGE protein methods 
 
Since protein bands on 1D PAGE will in most cases contain more than one protein 
species, 1D separation methods such as SDS-PAGE can resolve only a relatively small 
number of proteins.  In contrast two-dimensional (2D) PAGE allows separation of 
proteins by isoelectric point and mass, allowing proteins to be more effectively 
separated, and so increasing the number of proteins visible.  Furthermore each protein 
spot is more likely to be composed of a single protein, therefore allowing variations 
within individual proteins to be assessed.      
 
2.3.6.1.  Sample preparation for 2D PAGE 
 
Method 1:  Buffy coat cell pellets at a concentration of 1 x 10
7 were incubated in 500 µl 
pre-chilled cell lysis buffer (see section 2.2.4) before NaPTA precipitation as described 
in 2.3.4.5 and 2.3.4.7.   
 
Method 2: Buffy coat cell pellets at a concentration of 1 x 10
7 were washed twice in 
wash buffer (see section 2.2.10) and centrifuged at 15 800 g for 10 min at 4 º C.  Pellets 
were resuspended by sonication on ice for eight, 15 sec pulses in 500 µl sample 
preparation solution (see section 2.2.10).  Following a further 45 min with agitation, 
cell lysates were centrifuged at 15 800 g for 45 min.  The supernatant was transferred to 
a clean eppendorf tube and the protein concentration determined by a 2-D Quant kit (G 
Biosciences, UK) according to the manufacturers instructions.  Supernatant was frozen 
at a final concentration of 50 µg protein at – 80 º C.  
 
 
       78
2.3.6.2.  Sample rehydration and isoelectric focussing (IEF) 
 
Protein samples were combined with DeStreak rehydration buffer (see section 2.2.10) 
containing 10 %  immobilised pH gradient (IPG) buffers of pH 3-11 range, incubated 
for 45 min with agitation, and centrifuged at 15 800 g for a further 45 min.   
Supernatants were removed to a clean tube and samples were loaded into 18 cm 
immobilised pH gradients (IPG) strips by passive in-gel rehydration overnight covered 
in mineral oil (Amersham Biosciences, UK).  IPG strips were subjected to IEF on a 
Phast 12 IEF unit (Nextgen Science Plc, UK) for a total of 40 kV hr.  A typical IEF 
profile is shown in Appendix 4.  Following IEF, IPG strips were stored at – 80 º C.  
Focussing profiles were determined empirically for each sample type used.    
 
2.3.6.3.  2D SDS-PAGE Gel preparation 
 
Large format SDS PAGE gels for use in 2D PAGE were prepared using a 
2DeOptimizer (Nextgen Sciences plc).  This instrument enables automated pouring of 
both homogeneous and gradient gels.  All reagents (acrylamide, glycerol, Tris/SDS, 
TEMED and ammonium persulphate (APS) were supplied by Nextgen Sciences plc and 
with the exception of APS come ready to use.  Prior to gel preparation, all reagents are 
allowed to equilibrate to RT and APS is reconstituted to 1 % (w/v) in distilled water 
and allowed to agitate for 30 min.  Gel reagents were loaded on to a 2DeOptimizer for 
automated gel casting.  12 % homogenous gels were pre-cast into an autocast 12 large 
format gel caster and allowed to polymerize for 4 – 5 hr.   
 
2.3.6.4.  Second dimension separation 
 
IPG strips were incubated in SDS equilibration buffer (see section 2.2.10) containing 1 
% (w/v) dithiothreitol (DTT) for 15 min with agitation, followed by incubation in SDS 
equilibration buffer containing 2.5 % (w/v) iodoacetamide in the same way.  IPG strips 
were added to 12 % homogenous gels and sealed with agarose sealing solution (see 
section 2.2.10).  Gels were transferred to a Ettan DALT II gel tank containing 1 X   79
running buffer (see section 2.2.10) and electrophoresis performed at 12 W overnight at 
30 º C.   
 
2.3.6.5.  Silver staining (2D PAGE)      
 
Immediately after 2D SDS-PAGE, gels were removed from plates and immersed in 
fixative (see section 2.2.12) overnight with gentle agitation.  Fixative was decanted and 
sensitising solution (see section 2.2.12) added for 1 hr with gentle agitation.  Following 
four, 15 min washes with distilled water, silver reaction solution (see section 2.2.12) 
was added and gels incubated for 1 hr with gentle agitation.  After two, 1 min washes in 
distilled water, developing solution (see section 2.2.12) was added for approximately 5-
15 min, after which gels were transferred into stop solution (see section 2.2.12).  Gels 
were scanned using a Umax Powerlook III scanner (Amersham Pharmacia Biotech) 
sealed in clear polythene and stored at 4 º C.  
 
2.3.6.6.  In-gel protein digestion and peptide extraction 
 
Gel slices of approximately 1 cm
2 were excised from gels, washed in distilled water 
before centrifugation at 100 g for 2 min.  After resuspension in 50 % (v/v) acetonitrile 
(AnaChem) for 15 min, gel slices were centrifuged as above.  Gel slices were incubated 
in reduction buffer 1 (see section 2.2.7) for 1 hr at 37 º C before centrifugation as 
described above, and resuspension in 50 % (v/v) acetonitrile.  Following centrifugation 
as before the supernatant was removed, pellets resuspended in reduction buffer 2 (see 
section 2.2.7) and incubated in the dark for 20 min. The acetonitrile step was repeated 
and the pellet incubated in digestion buffer 1 (see section 2.2.7) for 45 min at 4 º C.  
Following centrifugation at 100 g for 2 min, pellets were incubated in digestion buffer 
2 (see section 2.2.7) overnight at 37 º C.  25 mM ammonium bicarbonate was added 
followed by incubation for 15 min at 37 º C.  After centrifugation for 2 min at 100 g the 
supernatant was incubated in 5 % (v/v) formic acid as described above.  After the 
addition of 50 % (v/v) acetonitrile and incubation as described above, pellets were 
dried using a Savant speed vac.  Dried pellets were stored at 4 º C.   
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2.3.6.7.  Mass spectrometry 
 
Protein peptides were analysed by electrospray ionisation (ESI) mass spectrometry, 
using a Q Tof Premier instrument (Waters Ltd) equipped with an atmosphere pressure 
electrospray ionisation source and calibrated using human glutamate fibrinopeptide.   
Mass spectrometry was performed by Dr A.C. Gill (Roslin Institute).  
Mass spectrometry was also performed by Dr P. Skipp (Southampton University) 
where protein peptides were separated by nano-reverse phase liquid chromatography, 
using a Dionex PepMap C18, 3 µm, 100  (150 mm x 75 µm, i.d.) column, and 
electrosprayed into a quadrupole time of flight tandem mass spectrometer (Waters Ltd).  
All data were acquired using a Q-tof Glabal Ultima (Waters Ltd) fitted with a 
nanoLockSpray
TM  source. 
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3.1. Introduction 
 
Transmissible spongiform encephalopathies (TSEs) or prion diseases are rare and fatal 
neurodegenerative disorders, characterized by the accumulation of an abnormal isoform 
of prion protein (PrP
Sc) in the central nervous system (Prusiner et al., 1998).  The 
appearance of variant Creutzfeldt-Jakob disease (vCJD) which is caused by the same 
TSE agent as bovine spongiform encephalopathy (BSE) in cattle (Will et al., 1996; 
Bruce et al., 1997) has raised concerns worldwide.  This is because the total number of 
vCJD infected people is unknown, there is a long pre-clinical phase of disease and 
affected individuals are able to potentially transmit infectious agent to others, possibly 
via blood and blood products or by contaminated surgical instruments.  The ability to 
detect the infectious agent in blood is therefore of major importance to understanding 
the pathogenesis of the disease, estimating the risk of infection associated with blood 
products and the development of non-invasive diagnostic tests to identify TSE-infected 
animals and humans before the onset of clinical symptoms.  
 
The only method which formally demonstrates the presence of infectious TSE agents is 
the bioassay, where infectious material is inoculated into animals of the same or 
different species.  These experiments, however, are difficult to perform, expensive and 
take months or even years to obtain results.  An alternative to bioassay is the detection 
of PrP
Sc which co-purifies with infectivity (Bolton et al., 1982) and is used as a 
biochemical marker for TSE disease.  Traditionally, immunohistochemistry (IHC) is 
used to detect PrP
Sc in tissues following post mortem, although it can also be used to 
screen samples from pre-clinical individuals (Schreuder et al., 1998).  PrP
Sc is 
distinguished from PrP
C by treating with proteinase K (PK), although this treatment is 
not routinely used for IHC.  Other pre-treatments commonly used such as trypsin and 
autoclaving, may destroy much of the PrP
C.  The effectiveness of IHC depends greatly 
on sample preparation and the nature of the antibodies used.  Although excellent for 
confirmation of infection, IHC is not a rapid method and the amount of PrP
Sc present 
cannot reliably be measured.          
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A relatively rapid, widely validated, well established method is Western blotting, which 
can be very sensitive for PrP
Sc detection (Lee et al., 2000).   Western blotting relies on 
proteinase K digestion to distinguish the abnormal protein from PrP
C. Extracts of PrP
Sc 
from infected tissues are treated with PK, run on an SDS-PAGE (sodium dodecyl 
sulphate polyacrylamide gel electrophoresis) gel, transferred to nitrocellulose 
membrane and then probed using specific antibodies to detect undigested PrP (Bolton 
et al., 1982). After digestion with PK, PrP
Sc gives a conventional pattern on Western 
blots where three distinct bands can be identified and resolve between 27-30 kDa.   
Hence the PK resistant core of PrP
Sc  is called p27-30.  The three bands represent 
differential glycosylation as PrP contains two N-linked glycosylation sites at codon 180 
(N180) and codon 196 (N196) in mice at which carbohydrates can be attached (Oesch 
et al., 1985). These N-linked glycosylation sites are highly conserved among 
mammalian species (van Rheede et al., 2003).   The diglycosylated form exists when 
both sites are occupied (35 kDa band), monoglycosylated forms occur when either one 
of the two sites are occupied (28 kDa band) and unglycosylated forms occur when 
neither site is occupied (22 kDa band) (Collinge et al., 1996).  Western blotting has the 
advantage of recognising different forms of PrP
Sc through the analysis of molecular 
mass in addition to relative abundance of di- mono- and unglycosylated bands.  This 
characterisation produces a “PrP signature” which varies among different forms of 
TSEs (Collinge et al., 1996). 
 
Western blot sensitivity can be increased by concentration of PrP
Sc in tissue samples by 
precipitation with sodium phosphotungstic acid (NaPTA).  Traditionally used in 
histology with haematoxylin for staining tissue elements such as striated muscle, 
smooth muscle and neuroglia fibres (Mallory, 1900), NaPTA (Na2H[PW12O40]) 
features the nearly spherical trianion [PW12O40] which belongs to a broad class of 
polynuclear transition metal-oxo complexes known as polyoxometalates (POM).   
POMs have been shown to non-specifically precipitate proteins (Yeang et al., 1995; 
Scott et al., 1971) and amino acids (Thimann, 1930).  Although the precise molecular 
mechanism of PrP
Sc interaction with NaPTA is largely unknown there is evidence to 
suggest that this is specific for both protease resistant and sensitive forms of PrP
Sc 
(Safar et al., 1998; Tremblay et al., 2004).  By incorporating a NaPTA concentration   84
step, Western blot sensitivity has been increased up to three-fold, allowing for the 
identification of extraneural abnormal PrP in spleen and muscle from sporadic CJD 
patients (Glatzel et al., 2003).   
 
This chapter describes the development and optimisation of a Western blot 
immunoassay for conventional PK resistant PrP
Sc, using scrapie-infected sheep brain 
homogenates. The aim of these experiments was to maximise the sensitivity of the 
assay using NaPTA concentration and exploiting a panel of novel PrP specific 
monoclonal antibodies, before applying it to detection of PrP
Sc in scrapie-infected 
sheep blood.   
 
3.1.1. Antibodies  
 
The panel of novel PrP specific monoclonal antibodies described in this thesis were 
generously donated by Dr S. McCutcheon (Roslin Institute).  The antibodies were 
raised by immunising PrP null mice with truncated recombinant ovine PrP using 
conventional techniques, the details of which will soon be published.   
 
At the beginning of this project, many of the commercial antibodies available were 
specific for epitopes present in the N- terminal octapeptide repeat region of PrP. For 
detection of PrP
Sc, this is not ideal as following PK digestion, the N terminal region of 
the protein is cleaved. Therefore, the vaccination strategy to immunise PrP null mice 
with truncated recombinant ovine PrP was used in order to generate an immune 
response directed against epitopes in the C- terminal region of the PrP protein.   
 
Some of the novel PrP specific monoclonal antibodies (BC6, BH1) do share a similar 
binding region (C-terminal globular domain) to the commercially available 6H4 
antibody, but due to reasons of cost, studies to compare the characteristics of the novel 
antibodies with other commercial products were not carried out. 
 
The reason the panel of antibodies were described as novel was simply a reference to 
the fact that they were a “new” panel of antibodies available for use. The detailed   85
biological characterisation and functionally of these antibodies will be described in 
detail by Dr S. McCutcheon (Roslin Institute) who is currently writing up this work for 
publication. 
 
Following epitope mapping studies carried out by Dr S.  McCutcheon (Roslin Institute) 
the location of four antibody core binding regions were identified and are summarised 
below. 
 
Anti-PrP Antibody  Amino Acids  Core Binding Region 
FH10 198-207  TETDIKMMER 
BC6 141-152  GSDYEDRYYREN 
BH1 136-152  PHILFGSDYEDRYYREN 
JB10 216-225  QRESQAYYQR 
        
Table 3.1: Epitope locations of anti-PrP antibodies.  Courtesy of Dr S. McCutcheon (Roslin 
Institute). 
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3.2. Materials and methods 
 
3.2.1. Sensitive Western blot method 
 
The methods developed from Safar et al., 1998 and Wadsworth et al., 2001 are 
described in detail in chapter 2, section 2.3.4.5.  Figure 3.1 shows a simplified diagram 
of the sensitive Western blot method.  
 
 
 
Figure 3.1:  Simplified flow diagram of the sensitive Western blot method  
                                                                                           
 
500 µl 10 % (w/v) scrapie brain 
Addition of nuclease 
30 min incubation at 37 ºC
Detergent extraction
10 min incubation at 37 ºC
Addition of 50 µg/ml PK for
1 hr 15 min at 37 ºC
Addition of 0.3 % (w/v) NaPTA overnight
SDS-PAGE / Western blot  87
3.3. Results 
 
3.3.1. Standard Western blotting technique 
 
Western blotting (see chapter 2, section 2.3.5.5) is a method for detection of 
conventional PrP
Sc that relies on PK digestion to distinguish the abnormal protein from 
PrP
C.  Figure 3.2 shows the detection of PrP from normal and scrapie brain 
homogenates using a standard Western blot method.  Without the PK step both forms 
of the protein give the same distinct pattern on Western blots, where three distinct 
bands (that represent differential glycosylation as described in the introduction) can be 
identified and resolve between 22-35 kDa (figure 3.2, lanes 1 and 3).  After PK 
digestion, PrP
C is fully degraded (figure 3.2, lane 2).  PrP
Sc is partially resistant to 
treatment with PK where the N terminal region of the protein is cleaved, resulting in a 
PK resistant core called p27-30 (figure 3.2, lane 4).      
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Figure 3.2: Western blotting for PrP
Sc detection.  Key: Lane 1 & 2, uninfected sheep brain 
homogenate; lane 3 & 4 scrapie-infected sheep brain homogenate.  As indicated lane 1 & 3 was 
not PK digested, lane 2 & 4 was digested with PK.  150 µg wet tissue equivalent was loaded in 
each well.  The blot was probed with BC6 at 1 µg/ml.  The blot was developed using standard 
ECL methods; the exposure time was 2 min.  Molecular masses are shown on the left (kDa). 
 
3.3.2.  Screening a panel of PrP-specific monoclonal antibodies on sheep and 
mouse brain homogenates. 
 
A panel of new monoclonal antibodies to sheep PrP (see table 3.1) were screened for 
specific PrP
Sc binding on Western blots of sheep scrapie brain homogenate samples.  
Figure 3.3 is a representative blot of the results.  All antibodies were used at the same 
concentration (1 µg/ml) and some gave a more intense signal on blots than others.  For 
instance, BH1 (figure 3.2, lanes 11 and 12), BC6 (lanes 9 and 10) and IH9 (lanes 7 and 
8) gave the most intense signal and therefore these antibodies may have a high affinity 
for ovine PrP.  Antibodies such as AE11 (lanes 3 and 4) and JB10 (lanes 1 and 2) also 
gave a positive, yet weaker signal.  FH6 (lanes 17 and 18) was weaker still, whilst 
DC12 (data not shown) was unable to detect PK -resistant PrP.   
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Figure 3.3:  Screening of monoclonal antibodies on Western blots of PK-resistant PrP
Sc from scrapie- infected sheep brains.  Wells were loaded 
with 2.1 mg wet tissue equivalent of PK digested scrapie sheep brain homogenate, and the membrane cut so it could be probed using different 
monoclonal antibodies at 2 µg/ml.  Samples were loaded in duplicate.  In some cases sample spilled over into a fresh lane (between lanes 6 and 7, 8 and 
9, and 12 and 13).  Key:  lanes 1 & 2, JB10; lanes 3 & 4, AE11; lanes 5 & 6, EA6; lanes 7 & 8, IH9; lanes 9 & 10, BC6; lanes 11 & 12, BH1; lanes 13 & 
14, BF5; lanes 15 & 16, IH11; lanes 17 & 18, FH6 and lanes 19 & 20, FD12.  In lane 21 & 22 uninfected sheep brain homogenate (300 µg) was probed 
with BC6 (1 µg/ml). Lane 22, the sample was PK digested. The blot was developed using standard ECL methods; the exposure time was 1 min.  
Molecular masses are shown on the left and far right (kDa).   90
 
Since the objective was to apply the optimized Western blot to cellular components of 
blood, a source of scrapie-infected cells was required as a positive control as an 
alternative to scrapie-infected brain homogenates. As there are no readily available 
scrapie-infected sheep cell lines, the SMB mouse cell line (Clarke and Haig, 1970) was 
chosen for this purpose.  Therefore it was important to select monoclonal antibodies 
from the panel of 24 which allow sensitive detection of both mouse and sheep PrP.  To 
achieve this, the same panel of antibodies were also screened against PK treated brain 
homogenates from mice infected with the scrapie strain 139A (figure 3.4).  A group of 
10 antibodies bind to mouse PrP
Sc, with varying signal intensities.  As for sheep, BH1 
(lane 8), BC6 (lane 9) and IH9 (lane 6) produced the most intense signal, whereas CF5 
(lane 5) was weaker. In contrast to the blots of sheep PrP
Sc, the monoglycosylated band 
in the 139 A mouse scrapie strain is more pronounced, producing a different 
glycosylation pattern.  
 
After comparison with the sheep blots a group of 6 antibodies were selected for further 
study (IH9, AE11, BH1, BC6, EG6, and FD12).  Based on the high signal intensity 
obtained with these antibodies on Western blots, it is likely that in both species they 
bind PrP
Sc with high affinity (table 3.2).  The three bands representing diglycosylated, 
monoglycosylated and unglycosylated PrP
Sc were clearly visible.  Subsequent Western 
blots of brain (for assay optimisation) were carried out using scrapie sheep brain 
homogenate only.  
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Figure 3.4:  Screening of monoclonal antibodies on Western blots of PK-resistant PrP
Sc from scrapie-infected mouse brains.  Wells were loaded 
with 2.1 mg wet tissue equivalent of PK digested  scrapie-infected (139A) mouse brain homogenate, and the membrane cut so it could be probed using 
various monoclonal antibodies at 1 µg/ml.  In lane 1, HC2; lane 2, AE11; lane 3, EG6; lane 4, FD12; lane 5, CF5; lane 6, IH9; lane 7, BF5; lane 8, BH1; 
lane 9, BC6; lane 10; JC4.  Lane 11, 300 µg uninfected mouse brain homogenate and lane 12, 300 µg PK digested uninfected mouse brain homogenate.  
The blot was developed using standard ECL methods; the exposure time was 5 sec.  Molecular masses are shown on the left and far right (kDa).  92
 
Monoclonal 
antibody 
Species cross-reactivity  Isotypes  Signal intensity  
AE11 Sheep,  mouse  IgG1  ++ 
EA6 Sheep  IgG1  ++ 
EG6 Sheep,  mouse  IgG1  +++ 
FD12 Sheep,  mouse  IgG1  ++ 
CF5 Sheep,  mouse  IgG2a  + 
EC9 Sheep  IgG2a  + 
IH9 Sheep,  mouse  IgG2b  +++ 
IH11 Sheep  IgG2a  ++ 
FD1 Sheep  IgG1  + 
FH10 Sheep  IgG2a  ++ 
HB4 Sheep  IgG1  ++ 
IF1 Sheep  IgG1  + 
DE3 Sheep  IgG1  + 
BF5 Sheep,  mouse  IgG1  ++ 
JB10 Sheep  IgG1  ++ 
BD12 Sheep  IgG1  + 
DC12 Sheep  IgG1  - 
DB12 Sheep  IgG1  + 
FH6 Sheep  IgG1  - 
HC2 Sheep,  mouse  IgG1  ++ 
BH1 Sheep,  mouse  IgG1  +++ 
BC6 Sheep,  mouse  IgG1  +++ 
HC7 Sheep  IgG1  + 
JC4 Sheep,  mouse  IgG1  ++ 
 
Table 3.2 Cross-reactivity of PrP specific monoclonal antibodies used in SDS-
PAGE and Western blotting to detect low PrP
Sc amounts.  Antibodies were used at 
2 µg/ml and 2.1 mg wet tissue was loaded.  Key: +++ = very intense signal , ++ = intense 
signal , + = good signal  , - = no signal   93
3.3.3. Concentration of PrP
Sc by NaPTA precipitation 
 
The sensitivity of Western blots can be improved by concentrating PrP
Sc using NaPTA 
precipitation (Wadsworth et al., 2001; Glatzel et al., 2003; Safar et al., 1998; 
McCutcheon et al., 2005) and therefore this concentration step was included in the 
method. Figure 3.5 shows experiments where scrapie sheep brain homogenates were 
PK treated and either NaPTA precipitated or not.  Samples were serially diluted (from 
2500 µg down to 5 µg wet tissue equivalent) then resolved and Western blotted.  After 
NaPTA precipitation, PrP
Sc could be detected in the equivalent of 9 µg of wet tissue 
(figure 3.5, lane 8, with NaPTA). Without this step the detection limit was 78 µg of wet 
tissue (figure 3.5, lane 6, without NaPTA). 
 
This result confirms that NaPTA precipitation increases sensitivity of PrP
Sc detection 
when compared to control samples in which PBS has been substituted in place of 
NaPTA, and this is in agreement with the findings of other investigators (Wadsworth et 
al., 2001; McCutcheon et al., 2005).  The 6 selected antibodies (IH9, AE11, BH1, BC6, 
EG6, and FD12) were then tested incorporating this concentration step to establish 
which gave the most sensitive detection of PrP
Sc. 
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Figure 3.5:  NaPTA precipitation before Western blot analysis of PK-resistant PrP
Sc increases sensitivity of detection.  Samples were treated with 
or without NaPTA following PK digestion as shown.  Wells were loaded with serial dilutions of the PK digestion products from scrapie infected sheep 
brains.  In lane 1 the equivalent of  2500 µg wet tissue was loaded, in lane 2, 1250 µg, in lane 3, 625 µg, lane 4, 313 µg,  lane 5, 156  µg, lane  6, 78 µg, 
lane 7, 19 µg, lane 8, 9 µg, and lane 9, 5 µg.   Lane 10, 500 µg NaPTA precipitated uninfected sheep brain homogenate; lane 11, 500 µg uninfected 
sheep brain homogenate without NaPTA precipitation. M = molecular weight marker.  The blot was probed with the mAb IH9 (1 µg/ml), and developed 
using standard ECL methods; with an overnight exposure.   Molecular masses are shown on the left and far right (kDa).   95
 
3.3.4. Comparing the end-points of detection for different primary antibodies 
 
The selected antibodies (IH9, AE11, EG6, FD12, BH1 and BC6) were initially tested at 
a concentration of 1 µg/ml on titrated samples of scrapie brain homogenate from 
prepared bulk samples (described in chapter 2, section 2.3.1.2). The scrapie brain 
homogenate pellet was serially diluted to produce a range of dilutions; 313 µg, 156 µg, 
78 µg, 39 µg, 19 µg and 9 µg wet tissue equivalent, respectively.  When used at 1 
µg/ml there were clear differences between antibodies.  The limit of detection for EG6 
and FD12 was 39 µg and 19 µg respectively (figure 3.6, EG6 and FD12, lanes 3 and 4).  
The limit of detection for AE11 was also 19 µg (figure 3.6, lane 2) however unlike 
FD12 the 3 glycoform bands were visible in all of the higher brain concentrations 
(figure 3.6, AE11, lanes 1-4).   The remaining 3 antibodies (IH9, BH1 and BC6) could 
detect down to 9 µg wet tissue equivalent (figure 3.6).  Therefore these antibodies and 
AE11 were selected for further testing. 
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Figure 3.6: Comparing the end-points of detection for different antibodies on Western blots of NaPTA precipitated PK-resistant PrP
Sc from 
scrapie-infected sheep brains. Wells were loaded with serial dilutions of the PK digestion products from natural scrapie infected sheep brains.  In lane 
1 the equivalent of  313 µg wet tissue was loaded, in lane 2, 156 µg, in lane 3, 78 µg, lane 4, 39 µg,  lane 5, 19  µg, and lane  6, 9 µg.  The blot was 
probed with various mAb, IH9, AE11, EG6, FD12, BH1 and BC6. The antibody used is labelled above each blot and all were used at a concentration of 
1 µg/ml. The blot was developed using standard ECL methods; the exposure time was 30 min.  Molecular masses are shown on the left (kDa).
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To determine whether a higher concentration of the primary antibody would further 
increase the sensitivity of PrP
Sc detection, the 4 selected antibodies were tested at 
concentrations of 2 and 5 µg/ml.  Because they were being used at higher 
concentrations than before (1 µg/ml), a lower range of dilutions were used.  A range 
from 78 µg wet tissue down to 2 µg was used for testing at 2 µg/ml, whereas for the 
higher antibody concentration (5 µg/ml) a dilution range between 39 µg wet tissue to 1 
µg was used.  At a concentration of 2 µg/ml, IH9 detected the diglycosylated PrP
Sc 
band in the equivalent of 5 µg wet tissue, while BC6 and BH1 detected PrP
Sc in as little 
as 2 µg wet tissue equivalent (figure 3.7).  This antibody concentration also allowed for 
the detection (in some cases) of all three bands, where  2 bands had previously been 
visible when probed with antibody at 1 µg/ml (e.g. IH9, 2 bands in 19  µg wet tissue at 
1 µg/ml, but all three bands in the same wet tissue equivalent at 2  µg/ml).   No 
difference in sensitivity was observed with AE11 (figure 3.7).  
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Figure 3.7: The effect of primary antibody concentration on the end-points of detection of 
PrP
Sc by Western blot. Wells were loaded with serial dilutions of the PK digestion products 
from natural scrapie infected sheep brains.  In lane 1 the equivalent of  78 µg wet tissue was 
loaded, in lane 2, 39 µg, in lane 3, 19 µg, lane 4, 9 µg,  lane 5, 5  µg, and lane  6, 2 µg.  The 
blot was probed with various mAb, BH1, BC6, IH9 and AE11 all at a concentration of 2 µg/ml. 
The antibody used is labelled above each blot. The blot was developed using standard ECL 
methods; the exposure time was 3 h.  Molecular masses are shown on the left (kDa). 
 
No further increase in sensitivity was observed when antibody concentrations were 
increased to 5 µg/ml, in fact in some cases binding was reduced compared to blots 
incubated with 2 μg/ml primary antibody (figure 3.8).  It is possible if concentrations   98
are too high, and too much unbound primary antibody remains after washing, some of 
the secondary antibody epitopes will be blocked, allowing less secondary antibody to 
bind.  This would decrease the sensitivity of detection.  The results of the titration of 
primary antibodies indicate that the highest sensitivity was achieved using BH1 and 
BC6 at an optimal concentration of 2 µg/ml (table 3.3). 
 
mAb Ab 
concentration 
313 
µg 
156 
µg 
78 
µg 
39 
µg 
19 
µg 
9 
µg 
4.5 
µg 
2 
µg 
1 
µg 
IH9 1 µg/ml 
2 µg/ml 
5 µg/ml 
 
+++ 
n/a 
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+++ 
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n/a 
+++ 
+++ 
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+++ 
+++ 
+++ 
++ 
+++ 
++ 
+ 
++ 
++ 
 
+ 
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AE11 1 µg/ml 
2 µg/ml 
5 µg/ml 
+++ 
n/a 
n/a 
+++ 
n/a 
n/a 
+++ 
+++ 
n/a 
++ 
++ 
+ 
+ 
++ 
+ 
+ 
+ 
    
EG6 1 µg/ml +++ 
 
+++ 
 
++ 
 
+ 
 
  
 
    
FD12 1 µg/ml +++ 
 
+++ 
 
+++ 
 
++ 
 
+ 
 
 
 
    
BH1 1 µg/ml 
2 µg/ml 
5 µg/ml 
+++ 
n/a 
n/a 
+++ 
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n/a 
+++ 
+++ 
n/a 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+ 
+++ 
++ 
 
+ 
++ 
 
+ 
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BC6 
BC6 
BC6 
1 µg/ml 
2 µg/ml 
5 µg/ml 
+++ 
n/a 
n/a 
+++ 
n/a 
n/a 
+++ 
+++ 
n/a 
+++ 
+++ 
+++ 
++ 
+++ 
+++ 
+++ 
+ 
++ 
+ 
++ 
+ 
 
+ 
+ 
 
+ 
 
 
 
Table 3.3: Summary table showing primary antibody concentrations and 
sensitivity of detection.  Each experiment was carried out at least three times.    
Key : +++ 3 bands, ++  2 bands,  +  1 band. 
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Figure 3.8:  Increasing primary antibody concentrations does not increase sensitivity.  Wells were loaded with serial dilutions of the PK digestion 
products from natural scrapie infected sheep brains.   The blot was probed with various mAb, BH1, BC6, IH9 and AE11 at a concentration of 2 µg/ml or 
5 µg/ml.  In 2 µg/ml concentrations in lane 1 the equivalent of  78 µg wet tissue was loaded, in lane 2, 39 µg, in lane 3, 19 µg, lane 4, 9 µg, lane 5, 5  µg, 
and lane  6, 2 µg.   In 5 µg/ml concentrations in lane 1 the equivalent of  39 µg wet tissue was loaded, in lane 2, 19 µg, in lane 3, 9 µg, lane 4, 5 µg,  lane 
5, 2  µg, and lane  6, 1 µg.    M = molecular weight markers.  The blot was developed using standard ECL methods; the exposure time was 3 h.  
Molecular masses are shown on the left (kDa).   100
 
3.3.5. Secondary antibody titration 
 
Using BH1 and BC6 as primary antibodies, the secondary antibody (goat anti-mouse 
HRP- Appendix 1) was titrated. Previously used at a 1:7000 dilution, concentrations of 
1:10 000, 1:5000 and 1:2.500 were also tested.  Results previously for BH1 and BC6 
indicate a maximum detection limit of 2 µg wet tissue equivalent seen with a secondary 
antibody concentration of 1:7000.  By using the secondary antibody at the 1:5000 and 
1:2500 concentrations stated above, it was difficult to determine the limit of detection 
due to high background (particularly with BH1) suggesting an overload of HRP in the 
system (figure 3.9 shows 1:5000 results as an example).  The maximum detection limit 
observed using a secondary antibody concentration of 1:10 000 was 20 µg equivalent 
wet tissue (Figure 3.9).  Using the secondary antibody at a concentration of 1:7000 is 
optimal and when used in conjunction with primary antibodies at 2 µg/ml there is no 
background staining and the maximal detection limit is 2 µg wet tissue equivalent 
(figure 3.7). 
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Figure 3.9:  Secondary antibody titration does not improve sensitivity of detection.   Wells were loaded with serial dilutions of the PK digestion 
products from natural scrapie infected sheep brains.   The blot was probed with BH1or BC6 at a concentration of 2 µg/ml.   The secondary antibody was 
used at a concentration of 1:10,000 or 1:5000 as indicated.  M = molecular weight markers. In lane 1 the equivalent of 20 µg wet tissue was loaded, in 
lane 2, 2 µg.  The blot was developed using standard ECL methods; the exposure time was 5 min.  Molecular masses are shown on the left (kDa).
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3.3.6. Comparison of an alternative sensitive detection system 
 
 
Western blot sensitivity has been increased by using different detection reagents 
(Wadsworth et al., 2001).  Therefore the enhanced sensitivity substrate, West Femto 
reagent (Pierce) was tested. Because the substrate is extremely sensitive, less primary 
and secondary antibody is required to obtain a signal.  Therefore, the primary (BH1 and 
BC6) and secondary antibodies were re-titrated using this system.  Primary antibodies 
were used at concentrations of 0.2 µg/ml, 0.5 µg/ml and 1 µg/ml.  Secondary antibodies 
were tested at 1:100,000, 1:200,000 and 1:500,000 dilutions. Figure 3.10 is a 
representative blot using BC6 and shows that the signal produced was similar using the 
3 different primary antibody concentrations. The optimal secondary antibody 
concentration appeared to be 1:200,000.  A dilution of 1:500,000 diminished the signal 
and concentrations higher than 1:200,000 produced an increased background.  PrP
Sc 
present in 20 µg wet tissue equivalent was clearly apparent (figure 3.10).  The 
diglycosylated band of disease-associated PrP in the equivalent of 2 µg wet tissue was 
also faintly visible, although the result was not conclusive because the background 
signal was high in all cases beyond a 30 second blot exposure.  
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Figure 3.10:  An enhanced sensitivity substrate does not increase sensitivity of detection.  Wells were loaded with serial dilutions of the PK 
digestion products from natural scrapie infected sheep brains.   The blot was probed with BC6 at a concentration of 0.2 µg/ml, 0.5 µg/ml  and 1 µg/ml as 
shown.  The equivalent of 20 µg wet tissue (lane 1) and 2 µg wet tissue (lane 2) was loaded.  The secondary antibody was used at 3 different 
concentrations, 1:100,000, 1:200,000, and 1:500,000 as indicated.  The blot was developed using the enhanced sensitivity West Femto substrate 
according to the manufacturer’s instructions.  The exposure time was 30 sec.  Molecular masses are shown on the left (kDa).
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To reduce background, different blocking buffers such as 3% casein in 0.05% Tween 
20, and 5% milk powder were tried (figure 3.11), but none successfully reduced the 
background signal on the blots. Increasing the concentration of Tween detergent in 
wash buffers (0.05%, 0.1%, and 0.5%) was also unsuccessful at reducing background 
(data not shown). Although West Femto is an extremely sensitive enhanced 
chemiluminescent substrate there was no enhanced detection of PrP
Sc when either BH1 
or BC6 were used.  Background signals were high even after titration of primary and 
secondary antibodies. Testing different blocking and wash buffers did not reduce the 
level of background signal.  The results obtained suggest that the limit of PrP
Sc 
detection by this Western blot assay has been reached and that the sensitivity could not 
be increased further by using this alternative substrate. 
 
 
 
                  
 
 
 
 
 
 
 
Figure 3.11: The use of different blocking buffers does not reduce background when using 
West Femto.  Wells were loaded with serial dilutions of the PK digestion products from 
natural scrapie infected sheep brains.   The blot was probed with BC6 or BH1 at a 
concentration of  0.2 µg/ml.  The equivalent of 20 µg wet tissue (1) and 2 µg wet tissue (2) was 
loaded. Lane 1* indicates where sample spilled over from lane 1.  The secondary antibody was 
used at a concentration of 1:200,000.  The membrane was cut and blocked in either casein or 
marvel milk powder blocking buffer as indicated.  The blot was developed using the enhanced 
sensitivity West Femto substrate according to the manufacturer’s instructions.  The exposure 
time was 30 sec.  Molecular masses are shown on the left (kDa). 
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3.3.7. Confirmation of the sensitivity of the optimised Western blot using scrapie 
brain spikes 
 
Spiking infected brain into uninfected brain confirms that the sensitivity of infection is 
maintained when the spike is recovered against a high background of normal PrP
C and 
other proteins.  The maximum sensitivity achieved with the optimized Western 
immunoassay was detection of PrP
Sc in the equivalent of 2 µg scrapie-infected brain 
(figure 3.8). To confirm that a similar level of sensitivity could be achieved using brain 
spikes, decreasing amounts of scrapie sheep brain homogenate were diluted into 
uninfected sheep brain homogenate (chapter 2, section 2.3.1.2). Detection of PrP
Sc was 
tested using the monoclonal antibodies BH1 and BC6 as previously described.  Both 
antibodies consistently detected PrP
Sc in samples spiked with 20 mg, 2 mg, and 200 µg 
wet tissue equivalent (figure 3.12, BH1 and BC6, lanes 1, 2 and 3).    
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Figure 3.12: Western blot analysis of PrP
Sc  recovered from spikes of scrapie-infected 
brain homogenate in a background of uninfected brain homogenate. Wells were loaded 
with the PK digestion products from scrapie infected sheep brains spiked into an uninfected 
sheep brain homogenate to give a combined wet tissue equivalent of approx 500μg per well.  
Key: lanes 1-4, brain spikes of 20 mg, 2 mg, 200 µg & 20 µg wet tissue equivalent, 
respectively; lane 5, 500μg wet tissue equivalent of scrapie-infected brain homogenate (PK 
digested). Lane 6, 500 μg wet tissue equivalent of uninfected brain homogenate (PK digested). 
The blot was probed with BC6 and BH1 mAb at a concentration of 2 µg/ml. The blot was 
developed using standard ECL methods; the exposure time was 1 min.  Molecular masses are 
shown on the left (kDa).   106
The diglycosylated band in the 20 µg brain spike was consistently visible using BC6 
although the intensity of the signal varied (data not shown). Detection of the same band 
was not obvious with BH1 which was surprising as both antibodies had previously been 
shown to detect PrP
Sc in the same amount of scrapie infected brain (figures 3.7, 3.8 and 
table 3.2). As brain spiked samples were prepared separately for each antibody it is 
possible that there is slight sample variation which may account for this result.   
Previously using these antibodies the di-, mono- and unglycosylated band were 
detected in the equivalent of 20 µg wet tissue scrapie brain homogenate and the 
diglycosylated band was detected in as little as 2 µg wet tissue (section 3.3.4 and table 
3.2).  It is possible in the spiking experiments that the PrP present in the normal brain 
caused the ratio of PK to total protein concentration to be altered and more undigested 
PrP
C was present.  This high background of PrP
C may have contributed to the reduction 
in the signal on the immunoblot as less PrP
Sc could be detected against the background 
of undigested PrP
C.  However, the levels of undigested PrP
C would have to be lower 
than are detectable by sensitive Western blotting as a signal was not observed in 
uninfected brain homogenate following digestion with the same concentration of PK as 
used in the spiked samples (figure 3.12, lane 6).  In addition to 50 µg/ml, higher 
concentrations of 75 µg/ml and 100 µg/ml of PK were also tested. Detection was not 
improved although further repeat experiments are required to confirm the effect of 
higher PK concentrations (data not shown). Brain contains material such as 
deoxyribonucleic acid (DNA) and connective tissues that are not easily disrupted by 
sonication.  The presence of such material may be affecting the recovery of spikes from 
uninfected brain. Therefore to try to overcome these matrix effects and to maximise 
solubility of the infected and normal brain material, samples were solubilised using 
different sonicators and in different buffers (6M guanidinium hydrochloride and 0.1 % 
sarcosyl).  However again, the smallest recoverable spike was 20 µg wet tissue 
equivalent (data not shown). 
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To overcome potential variability in results (see above), spiked scrapie brain samples 
were prepared in bulk and directly compared to non-spiked brain samples (figure 3.13, 
panel 1 and 2).  
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Figure 3.13: The sensitivity of Western blot detection of PrP
Sc is similar for spiked and 
unspiked samples.  Wells were loaded with the PK digestion products from scrapie-infected 
sheep brains spiked into an uninfected sheep brain homogenate to give a combined wet tissue 
equivalent of approx 500 µg per well.  The equivalent unspiked samples are also shown.   Key:  
lanes 1 & 5, 200 µg; lanes 2 & 6,100 µg; lanes 3 & 7, 50 µg and lanes 4 & 8, 25 µg wet tissue 
equivalent, respectively.  The blot was probed with BC6 at a concentration of 2 µg/ml. The blot 
was developed using standard ECL methods; the exposure time was 30 min.  Molecular masses 
are shown on the left (kDa). 
 
These experiments consistently demonstrated a reproducible detection limit that was 
similar for spiked scrapie brain samples when compared to scrapie brain that was not 
spiked into normal brain homogenate (figure 3.13).    Again there were differences 
between the overall recovery of detection in spiked samples (faint diglycosylated band 
in 25 µg wet tissue in figure 3.13 yet a more intense signal seen with 20 µg wet tissue 
in figure 3.12).  Also, based on previous results it would be expected that all PrP 
glycoforms would be visible in 200, 100, 50 and 25 µg wet scrapie brain tissue 
although this is not apparent (figure 3.13).    These differences may be due to slight 
variations of the amount of PrP
Sc in individual scrapie brain aliquots or loss of PrP 
during long term sample storage.  Additionally, although great care was taken to ensure 
that samples were processed in an identical manner and that equal amounts were loaded 
onto the gels, it is possible that variability in protein loading could also account for   108
differences in immunoblot signals. However, because recovery of brain spikes is 
similar to non-spiked samples this demonstrates that the sensitivity of the Western 
immunoassay is not substantially altered when recovering small quantities of PrP
Sc 
against a high background of other proteins. This confirms that the assay is suitable for 
PrP
Sc detection in tissue samples where the protein in present at low concentrations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   109
3.4. Discussion 
 
The aim of the research presented in this chapter was to develop a sensitive Western 
blot immunoassay that could be applied to conventional PK-resistant PrP
Sc detection in 
blood.  Overall sensitivity was increased by incorporating a NaPTA precipitation step 
to concentrate PrP
Sc, and screening a panel of novel monoclonal antibodies raised 
against recombinant sheep PrP.  Using the optimised method, conventional PrP
Sc was 
detected in as little as 2 µg wet brain equivalent, although in brain spiking experiments 
to mimic in vivo conditions, the sensitivity was slightly reduced, with consistent 
recovery of 20 μg brain spikes.   
 
Sensitive methods are required for TSE diagnosis, especially when applied to 
peripheral tissues during pre-clinical infection. Even in clinical cases of some TSE 
diseases (e.g. vCJD, scrapie), PrP
Sc positive peripheral tissues contain PrP
Sc levels in 
the range of 0.1-15 % of those found in brain (Wadsworth et al., 2001; Andreoletti et 
al., 2002).  Therefore, a variety of procedures to concentrate PrP
Sc have been employed 
to improve assay sensitivity.  NaPTA precipitation has previously been shown to 
concentrate PrP
Sc (Safar et al., 1998; Wadsworth et al., 2001), allowing for detection of 
PrP
Sc in tissues previously thought to be negative (Glatzel et al., 2003). In agreement 
with other investigators, when a NaPTA concentration step was included in the 
protocol for Western blotting of sheep PrP
Sc,
 the sensitivity of detection was increased  
   
approximately four-fold.  The exact molecular mechanism of PrP
Sc interaction with 
NaPTA is unknown but may be specific for PK resistant and sensitive forms of PrP
Sc 
(Safar et al., 1998; Tremblay et al., 2004).  The extent of PrP
Sc concentration may also 
be dependent on the size, shape and charge of the NaPTA molecules (Lee et al., 2005) 
and it is possible that this could be experimentally manipulated to further maximise 
PrP
Sc concentration.  In addition to NaPTA precipitation, other approaches have been 
used to concentrate PrP
Sc.  Examples include commercially developed ligands for 
specific PrP
Sc capture (Nazor et al., 2005), use of fluorescence labelled palindromic PrP 
peptides to detect misfolded PrP (Pan et al., 2007) and ELISA based assays using the 
same monoclonal antibody for both capture and detection (Pan et al., 2005).  However, 
these methods use commercially developed reagents that are not available for general   110
use, which is why these approaches were not employed to develop or combine with the 
sensitive Western blot.     
 
The European Commission validated three diagnostic tests in 1999 for cattle PrP
Sc. The 
Prionics test is based on a Western blot using the monoclonal antibody 6H4 (epitope in 
the C-terminus, sequence DYEDRYYRE).  The Enfer test (produced by Enfer 
Technology Ltd) is a high throughput chemiluminescent ELISA that uses a polyclonal 
anti-PrP antibody for detection. The TeSeE test (Bio-Rad) is also based on an ELISA 
where PrP
Sc is treated with PK, solubilised and denatured before detection by a 
sandwich ELISA using two monoclonal antibodies. These validated tests are for cattle 
and BSE and have not been found to directly cross over to small ruminants. To address 
this, Bio-Rad have developed a separate sheep and goat TeSeE rapid assay kit as the 
original cattle TsSeE kit did not contain monoclonal antibodies with high affinities to 
sheep and goat PrP
Sc. PrP
Sc  detection limits in cattle brain can be estimated using 
reports in previous publications where the Prionics test has a detection limit of 5-20 
pmol, the TeSeE test, 0.5-2 pmol and the Enfer test, 1-10 pmol (Brown et al., 2001; 
Ingrosso et al., 2002; Soto et al 2004).  However, it is very difficult to compare the 
sensitivities of commercial TSE tests with the sensitive Western blot described in this 
thesis. This is because commercial reagents are often tested using dilutions of brain 
from species other than sheep. The concentration of PrP in brain material will vary 
depending on the species, the TSE agent and the area of brain sampled.  In order to 
perform a true comparison, commercial antibodies and reagents would have to be tested 
alongside the panel of novel monoclonal antibodies described in this thesis using 
standardized brain samples.  Due to time considerations, these experiments were not 
carried out.      
   
Screening of the panel of novel anti-PrP monoclonal antibodies against PK digested 
sheep and mouse scrapie brain samples identified antibodies that appeared to bind PrP
Sc 
with high affinity on Western blots, as reflected by differences in the signal intensities. 
The epitopes of these antibodies are located towards the C terminus of ovine PrP 
(between amino acids 90-233), but the conformation of PrP
Sc might influence how 
accessible certain epitopes are to antibody binding, and this could also explain some of   111
the observed difference in signal intensity with different antibodies. Titrations of 
primary and secondary antibodies were performed to optimise the concentrations 
required to achieve maximum assay sensitivity, while minimising the effects of non-
specific binding (at higher antibody concentrations), resulting in high background 
staining. Attempts to increase sensitivity by using an alternative chemiluminescence 
substrate resulted in unacceptably high levels of background staining, and did not 
improve assay sensitivity, although it did have the advantage that less primary and 
secondary antibody was required to obtain a signal.    
 
The level of sensitivity achieved with the optimized Western blot for sheep PrP
Sc 
compares well with that reported by other authors using similar methods. Wadsworth et 
al. (2001) were able to detect PrP
Sc  in 5 nl of 10 % vCJD brain homogenates 
(equivalent to 0.5 µg wet tissue weight) by using NaPTA precipitation in conjunction 
with high sensitivity detection systems, which is only slightly more sensitive than the 
optimised Western blot assay developed here. However, using the hamster 263K 
scrapie model, Lee et al. (2000) demonstrated PrP
Sc detection in 10-20 ng brain tissue 
equivalents, which is approximately 100 fold more sensitive than the detection limit 
achieved using the method described here. A likely explanation for the observed 
differences is that the PrP
Sc concentration in the starting samples is not the same, 
because of differences in the species and/or TSE agent. In particular, hamsters infected 
with the 263K scrapie strain are known to have unusually high concentrations of PrP
Sc 
in brain and other tissues,
  whereas in sheep with natural scrapie there is much 
variability in the amount of PrP
Sc deposited in brain.  Evidence suggests that this could 
be influenced by sheep PrP genotype with the highest levels of PrP
Sc deposition found 
in VRQ/VRQ sheep, the genotype of the sheep samples used in these experiments 
(McCutcheon  et al., 2005).  The different detection limits reported for different 
immunoassays may also reflect apparent variations in the relative amounts of PK 
resistant and PK sensitive PrP
Sc shown in different TSE strains (Safar et al., 1998) or 
species.  If samples contain high levels of PK sensitive PrP
Sc, overall assay sensitivity 
may be reduced.   
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In conclusion, a highly sensitive, rapid, Western blot assay for detection of 
conventional sheep PK-resistant PrP
Sc  has been developed.  The sensitivity of the 
method was increased by incorporation of a NaPTA precipitation step and use of new 
monoclonal antibodies raised against sheep PrP, to give a reliable detection limit of 
approximately 20µg scrapie brain tissue equivalents, similar to that achieved in other 
published Western blot methods. The next aim was to apply the optimised assay to 
detection of conventional PK resistant PrP
Sc in blood samples from scrapie-infected 
sheep.  
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Chapter 4 
Can PrP
Sc Be Detected In Blood From 
Scrapie-Infected Sheep Using A Sensitive 
Western Blot Immunoassay?  
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4.1.  Introduction 
 
Despite a wealth of research in recent years, several fundamental issues concerning the 
transmissibility of TSE disease through blood transfusion remain unsolved, such as the 
nature of the infectious agent and the distribution of infectivity in blood components.  
The latter is of particular importance for the development of safer methods of blood 
transfusion in humans, where commonly used blood components include plasma, 
platelets and red cells.  Since October 1999 leukocytes have been depleted from all 
blood used for transfusion in the United Kingdom, but the effectiveness of this measure 
in preventing or reducing vCJD transmission is unknown.  Leucoreduction appears to 
remove only about 42 % of TSE infectivity (Gregori et al., 2004), although 
leucoreduced blood that is passed through prion removal filters containing resin 
appears to remove all the residual infectivity (Gregori et al 2006).  However, 
leucoreduction does not remove all TSE infectivity and defining exactly which blood 
components are infectious remains crucial.      
 
In some TSE diseases such as scrapie, vCJD and some experimental rodent TSE 
models, the agent is replicated in lymphoreticular tissues before infection of the CNS 
(Eklund et al., 1967; Hadlow et al., 1982; Hill et al., 1999).  Lymphocytes recirculate 
between lymphoid tissues and blood and in TSE infected animals it is likely that 
infectivity is spread in this manner, although it is not believed significant for 
neuroinvasion (Blattler et al., 1997).  Experimental rodent TSE models have 
demonstrated low levels of infectivity in blood during preclinical and clinical stages of 
disease (Brown et al., 1998, 1999; Cervenakova et al., 2003).  Despite these 
experiments it has proved difficult until recently to demonstrate that blood from natural 
TSE cases contains infectivity (Hadlow et al., 1980; Hadlow et al., 1982; Fraser et al., 
1994). This is because in rodents only small volumes of blood or blood components can 
be assayed by i/c inoculation.  Also transmission of infection may be limited by species 
barrier effects.  However, transfusion of large volumes (up to 500ml) of whole blood or 
buffy coat from sheep with natural scrapie or experimentally infected with BSE 
resulted in efficient transmission of disease to recipient sheep in the absence of a 
species barrier (Hunter et al., 2002; Houston et al., 2000; Houston et al., 2008).   
Transmission can occur with blood collected early enough in the incubation period that   115
the donor sheep had no accumulation of abnormal PrP elsewhere (palatine tonsils, 
mesenteric lymph nodes and spleen) (Siso et al., 2006; Houston et al., 2008).    
Transmission of BSE from the blood of an experimentally infected primate 
(Microcebus murinus) has also been reported (Bons et al., 2002) and more recently 
CWD was transmitted via blood in white tailed deer fawns (Mathiason et al., 2006).  In 
addition, four cases of vCJD infection in recipients of non-leucodepleted red blood 
cells from known vCJD cases have occurred in humans (Llewelyn et al., 2004; Peden 
et al., 2004; Wroe et al., 2006; Health Protection Agency, 2007).  One of the 
individuals was also heterozygous for codon 129 of the prion protein gene (Peden et 
al., 2004).   
 
In humans and sheep, the distribution of infectivity between different blood 
components is unknown, but evidence from rodent TSE models suggests that the 
highest levels of infectivity are found in the buffy coat fraction of blood.  In mice 
infected with vCJD or a Gerstmann-Straussler-Scheinker (GSS) disease isolate 
(Fukuoka-1), there were similar infectivity levels of approximately 18-30 infectious 
units (IU) per ml in buffy coat, but no detectable infectivity in red cells (Cervenakova 
et al., 2003). Brown et al (1998) carried out experiments where scrapie-infected 
hamster brain homogenate was “spiked” into normal human blood and found that the 
highest levels were also in the buffy coat fraction with slightly lower levels in plasma.  
In follow up studies using the GSS mouse model described above, they found that 
preclinical blood contained 6-12 IU per ml in buffy coat, but infectivity was absent or 
present only in trace amounts in plasma.  Infectivity in the blood of clinical mice rose 
to 100 IU per ml in buffy coat, and 20 IU per ml in plasma (Brown et al., 1999).  In 
hamster scrapie, very little infectivity was found in association with purified platelets, 
although 22.6 IU per ml was associated with the buffy coat subset of mononuclear 
leukocytes (Holada et al., 2002).  In sheep, TSE infectivity was found in the buffy coat 
fraction of blood (Hunter et al., 2002; Houston et al., 2000) and more recent results 
revealed that infectivity appears mainly linked to the monocyte (CD14
+) subset of 
leukocytes in sheep (Andreoletti et al., 2007).  In addition to cell-associated PrP
Sc it is 
possible that PrP
Sc may be associated with blood cell membrane fragments.  Evidence 
exists which demonstrates an association between PrP
Sc released into the extracellular   116
environment and exosomes, suggesting their role in cell to cell agent transmission 
(Fevrier et al., 2004).  
 
The detection of PK resistant PrP
Sc is used as a biochemical marker for the presence of 
infectivity.  So far, most attempts to detect PrP
Sc in blood have been unsuccessful.  
Methods used to date include immunocapillary electrophoresis (Schmerr et al., 1999), 
immunocytochemistry (Hermann et al., 2002), and Western blotting (Wadsworth et al., 
2001), but the results so far have been negative or inconclusive. Levels of PrP
Sc in 
blood may be low, which presents challenges for assay sensitivity.  Although little is 
known regarding the distribution of TSE infectivity in blood, studies on the distribution 
of host PrP
C in blood have been carried out.  In healthy sheep there are significant 
levels of cell-surface PrP
C on peripherial blood mononuclear cells (PBMCs) with 
platelets containing high levels of intracellular PrP
C (Barclay et al., 2002; Halliday et 
al., 2005).  Therefore, PrP
Sc has to be identified against a high background of PrP
C.  
There is evidence for the existence of PK sensitive forms of PrP
Sc (Tremblay et al., 
2004) and very little is known about the biochemical properties of blood-associated 
PrP
Sc.  For instance, because PrP
Sc is present in very low amounts, in an environment 
with constant biochemical changes, it is unclear if PrP
Sc in blood can form aggregates 
resistant to PK digestion. 
 
Despite these challenges PrP
Sc has been amplified to detectable levels in TSE infected 
blood using a relatively new technique termed protein misfolding cyclic amplification 
(PMCA) therefore showing that if the assay has the required sensitivity then PrP
Sc 
detection in blood is possible (Castilla et al., 2005 ; Saa et al., 2006). Other recent 
detection techniques include aggregate specific ELISA where PrP
Sc aggregates were 
detected in plasma from mice or deer infected with scrapie or CWD (Chang et al., 
2007) or detection of misfolded PrP in TSE-infected plasma from mice using 
fluorescence labelled pallindromic PrP peptides (Pan et al., 2007).  These are very 
recent methods however, and use reagents that are not yet commercially available, 
hence they were not used/combined with the sensitive Western blot.    
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Chapter 3 describes a sensitive Western blot immunoassay for PK resistant PrP
Sc using 
scrapie infected sheep brain homogenates. The next step was to apply this new method 
to blood.  PrP
Sc is recognised conventionally as PK resistant, having a distinctive triple 
band pattern (between 27-30 kDa) on Western blots.  One aim of this thesis was to use 
the sensitive Western blot method to address the question of whether PrP
Sc is present in 
sufficient quantities to explain infectivity levels detected by bioassay and to be able to 
state clearly whether or not TSE infectivity in blood is associated with conventional 
PrP
Sc.  Attempts to detect PrP
Sc in blood using Western blotting have so far been 
unsuccessful.   When the method developed by Wadsworth et al. (2001) was applied to 
a buffy coat fraction from a single vCJD case PrP
Sc was not detected.  However only 
one 15 ml sample was tested and it is possible that assaying larger volumes of blood 
from multiple patients may allow detection PrP
Sc in at least some individuals. The 
optimised Western blot assay for sheep PrP
Sc clearly does not have the analytical 
sensitivity of the PMCA assay which can detect as few as 8,000 equivalent molecules 
of PrP
Sc in the hamster scrapie model (Saa et al., 2006). However, the advantage of 
applying the new method to blood samples from sheep experimentally infected with 
scrapie is that larger volumes of blood from multiple animals can be tested, which may 
overcome the need for amplification of PrP
Sc.  In Chapter 4, the detection limits of the 
new assay were established for PK resistant PrP
Sc in cellular components using SMB 
cells.  This allowed the development of modifications for use with cell extracts (rather 
than brain homogenate) before applying to blood. 
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4.2. Results 
 
4.2.1.  Establishing SMBs15 and SMB-PS cell lines 
 
The SMBs15 (Scrapie-infected mouse brain) cell line was established originally in 
culture from a brain taken from a mouse affected by the Chandler scrapie isolate 
(Clarke and Haig, 1970) and shown to be of mesodermal origin (Haig and Clarke, 
1971).  Cells continuously produce low levels of PrP
Sc, but can be cured of infection 
with pentosan sulphate.  Such uninfected cells are referred to as SMB-PS cells (Birkett 
et al., 2001). SMBs15 and SMB-PS cells obtained from the TSE Resource Centre at 
IAH Compton were grown as described in chapter 2, section 2.3.2.  Figure 4.1 
illustrates the phenotypic characteristics of these cells.  
 
 
 
SMB-PS p3    x10           SMBs15 p3     x10 SMB-PS p3    x40          SMBs15 p3     x40 SMB-PS p3    x10           SMBs15 p3     x10 SMB-PS p3    x40          SMBs15 p3     x40
 
 
Figure 4.1:  Phenotypic characteristics of SMB-PS and SMBs15 cells.  Cells were passaged 
three times (p3) and photographed at forty times magnification (x 40). 
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4.2.2.   Application of the sensitive Western blot method developed in brain to 
SMB cells 
 
Using Western blot analysis it was confirmed that infected SMBs15 cells showed 
evidence of conventional PK resistant PrP
Sc (figure 4.2, lanes 6-8) unlike uninfected 
SMB-PS cells (figure 4.2, lanes 2-4).  It was surprising that a signal on the Western blot 
was not seen in SMB-PS cells without PK digestion (figure 4.2, lane 1) as these cells 
have been shown to contain PrP
C (Birkett et al., 2001).  A signal may have been 
apparent if more sample was used, although this was not pursued as all subsequent 
experiments were carried out on infected SMBs15 cells.  
 
Following treatment with varying concentrations of PK, a similar signal was observed 
in SMBs15 cells under all PK conditions (figure 4.2, lanes 6-8). As an intense PrP
Sc 
signal was seen using 75 µg/ml PK and PK concentrations of 75-100 µg/ml are 
routinely used in SMB blotting methods (Birkett et al., 2001; Rudyk et al., 2000) a 
final PK concentration of 75 µg/ml was used in all subsequent Western blot 
experiments with SMB cells.   
 
 
 
 
 
 
   120
30.2
25.1
12.7
1    2    3    4     5    6     7    8    9
SMB-PS           SMBs15       MB
PK               - +   +    +      - +    +    +    +
30.2
25.1
12.7
1    2    3    4     5    6     7    8    9
30.2
25.1
12.7
1    2    3    4     5    6     7    8    9
30.2
25.1
12.7
30.2
25.1
12.7
1    2    3    4     5    6     7    8    9
SMB-PS           SMBs15       MB
PK               - +   +    +      - +    +    +    +
 
 
Figure 4.2:  Testing optimal PK digestion on Western blots of PrP
Sc  and PrP
c from   
SMBs15 and SMB-PS cell lysates (approx 1 x 10
6 cells).  Key: lanes 1-4, SMB-PS lysates: 
lanes 5-8, SMBs15 lysates.  Lane 1 & 5, cells were not PK digested: lane 2 & 6, 20 µg/ml PK: 
lanes 3 & 7, 50 µg/ml PK:  lanes 4 & 8, 75 µg/ml PK.  Lane 9, 500 µg wet tissue equivalent of 
PK digested (50 µg/ml) 139 A scrapie infected murine brain homogenate (MB). The blot was 
probed with the mAb BH1, and developed using standard ECL methods; the exposure time was 
30 sec.  Molecular masses are shown on the left (kDa).  
 
The effect of NaPTA precipitation was then examined and resulted in an enhancement 
in the signal for PrP
Sc (figure 4.3, lane 1 compared to lane 2) and was therefore used in 
all subsequent experiments.  The antibodies BH1 and BC6 were tested as these gave the 
highest sensitivity of detection on blots using scrapie brain as described in chapter 3.  
Similarly in SMBs15 cells a signal was observed when both antibodies were used 
(figure 4.3).  The primary and secondary antibody concentrations (2 µg/ml and 1:7000) 
that were used in the optimised Western for brain homogenates were also used in 
SMBs15 cell experiments.    
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Figure 4.3: Testing the effect of NaPTA and different mAbs on Western blots of PrP
Sc and 
PrP
c from SMBs15 cell lysates.  Samples were NaPTA precipitated and/or PK digested and 
probed with antibodies as indicated at a concentration of 2 µg/ml.  In each lane approx 1 x 10
6 
cells were lysed. The blot was developed using standard ECL methods; the exposure time 30 
sec.  Molecular masses are shown on the left (kDa).  
 
4.2.3.    Estimation of the sensitivity of Western blotting for detection of PrP
Sc 
positive cells in blood using SMB cell spikes  
 
A titration series of SMBs15 cells were analysed by Western blot to indicate the limits 
of detection of PrP
Sc in this cell line, and to establish the approximate number of cells 
needed to represent a PrP
Sc signal (well resolved bands). A PrP
Sc signal showing the 
three glycosyl bands without over-saturation of the signal was obtained with 1.25 x 10
5 
and 6 x 10
4 cells (figure 4.4, lanes 4 and 5, red stars).  The detection limit was reached 
at approximately 6 x 10
4 SMBs15 cells (figure 4.4, lane 5).  
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Figure 4.4:  Establishing limits of detection of PrP
Sc  from SMBs15 cells.   C e l l s  w e r e 
serially diluted in PBS from approx 1 x 10 
6 cells in lane 1, 5 x 10
5 cells in lane 2, 2.5 x 10
5 in 
lane 3, 1.25 x 10
5 in lane 4, 6 x 10
4 in lane 5, 3 x 10
4 in lane 6, 12 x 10
3 in lane 7, 6 x 10
3 in lane 
8 and 3 x 10 
3 cells in lane 9. The blot was probed with the mAb BH1 (2 µg/ml) and developed 
using standard ECL methods; the exposure time was 1 min.  Molecular masses are shown on 
the left (kDa).     
 
The sensitivity of the Western immunoassay was also assessed following spiking of 
SMBs15 cells into uninfected peripherial blood mononuclear cells (PBMC).   
Uninfected PBMCs were used as diluent because ultimately the Western assay would 
be applied to buffy coat samples (which include PBMCs) from clinical scrapie cases.  
Decreasing numbers of SMBs15 cells were added to increasing numbers of uninfected 
PBMCs, and these results were compared with a titration of SMBs15 cells only (figure 
4.5).  The results were very similar, confirming that the limit of PrP
Sc detection was 
reached at 6 x 10
4 SMBs15 cells, in both spiked and unspiked samples.  Thus the 
sensitivity of the assay is maintained even when SMBs15 cells are diluted into much 
larger numbers of uninfected cells.  
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Figure 4.5: The detection limit of PrP
Sc from SMBs15 cells and SMBs15 cells spiked into 
uninfected PBMCs on Western blots is the same.  Numbers of SMBs15 cells per well: lanes 
1 & 10, 2 x 10 
6 : lanes 2 & 11, 1 x 10 
6  : lanes 3 & 12, 5 x 10
5 : lanes 4 & 13, 2.5 x 10
5 : lanes 
5 & 14, 12 x 10
4 : lanes 6 & 15,  6 x 10
4 : lanes 7, 8, 9 & 16, 1.5 x 10
4.  SMBs15 cells were 
mixed with differing numbers of uninfected PBMCs to give a total number of 4 x 10 
6 cells per 
well (shown as spiked above the blot). Lane 17, 4 x 10 
6 PBMC cells only. Lane 18, 500 µg wet 
tissue equivalent of 139 A scrapie infected murine brain homogenate (PK digested). Lane M 
indicates the presence of markers.  The blot was probed with the mAb BC6 at a concentration 
of 2 µg/ml and developed using standard ECL methods; the exposure time was 1 min.   
Molecular masses (kDa) are shown on the left on the un-spiked blot and the right on the spiked 
blot.     
 
To test this further and to establish how many cells could physically be loaded and well 
resolved on a gel, SMBs15 cell spikes (12 x 10
4 and 6 x 10
4) were mixed with greater 
numbers of PBMCs (1 x 10
7, 5 x 10
7 and 1 x 10
8).  The results obtained give an  
indication of numbers of PBMCs that can be pooled into one sample to be resolved on 
a gel. The signal from 12 x 10
4 and 6 x 10
4 SMBs15 cells could still be recovered even 
after dilution into 1 x 10
8 PBMCs, with a similar signal intensity to that obtained from 
unspiked SMBs15 cells (figure 4.6, lanes 5 and 6 compared to lanes 7 and 8).  When 
SMBs15 cells were spiked into uninfected PBMCs, in addition to the conventional 
PrP
Sc signal from the cell line, high molecular weight bands were also visible (40-133 
kDa) which are discussed in more detail in section 4.3.   
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Figure 4.6:  Cell loading limits and recovery of PrP
Sc  from SMBs15 cells spiked into 
increasing numbers of uninfected PBMCs.   Numbers of SMBs15 cells per well: lanes 1, 3, 5 
& 7,  12 x 10 
4 : lanes 2, 4, 6 & 8, 6 x 10
4.  Numbers of PBMCs per well: lanes 1 & 2, 1 x 10
7: 
lanes 3 & 4, 5 x 10
7: lanes 5 & 6, 1 x 10
8.  Lane 9, 500 µg wet tissue equivalent of 139 A 
scrapie infected murine brain homogenate (PK digested). The blot was probed with the mAb 
BC6 at a concentration of 2 µg/ml and developed using standard ECL methods; the exposure 
time was 1 min.  Molecular masses are shown on the left (kDa).     
 
  
4.2.4. Application of the sensitive Western blot method to frozen buffy coat 
preparations from uninfected sheep blood 
 
Given the success of results when the sensitive Western blot method was applied to 
SMBs15 cells, this assay was tested on uninfected blood in order to establish the 
biochemical conditions for these cell types. There is strong evidence from rodent 
(Brown et al., 1998, 1999), sheep (Hunter et al., 2002;  Houston et al., 2008) and 
primate models (Bons et al., 2002)  to suggest that infectivity is mainly associated with 
leukocytes and this was the reason for initially studying buffy coat (which largely 
consists of leukocytes, including PBMC and granulocytes) and PBMC subsets.  
 
Experiments (figures 4.7, 4.8, 4.9, 4.12 and 4.14) were carried out using a starting 
volume of 50 ml of blood from four uninfected sheep. The number of buffy coat or 
PBMC cells obtained from 50 ml of blood ranged from between 1 x 10
6 to 1 x 10
8 cells.   125
The cell numbers analysed in each blot are detailed in each figure legend. Each 
experiment was repeated three times and representative blots are shown.  
 
One main difference between the sample preparation when using blood compared to 
either brain or SMBs15 cells was that buffy coat samples were  extremely viscous, 
which not only proved difficult to load but also resulted in ‘smearing’ of the samples 
during SDS-PAGE.  After Western blotting, samples did produce a signal which was in 
the region of 83-41 kDa (figure 4.7 lanes 1 and 2).  Conventional PrP
C has a molecular 
weight of around 25-35 kDa so the signal produced in the region of 83-41 kDa was 
unexpected.  It is possible that this represents non-specific binding.  Alternatively 
NaPTA could be concentrating PrP associated with other proteins or possibly causing 
the artificial aggregation of PrP in the buffy coat.   
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Figure 4.7:  Western blot analysis of PrP
C from uninfected buffy coat samples.   Key:  
Lanes 1 & 2, approx 1 x 10 
7 buffy coat cells from two different uninfected sheep. In lanes 1 & 
2 samples were lysed, before NaPTA precipitation.  Samples were not PK digested.  Lane 3, 1 
x 10 
6  PK digested SMBs15 cell lysate. The blot was probed with the mAb BC6 at a 
concentration of 2 µg/ml and developed using standard ECL methods; the exposure time was 4 
hr.  Molecular masses are shown on the left (kDa).     
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To reduce the viscosity of the samples and to improve loading, uninfected buffy coat 
samples were treated with four buffers (summarised in table 4.1) each containing 
varying concentrations/combinations of nucleases in PBS.  It was found that viscosity 
was reduced significantly when a combination of 2.5 µg DNase and 50 U/ml 
Benzonase was added (buffer 1, table 4.1, figure 4.8, lane 5).  To check how efficiently 
the samples had resolved using the varying nuclease conditions the gel was also stained 
with Ponceau S to show total protein on the membrane (figure 4.8). It was found that 
the buffy coat proteins had resolved well. After blotting with an anti-PrP antibody 
bands as observed previously in the range of 83-40 kDa and also between 133 and 83 
kDa (in figure 4.7) were again apparent (figure 4.8, all lanes).  
 
                Buffer  Amount of Benzonase  Amount of DNase 1 
1  50 units / ml  2.5 µg 
2  50 units / ml   5 µg 
3  100 units / ml  2.5 µg 
4  100 units / ml  5 µg 
 
Table 4.1:  Buffers containing varying concentrations/combinations of nucleases used to 
improve sample preparation of buffy coat samples. 
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Figure 4.8:  Screening of nuclease conditions on Western blots of NaPTA precipitated 
PrP
C from uninfected buffy coat samples.  A Western blot and Ponceau S stained membrane 
are shown. Buffy coat samples tested were obtained from a single uninfected sheep. A 
combination of Benzonase (Ben.) and DNase 1 was used as shown. Key: Lanes 1, 5, 6, 9 & 10, 
50 U/ml Benzonase.: lanes 2 & 7, 100 U/ml Benzonase : lanes 3, 5 & 9, 2.5 µg  DNase 1: lanes 
4, 6, 8 & 10, 5 µg DNase 1  Samples in lane 7-10 were pre-washed in PBS before nuclease 
treatment.  The blot was probed with the mAb BC6 at a concentration of 2 µg/ml and 
developed using standard ECL methods; the exposure time was 4 hr.  Molecular masses are 
shown on the left (kDa).     
 
Because sheep granulocytes do not express PrP
C (Halliday et al., 2005) and the 
contents of lysed granulocytes could be compromising the assay and possibly 
contributing to the production of bands in the 40-133 kDa region, it was decided to 
remove the granulocytes from the buffy coat samples.  Platelets which are also present 
in buffy coat fractions have been shown, when activated, to produce high molecular 
weight complexes on Western blots (Jones et al., 2005), although minimal numbers of  
platelets within the buffy coats tested here are likely to be present.  However, to 
increase purity, buffy coat fractions were subjected to density gradient centrifugation to 
isolate PBMCs (chapter 2, section 2.3.3.2).    The 40-133 kDa bands were again evident 
in uninfected PBMCs, although there was also a band seen around 35-40 kDa which 
could correspond to the diglycosylated form of the PrP protein.  Bands corresponding 
to the mono and unglycosylated forms of PrP may also have been present in non-  128
NaPTA treated uninfected PBMCs (figure 4.9, lanes 7-10, indicated by the arrows).  
However, to conclusively show conventional PrP
C in blood by Western blotting, further 
optimisation of the method (carried out in section 4.5.) was required. 
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Figure 4.9:  Establishing the effect of NaPTA precipitation on titrations of uninfected 
PBMCs.      Number of PBMCs per well: lane 3 & 7, 5 x 10 
7: lane 4 & 8, 1 x 10 
7: lane 5 & 9, 
5 x 10 
6: lane 6 & 10,1 x 10 
6 . PBMC samples tested were obtained from a single uninfected 
sheep. Lanes 3-6, samples have been NaPTA precipitated, lanes 7-10 samples have not been 
NaPTA precipitated.  Lane 1, 500 µg wet tissue equivalent of NaPTA precipitated uninfected 
sheep brain homogenate: lane 2, 500 µg wet tissue equivalent of uninfected sheep brain 
homogenate (UB).  Signals in lane 1 &2 are almost identical due to blot exposure. The blot was 
probed with the mAb BC6 at a concentration of 2 µg/ml and developed using standard ECL 
methods; the exposure time was 2 hr.  Molecular masses are shown on the left (kDa).    
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4.2.5.  Major modification to the sensitive Western blot method to allow for the 
detection of conventional PrP
C in  blood components from uninfected and scrapie-
infected sheep   
 
Many months were spent changing and developing new biochemical extraction 
procedures which would allow for detection of ‘conventional’ PrP
C in blood. In fact 
each step of the original method (which although worked well for both brain and SMB 
cells) was re-optimised. The changes are schematically illustrated in figure 4.10 and the 
output results, from initial tests on uninfected and scrapie brain, shown in figure 4.11. 
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1 x 106 PBMCs lysed in cell lysis buffer
Incubate on ice for 5 min
Spin for 5 min at 3,500 rpm
Addition of 50 µg/ml (w/v) PK to the supernatant 
(infected cells only)
Addition of 0.3 % (w/v) NaPTA overnight
SDS PAGE / Western blot
Nuclease / Sarcosyl
treatment omitted
No incubations at
37 ° C
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Spin for 5 min at 3,500 rpm
Addition of 50 µg/ml (w/v) PK to the supernatant 
(infected cells only)
Addition of 0.3 % (w/v) NaPTA overnight
SDS PAGE / Western blot
1 x 106 PBMCs lysed in cell lysis buffer
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Spin for 5 min at 3,500 rpm
Addition of 50 µg/ml (w/v) PK to the supernatant 
(infected cells only)
Addition of 0.3 % (w/v) NaPTA overnight
SDS PAGE / Western blot
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Incubate on ice for 5 min
Spin for 5 min at 3,500 rpm
Addition of 50 µg/ml (w/v) PK to the supernatant 
(infected cells only)
Addition of 0.3 % (w/v) NaPTA overnight
SDS PAGE / Western blot
Nuclease / Sarcosyl
treatment omitted
Nuclease / Sarcosyl
treatment omitted
No incubations at
37 ° C
No incubations at
37 ° C
 
 
Figure 4.10:  Major modifications to the sensitive Western blot method allow for detection 
of conventional PrP
C.  Each step of the original method was re-optimised.  As indicated by the 
red text in the boxes, the final method did not include treatment with nucleases or sarcosyl or 
incubation at 37 º C.  Following optimisation, the flow diagram represents the final Western 
blot method used in blood.  
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Figure 4.11:  Harsh detergents and long incubation steps used in the Western blot protocol result in degradation of PrP
C.  Wells were loaded 
with 300 µg wet tissue equivalent of uninfected sheep brain homogenate or the PK digestion products from 300 µg wet tissue equivalent of scrapie 
infected sheep brain homogenate as indicated.  The sensitive Western blot method (chapter 3) was applied to samples in lane 1.  In lane 2, the nuclease 
step and incubation for 30 min at 37 º C was omitted.  In lane 3, the detergent extraction and incubation step for 10 min at 37 ºC were omitted.  In lane 4 
& 5, samples were lysed in cell lysis buffer, the pellet and supernatant loaded after incubation for 10 min at 37 ºC and NaPTA precipitation respectively.  
This was repeated but without the incubation step for 10 min at 37 º C, the supernatant loaded in lane 7, the pellet in lane 8, repeated in lane 9.  In lane 6, 
cell lysis buffer instead of 4 % sarcosyl was used in the detergent extraction step.  The blot was probed with the mAb BC6 at a concentration of 2 µg/ml  
and developed using standard ECL methods; the exposure time was 10 min.  Molecular masses are shown on the left (kDa).             132
 
It was discovered that when the original sensitive Western blot was applied to 
uninfected brain, there was no signal for conventional PrP
C (figure 4.11, lane 1).  This 
was unusual, but highlighted the need for these further optimisation experiments.     
When sample incubation steps at 37 º C were omitted from the methodology, the 
amount of PrP
C recovered in uninfected sheep brain was increased (figure 4.11, lanes 2 
and 3 compared to lane 1).  Additionally the use of sarcosyl appeared to result in PrP
C 
degradation (figure 4.11, lane 6) whereas cell lysis buffer (chapter 2, section 2.2.4) 
which contains 0.5 % (v/v) igepal and 0.5 % (v/v) sodium deoxycholate results in a 
greater PrP
C recovery (figure 4.11, lanes 7 and 8).  Interestingly no difference in the 
Western blot signal was observed in PK digested scrapie brain homogenates.  It may be 
that the conformation of PrP
Sc is more robust and less prone to degradation in certain 
detergents and at 37 º C (figure 4.11).  
 
Optimum recovery of PrP
C was achieved using cell lysis buffer with incubation on ice 
(figure 4.11, lane 7) and this method was then applied to uninfected PBMCs purified 
from whole blood taken from healthy sheep as shown in figure 4.12.  All subsequent 
experiments were carried out using the modified method which will be referred to as 
the blood Western blot method. 
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Figure 4.12:  PrP
C detection in uninfected PBMCs and the appearance of high molecular 
weight bands after NaPTA precipitation.  Key: Lanes 1 – 5 and 7 – 11 approx 1 x 10
6 
uninfected PBMCs. PBMC samples tested were obtained from a single uninfected sheep. Lane 
6 & 12 wells were loaded with 300 µg wet tissue equivalent of uninfected brain homogenate 
(UB).   Samples were PK digested and NaPTA precipitated as indicated.  The blot was probed 
with the mAb BC6 at a concentration of 2 µg/ml and developed using standard ECL methods; 
the exposure time was 10 min.  Molecular masses are shown on the left (kDa).     
    
Conventional PrP
C was detected in uninfected frozen PBMCs (figure 4.12, lanes 1, 2) 
and the glycoform profile was similar to that seen in uninfected brain (figure 4.12, lane 
6).  As expected PK digestion resulted in degradation of PrP
C (figure 4.12, lanes 3, 4 
and 5).  Interestingly, bands of higher molecular weight than PrP
C (approximately 40 – 
60 kDa and 109 kDa) were seen after NaPTA precipitation of PBMC samples (figure 
4.12, lanes 8 and 9) but were absent in PK treated samples (figure 4.12, lanes 10 and 
11).  This effect was not observed in uninfected brain (figure 4.12, lane 12).  High 
molecular weight bands were still present even when low concentrations of NaPTA 
(0.0075 %) were used (data not shown given that the outcome was the same as seen in 
figure 12).    Uninfected animals were confirmed as TSE free by immunohistochemical 
analysis of medulla brain sections (data not shown). 
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After testing uninfected PBMCs, the blood Western blot method was applied to frozen 
PBMCs from sheep clinically affected with scrapie. Blood (50 ml) was obtained from 
ten scrapie-infected sheep. The number of buffy coat or PBMC cells obtained from 50 
ml of blood ranged from between 1 x 10
6 to 1 x 10
8 cells. The cell numbers analysed in 
each blot are detailed in each figure legend. Each experiment was repeated three times. 
Figure 4.13 shows a representative blot from two scrapie-infected sheep.  Figure 4.14 is 
a representative blot from a third scrapie-infected animal. Representative blots where 
blood from the remaining seven sheep clinically affected with scrapie was tested are 
shown in Appendix 5. 
 
As observed for the uninfected PBMC samples, without PK digestion or NaPTA 
precipitation the glycoform profile for PrP in PBMCs (figure 4.13, lane 1) from 
scrapie- infected animals and brain were similar (figure 4.13, lanes 5 and 6).  When 
PBMC samples were PK digested no signal was observed (figure 4.13, lane 3 and 4).  
This indicated that the conventionally defined PrP
Sc is undetectable in the sample using 
this very sensitive method. 
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Figure 4.13:  Western blot analysis of PBMCs from scrapie-infected sheep without 
NaPTA precipitation.  Key: Lanes 1 & 3 and 2 & 4, approx 1 x 10
6 PBMC from two different 
scrapie infected sheep. Lanes 5 – 7, wells were loaded with 300 µg wet tissue equivalent of 
scrapie brain homogenate (SB).  M indicates markers.  Samples were PK digested without 
subsequent NaPTA precipitation as shown.   The blot was probed with the mAb BC6 at a 
concentration of 2 µg/ml and developed using standard ECL methods; the exposure time was 5 
min.  Molecular masses are shown on the left (kDa).     
 
NaPTA precipitation of samples resulted in high molecular weight bands of a similar 
molecular weight (approximately 40-60 kDa) as observed in uninfected PBMC 
samples.  Unlike uninfected PBMC samples (figure 4.14, lanes 1 and 2) the high 
molecular weight bands present in NaPTA treated samples appeared to be PK resistant 
(figure 4.14, lanes 3 and 4).  Conventional PrP bands were also observed in NaPTA 
treated PBMCs from uninfected (figure 4.14, lane 1) and scrapie-infected sheep and 
these were sensitive to PK (figure 4.14, lane 3).  Also, as previously observed, no high 
molecular weight bands were seen in scrapie infected (figure 4.14, lane 7 and 8) or 
uninfected brain homogenates treated the same way (figure 4.14 lanes 5 and 6).       
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Figure 4.14:  High molecular weight bands are PK resistant in PBMCs from scrapie-
infected sheep.  Key: In lanes 1 & 2 approx 1 x 10
6 uninfected PBMCs from one uninfected 
sheep. Lanes 3 & 4, approx 1 x 10
6 PBMCs from one scrapie-infected sheep.  In lanes 5 & 6 
wells were loaded with 300 µg wet tissue equivalent of uninfected sheep brain homogenate.  In 
lanes 7 & 8 wells were loaded with 300 µg wet tissue equivalent of sheep scrapie brain 
homogenate.  Samples were PK digested and NaPTA precipitated as indicated.  M indicates 
markers.  The blot was probed with the mAb BC6 at a concentration of 2 µg/ml and developed 
using standard ECL methods; the exposure time was 10 min.  Molecular masses are shown on 
the left (kDa).     
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4.3.  Discussion 
 
TSE agents can be transmitted via blood using sheep models (Houston et al., 2000; 
Hunter  et al., 2002; Houston et al., 2008) and in humans vCJD cases have been 
reported that were probably the result of infected blood transfusions (Llewelyn et al., 
2004; Peden et al., 2004; Health Protection Agency, 2007).  However, it is not known 
which blood components carry infection
  and in previous studies using various 
approaches, PrP
Sc  had not been detected in TSE-infected blood (Wadsworth et al., 
2001; Schmerr et al., 1999).  More recently a new technique (where PrP
Sc is amplified 
to detectable levels) termed PMCA has been applied to TSE infected buffy coat 
samples successfully (Castilla et al., 2005; Saa et al., 2006). However, the levels of 
PrP
Sc in blood prior to PMCA amplification are very low. Using a sensitive Western 
blot assay (described in chapter 3) the aim of this chapter was to establish if 
conventional PrP
Sc is present in blood.  The sheep model has the advantage of having 
large blood volumes and combined with this new sensitive Western blot analysis, it is 
clear that the patterns of protein detected with an anti-PrP antibody on Western blots 
are very different from the conventional triple banded pattern of PrP
Sc.  These 
observations are intriguing and could form the basis of a TSE diagnostic blood test if 
confirmed.     
 
Initially the detection limit of the assay for cellular components was tested using SMB 
cells that express low levels of conventional PrP
Sc.  The minimum number of SMB 
cells in which a PrP
Sc signal could be detected using the optimized Western blot was
 6 x 
10
4 cells.  In spiking experiments where 6 x 10
4  SMB cells were spiked into increasing 
numbers of uninfected PBMCs, the same signal could be recovered even after dilution 
into 1 x 10
8 PBMCs.  This means that the ratio of infected cells in the total population 
was 0.01 %.  Therefore it can loosely be assumed in a buffy coat where conventional 
PrP
Sc was not detected that the number of infected blood cells is less than 0.01 %.  This 
indicates that a high level of sensitivity has been achieved, although it is based on the 
assumption that infected sheep blood buffy coat cells contain similar levels of PrP
Sc to 
SMB cells.  Also SMB cells are murine brain cells and therefore physiologically 
different to sheep blood cells and it is possible that not all of the SMB cells within the   138
population were infected.  However, although not ideal carrying out spiking 
experiments using a cellular system gives more of an indication of the level of 
sensitivity required for conventional PrP
Sc detection in blood than preparing brain 
homogenate spikes only. 
 
In order to apply the sensitive Western blot to buffy coat samples from sheep clinically 
affected with scrapie, the method had to be modified to incorporate additional nuclease 
treatments to reduce viscosity and improve sample loading.  Experiments to optimise 
conditions for electrophoresis and blotting of buffy coat samples were carried out using 
samples from uninfected sheep. However, bands corresponding to the molecular 
weights expected for PrP
C (between 20 and 40 kDa) were not observed on the blots, 
although higher molecular weight signals were consistently seen (40-133 kDa range).  
It is possible that the high molecular weight bands represent non-specific binding or 
that NaPTA precipitation is concentrating PrP associated with other proteins, or 
causing artifical aggregation of PrP.  This result was unexpected, since PrP
C has 
previously been detected in uninfected sheep PBMC by Western blotting (Halliday et 
al., 2005).  There were, however, differences in the methods used, for instance Halliday 
and colleagues did not use NaPTA precipitation. The buffy coat fractions tested in the 
present study contain granulocytes and platelets as well as PBMC, so it is possible that 
components of these cells may have interfered with the detection of PrP
C.  However, 
when PBMC were isolated from the sheep buffy coat samples, and analysed by 
Western blot, bands corresponding to the molecular weight of diglycosylated PrP
C were 
still inconclusive.  
 
Because of the problems detecting conventional PrP
C, the original method was 
significantly altered for PrP
C detection using uninfected and scrapie infected brain 
homogenate.  Although PrP
C and PrP
Sc have the same primary sequence and are 
covalently indistinguishable, they can be discriminated in several ways.  PrP
C exists as 
a monomer and has 43 % α-helix and 3 % β-sheet, whereas PrP
Sc tends to form 
aggregates and has 34 % α-helix and 43 % β-sheet (Pan et al., 1993).  Due to these 
structural differences, degradation of PrP
C in brain and blood samples may be more 
likely under conditions that include treatment with harsh detergents or incubation at   139
certain temperatures.  It was found that some steps in the methodology (i.e sample 
treatment with sarcosyl and long incubations at 37 º C) resulted in degradation of PrP
C 
from uninfected brain.  Structural analysis of PrP
C and PrP
Sc has proved difficult but 
refolded recombinant PrP (rPrP), which is soluble, monomeric and α-helical in 
structure, is thought to be representative of PrP
C and has been used for NMR analysis of 
the tertiary structure (Zahn et al., 2000; James et al., 1997; Lopez Garcia et al., 2000; 
Riek et al.,  1997) and x-ray crystal structures have been published (Knaus et al., 2001; 
Eghiaian et al., 2004; Haire et al., 2004).  Also models of PrP
Sc have been described 
(Wille et al., 2002).  Whether these models are accurate in terms of blood associated 
PrP
C and PrP
Sc remains to be seen but the different structural qualities of both forms of 
the prion protein may account for the differences seen when steps in the method were 
altered and tested on uninfected and scrapie infected brain homogenates.   
 
The re-optimised method (referred to as the blood Western blot method) was re- 
applied to PBMC samples from six uninfected and seven scrapie infected sheep.  Bands 
corresponding to the molecular weights expected for PrP
C (between 25 and 35 kDa) 
were observed on the blots after the modifications, but after the addition of NaPTA to 
this protocol, higher molecular weight signals were still consistently seen (40-133 kDa 
range).  High molecular weight bands have been reported in blood previously.  In 
activated human platelets, Jones and colleagues (2005) described a band of 
approximately 250 kDa on Western blots which they suggested was cellular PrP 
complexed with an unidentified protein.  One vCJD blood sample has also been tested 
using NaPTA precipitation (Wadsworth et al., 2001).  However bands between 40 – 
133 kDa in buffy coats or PBMCs have not been reported.  These bands may represent 
unspecific binding or it is possible they may be PrP that has been complexed with other 
blood proteins as a result of NaPTA precipitation.   These results are intriguing though 
as the bands appeared to be PK resistant in scrapie infected but PK sensitive in 
uninfected PBMCs.   
 
Using the blood Western blot it was not possible to detect conventional PrP
Sc in blood 
components from TSE infected animals although bands of other molecular weights 
(approximately 40-60 kDa, 80-83 kDa and 109 kDa) were detected and could represent 
a blood specific form of PrP
Sc. If TSE infectivity in sheep blood is related to a non-  140
conventional form of PrP
Sc, this could explain the difficulty found in many labs, 
including this one, in detection of the conventional form of PrP
Sc in blood. 
 
After NaPTA precipitation high molecular weight complexes that cross-react with an 
anti-PrP antibody are present in blood.  In uninfected PBMCs these bands appear to be 
sensitive to PK degradation.  However in PBMCs from scrapie-infected animals these 
bands appear resistant to PK.  These results are interesting as it is possible that the 
bands may represent a blood specific form of PrP
Sc, different from the conventionally 
defined PrP
Sc found in brain and lymphoid tissues.  It may be that PrP is being 
complexed with other proteins due to an effect of NaPTA. PrP in blood may have a 
different conformation to PrP in brain and there may be PK sensitive forms of PrP in 
blood.  These results warrant further investigation which is discussed in chapter 5.   141
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Investigating High Molecular Weight Bands 
In Scrapie-Infected And Uninfected Sheep 
Blood  
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5.1.  Introduction 
 
The previous chapter described attempts to detect the conventional form of PrP
Sc in 
scrapie-infected sheep blood, using a sensitive immunoassay incorporating a NaPTA 
concentration step.  Although it was not possible to detect conventional PrP
Sc,
 results 
showed that after the addition of NaPTA, high molecular weight bands that cross react 
with a PrP antibody were present in blood.  In uninfected frozen PBMC samples these 
bands appeared to be sensitive to PK digestion.  In frozen PBMCs from scrapie-
infected sheep the bands were resistant to PK.  These initial results indicated that 
NaPTA precipitation of PBMC preparations enables discrimination between scrapie-
infected and uninfected sheep which may be extremely important in the development of 
a diagnostic TSE blood test.  To characterise the high molecular weight bands in more 
detail and to investigate if they could be used as a marker for TSE disease in blood the 
following questions were addressed: 
 
Are the high molecular weight bands present in different TSE agents? 
 
Are the high molecular weight bands disease-specific? 
 
Are the high molecular weight bands present in PBMC subsets? 
 
 Are the high molecular weight bands artefacts? 
 
Are the high molecular weight bands sensitive to high concentrations of PK? 
 
Are the high molecular weight bands PrP? 
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5.2.  Results 
 
5.2.1.  Testing purified BSE-infected cell subsets for PrP
Sc 
 
To investigate if conventional PrP
Sc and high molecular weight bands could be detected 
in blood infected with a different TSE agent, the blood Western blot method (chapter 4, 
section 4.4) was applied to frozen PBMCs (chapter 2, section 2.3.3.2) CD21
+ B cells 
(chapter 2, section 2.3.3.4) and unbound cells (the CD21
+ B cell negative population) 
from one pre-clinical BSE-infected sheep.  Figure 5.1 represents these results 
 
25 -
35 -
60 -
112 -
195 -
1    2    3    4   5    6    7   8   9  10
PK          - - - - - - +   +   +    +
+    +    +    - - - +   +   +    + NaPTA
25 -
35 -
60 -
112 -
195 -
1    2    3    4   5    6    7   8   9  10
PK          - - - - - - +   +   +    +
+    +    +    - - - +   +   +    + NaPTA
 
 
Figure 5.1:  Conventional PrP
Sc and high molecular weight bands were not detected in 
PBMCs, unlabelled cells or CD21
+ B cells from one pre-clinical BSE-infected sheep.  Key; 
lanes 1, 4 and 7, 1 x 10
6  PBMCs, lanes 2, 5, and 8, 1 x 10
6  unlabelled cells,  lanes 3, 6, and 9,  
1 x 10
6   CD21 
+ B cells.  Lane 10, 300 µg scrapie-infected brain homogenate.  Samples were 
PK digested and NaPTA precipitated as shown. The blot was probed with BC6 at a 
concentration of 2 µg/ml.  The blot was developed using standard ECL methods; the exposure 
time was 20 min.  Molecular masses are shown on the left (kDa).   
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As expected, NaPTA precipitation increases the overall sensitivity of detection (figure 
5.1, lanes 1-3 compared to lanes 4-6).  When samples were PK digested, no 
conventional PrP
Sc signal was observed (figure 5.1, lanes 7-9).  This indicates that 
conventional PrP
Sc was undetectable in PBMCs, unlabelled cells and CD21
+ B cell 
subsets from a pre-clinical BSE infected animal (figure 5.1, lanes 7-9).  Detection may 
have been possible if clinical blood from different animals was tested, or experiments 
applied to a larger volume of blood although this was not tested due to unavailability of 
samples.   
 
There was a possible signal present at 60-112 kDa (with and without NaPTA) in 
PBMCs and subsets from pre-clinical BSE-infected animals (figure 5.1, lanes 1-3 and 
7-9) which is similar to the size of high molecular weight bands observed in uninfected 
or clinical scrapie blood (figure 5.1 and chapter 4, figures 4.12, 4.13 and 4.14, 40-109 
kDa).  However, the signal was weak, had previously only been observed in NaPTA 
treated samples and may not represent high molecular weight bands.  However, if high 
molecular weight bands with lower signal intensities were confirmed, they may not be 
as prominent in the BSE-infected blood cell fractions as these are pre-clinical unlike 
clinical scrapie-infected samples.  Alternatively, the conformation of PrP
Sc in BSE 
compared to scrapie may be different enough to change the effect of NaPTA in forming 
possible complexes.  
     
5.2.2. High molecular weight bands are present in uninfected and scrapie-infected 
sheep blood 
 
Varying numbers of buffy coat or PBMC cells (in a starting volume of 50 ml of blood) 
from ten scrapie infected sheep and four uninfected sheep (chapter 4 and Appendix 5) 
were analysed using the blood Western blot method. Although conventional PrP
Sc was 
undetectable, high molecular weight bands were observed (chapter 4).  To further 
characterise the high molecular weight bands, fresh uninfected PBMCs from an 
additional six disease free sheep were analysed. Frozen PBMCs from an additional four 
clinical scrapie-infected sheep were also tested. PBMC samples (cell numbers tested 
shown in the figure legends) were resolved on 4-12 % Bis-Tris gels (chapter 2, section   145
2.3.5) which separate with accuracy high molecular weight proteins.  Figure 5.2 shows 
a representative blot of these experiments. 
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Figure 5.2: High molecular weight bands are present in PBMCs from fresh uninfected 
and frozen scrapie-infected sheep blood following NaPTA precipitation.  Wells were 
loaded with 1 x 10
6 PBMCs in lanes 1-8.  Lane 9 was loaded with 300 µg wet tissue equivalent 
of PK digested scrapie sheep brain homogenate.  Samples were treated with PK and NaPTA as 
indicated.  Lanes 1-4 represent PBMCs from one animal and lanes 5-8 from a second animal.  
The blot was probed with BC6 at a concentration of 2 µg/ml.  The blot was developed using 
standard ECL methods; the exposure time was 5 min.  Molecular masses are shown on the left 
(kDa).   
 
High molecular weight bands were observed in NaPTA precipitated frozen clinical 
scrapie-infected (figure 5.2, lanes 2 and 4) and fresh uninfected PBMCs (figure 5.2, 
lanes 6 and 8) with or without PK digestion.  This suggests that the high molecular 
weight bands are not disease-specific.  As previously shown in chapter 4 (figures 4.12, 
4.13 and 4.14) these high molecular weight bands were not seen in scrapie or 
uninfected brain samples processed under the same conditions.  The molecular weights 
of the bands were approximately 195 kDa, 60 kDa, and 112 kDa where a doublet band 
was seen.  In initial experiments (chapter 4 figure 4.14) the high molecular weight 
bands appeared PK resistant in frozen PBMCs from scrapie-infected animals and PK 
sensitive in frozen uninfected PBMCs.  However, in fresh uninfected PBMCs, high   146
molecular weight bands were present in both PK treated and non-PK treated samples 
(figure 5.2, lanes 4 and 8).  The uninfected PBMCs tested in chapter 4 had been stored 
at – 80 º C for up to 12 months and when these samples were lysed there were no 
protease inhibitors in the cell lysis buffer (chapter 2, section 2.2.4).  It is possible that 
some sample degradation occurred as a result of long-term storage combined with lack 
of protease inhibitors, resulting in no signal on a Western blot following PK digestion 
and NaPTA precipitation.  Uninfected PBMCs described in this chapter were fresh and 
lysed in cell lysis buffer containing protease inhibitors.  These factors may have 
contributed to the intense signals observed following NaPTA percipitation with and 
without prior PK digestion (figure 5.2, panel 2).  Uninfected animals were confirmed to 
be TSE free by immunohistochemical analysis (data not shown).   
 
Although the high molecular weight bands are not disease-specific, it was still 
important to characterise them further.  Bands with molecular weights of 60 kDa, 112 
kDa and 195 kDa have not been described in blood before using PrP specific 
antibodies, and subtle differences may be revealed between uninfected and scrapie-
infected sheep blood on more detailed examination.  If levels of TSE infectivity in 
sheep blood are related to a non-conventional form of PrP
Sc it is possible these high 
molecular weight bands may represent where the infectivity resides.  
 
5.2.3.  High molecular weight bands are present in CD21 
+ B cell subsets 
 
To characterise the expression of high molecular weight bands in sheep blood 
components in greater detail, CD21 
+ B cell PBMC subsets from uninfected and 
scrapie-infected sheep were isolated (chapter 2, section 2.3.3.4) and analysed.  PrP 
expression appears to be up-regulated on CD21 
+ B cells in some scrapie-infected sheep 
so these cells were of particular interest (Halliday et al., 2005).  Acquired CD21 
+ B 
cell populations were assessed for purity by flow cytometry (chapter 2, section 2.3.3.5) 
which is shown in figures 5.3a and 5.3b.    
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Figure 5.3 A:  Flow cytometry analysis of PBMCs from uninfected sheep blood prior to 
CD21 
+ B cell sorting, unbound cells following sorting and the final CD21 
+ B cell sort.   
Cells were gated according to their light scattering characteristics.  Histograms depicting 
surface expression levels of various cell markers (as shown) on PBMCs, unbound cells and 
CD21 
+ B cells.  Red lines, isotype matched negative controls (TrT1: IgG1 isotype matched 
control for CD14, CD4 and CD21).  Analysis was carried out using FACS express version 3.  
Key: N.D. represents no data.    148
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Figure 5.3 B: Flow cytometry analysis of PBMCs from uninfected sheep blood prior to 
CD21 
+ B cell sorting, unbound cells following sorting and the final CD21 
+ B cell sort.  
Cells were gated according to their light scattering characteristics.  Histograms depicting 
surface expression levels of various cell markers (as shown) on PBMCs, unbound cells and 
CD21 
+ B cells.    Red lines, isotype matched negative controls (TrT1: IgG1 isotype matched 
control for T cells. TrT2: IgG2a isotype matched control for CD8 and g/d. IgM-FITC: 
secondary only control for B cells).  Analysis was carried out using FACS express version 3.  
Key: N.D. represents no data.   149
Sheep PBMCs appeared to consist of approximately 5% monocytes (CD14), 44% T 
cells expressing CD2 alpha/beta T cells, 24% CD4
+ T cells , 19% CD8
+ T cells, 7% γ/δ 
T cells, and 14 % B cells (figures 5.3, A and 5.3, B).  B cells were labelled with a pan B 
cell antibody (Du2-104) that is thought to bind to CD72 (Young et al., 1997).  CD21 is 
expressed on a subset of B cells and was found on approximately 9% of ovine PBMCs.  
Other investigators report higher percentages of CD21 
+ B cells in sheep blood (17%, 
personal communication with Dr E. Lefreve (IAH, Compton) and 20%, personal 
communication with Dr F. Houston (Glasgow University) although the age, sex and 
disease status of the animal may account for such differences (Chevallier et al., 1998). 
 
The efficiency of the separation of CD21 
+ B cells was confirmed by antibody staining 
of the unlabelled cells and purified cell fraction, following cell sorting (figures 5.3, A 
and 5.3, B).  No CD21 
+ B cells were present in the unlabelled fraction and the total 
number of B cells was reduced from 14% (unsorted PBMCs) to 11% (figure 5.3, B).  
CD21 was expressed on 91% of the cells isolated by magnetic cell sorting (figure 5.3 
B).  There was no contamination from other cell types, indicating that the majority of 
the purified cells were CD21 
+ B cells (figure 5.3, B). 
 
The blood Western blot was applied to PBMCs, unlabelled cells (following CD21 
+ B 
cell sorting) and purified CD21 
+ B cell fractions from uninfected and scrapie-infected 
sheep.  Figure 5.4 however shows a representation of PBMCs and CD21
+ B cells from 
uninfected sheep, and unlabelled cells from scrapie-infected sheep.  Examples of all 
cell fractions in uninfected and scrapie-infected animals are not shown as the high 
molecular weight bands have similar characteristics in both.  Alongside blots, samples 
were also resolved on gels which were stained using coomassie techniques (chapter 2, 
section 2.3.5.2).  If high molecular weight bands observed on blots could be matched 
with gels, this would aid in excising the correct bands for ultimate identification using 
mass spectrometry.   
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Figure 5.4:  High molecular weight bands are present in PBMCs, unlabelled cells and 
CD21 
+ B cells from uninfected and scrapie-infected sheep.  Key; A = uninfected PBMCs.  
B= unlabelled cells from scrapie-infected sheep, C = uninfected CD21 
+ B cells .  In all cases, 
wells were loaded with 1 x 10
6 cells.  In A and C, lanes 5 - 6, wells were loaded with 300 µg 
wet tissue equivalent of uninfected sheep brain homogenate. In B, wells were loaded with 300 
µg wet tissue equivalent of scrapie sheep brain homogenate. The blots were probed with BC6 
at a concentration of 2 µg/ml or gels stained with coomassie as shown.  The blot was developed 
using standard ECL methods; the exposure time was 5 min.  Molecular masses are shown on 
the left, and indicated by M in the coomassie gel (kDa).     151
High molecular weight bands were observed in NaPTA treated uninfected PBMCs 
(figure 5.4, A) and CD21 
+ B cells (figure 5.4, C) in addition to unlabelled cells from 
scrapie-infected sheep (figure 5.4, B).  However, high molecular weight bands were 
present in all three cell fractions from uninfected and scrapie-infected sheep (data not 
shown).  The high molecular weight bands on the blot appeared to have a similar 
molecular weight to diffuse bands present on the gels stained with coomassie blue.  The 
PBMC fraction of blood (lymphocytes and monocytes) appears to contain more cellular 
proteins than the same number of purified CD21
 + B cells only.  This was reflected in 
the stained gels, resulting in diffuse bands possibly corresponding to the observed high 
molecular weight bands being more apparent in NaPTA precipitated CD21 + B cells 
compared to PBMCs (figure 5.4, A compared to C).   
 
5.2.4.  High molecular weight bands are recognised using several PrP antibodies 
and are not caused by non-specific cross-reactivity   
 
To determine whether the high molecular weight bands are caused by non-specific 
cross-reactivity of the particular monoclonal antibody used (BC6) experiments testing 
other anti-PrP antibodies with different specificities were carried out.  These 
experiments were carried out on PBMCs from uninfected sheep only (as further 
characterisation of uninfected and scrapie-infected bands was not the objective).   
Figure 5.5 represents experiments where non-PK treated uninfected PBMCs and brain 
homogenates were probed with four different anti-PrP antibodies. 
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Figure 5.5:  High molecular weight bands are recognised by several PrP antibodies.   In 
lanes 1 and 2, wells were loaded with 1 x 10
6 uninfected PBMCs.  In lanes 3 and 4, wells were 
loaded with 300 µg wet tissue equivalent of uninfected sheep brain homogenate.  Samples were 
treated with or without NaPTA as indicated.  The blots were probed with different primary 
antibodies as indicated at a concentration of 2 µg/ml.  The blot was developed using standard 
ECL methods; the exposure time was 10 min.  Molecular masses are shown on the left (kDa).   
 
The weak signal observed in uninfected PBMCs with and without NaPTA precipitation 
using BC6 was surprising (figure 5.5, lanes 1 and 2).  Previously this antibody 
produced intense signals on Western blots (figure 5.2 and 5.4).  Following several 
repeats of this experiment, intense signals on blots were always seen when JB10 was 
the primary antibody, weak to intense signals using BC6 and BH1, and weak to no 
signals using FH10.  This may reflect conformational changes in the prion protein due 
to NaPTA where the JB10 epitope (at the extreme C terminal end of the molecule) is 
exposed, and other epitopes buried.   
 
To determine if the high molecular weight bands observed in blood were due to non-
specific antibody binding, experiments were repeated and blots probed with the 
secondary antibody, a monoclonal antibody with an irrelevant specificity, or BC6 and 
JB10 as positive controls.     153
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Figure 5.6:  High molecular weight bands are not due to non-specific antibody binding.   
In lanes 1 and 2, wells were loaded with 1 x 10
6 uninfected PBMCs.  In lanes 3 and 4, wells 
were loaded with 300 µg wet tissue equivalent of uninfected sheep brain homogenate.  Samples 
were treated with or without NaPTA as indicated.  The blots were probed with BC6, turkey 
rhinotracheitis (TrT 1) or JB10 at a concentration of 2 µg/ml.  One blot was probed with the 
secondary antibody only (1:7000 dilution).  The blot was developed using standard ECL 
methods; the exposure time was 30 min.  Molecular masses are shown on the left (kDa).   
 
Figure 5.6 shows that as expected, high molecular weight bands were recognised by the 
anti-PrP antibodies BC6 and JB10 in NaPTA precipitated uninfected PBMCs (lane 2).  
When the membrane was probed with secondary antibody only or an antibody raised 
against turkey rhinotracheitis virus (TrT 1) there was no signal.  This supports the view 
that the high molecular weight bands observed in lane 2 result from specific binding of 
anti-PrP primary antibodies.   
 
Further evidence indicating that the high molecular weight bands may include PrP was 
obtained following monoclonal antibody blocking studies.  Incubation with full length 
recombinant ovine PrP sufficiently blocked the binding sites of the anti-PrP   154
monoclonal BC6 antibody, as no signal was observed on Western blots after antibody 
blocking compared to BC6 alone (figure 5.7).   
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Figure 5.7:  Monoclonal antibody blocking studies revealed that the high molecular 
weight bands may be PrP.  In lanes 1, 2, and 5 wells were loaded with 1 x 10
6 uninfected 
PBMCs.  In lanes 3 and 4, wells were loaded with 300 µg wet tissue equivalent of uninfected 
sheep brain homogenate.  Lane 6 was loaded with 50 ng of full length ARR alpha recombinant 
ovine PrP.   Samples were treated with or without NaPTA as indicated.  The blots were probed 
with BC6 at a concentration of 1 µg/ml, or BC6 blocked with full length ARR genotype, α-
conformation recombinant ovine PrP as indicated.  The secondary antibody was used at a 
1:7000 dilution.  The blot was developed using standard ECL methods; the exposure time was 
10 min.  Molecular masses are shown on the left (kDa).  
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5.2.5.  High molecular weight bands may not be composed of protein 
 
Strong evidence has been described to suggest that high molecular weight bands 
observed in clinical scrapie-infected and uninfected blood may be composed of PrP.  
However conclusive evidence is required, particularly as the high molecular weight 
bands remain in uninfected PBMCs, unlabelled cells and CD21 
+ B cell subsets 
following PK digestion and NaPTA precipitation.  Therefore experiments investigating 
if high molecular weight bands are sensitive to higher PK amounts were carried out.  
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Figure 5.8:  High molecular weight bands are not sensitive to PK digestion.  In lanes 1 - 5, 
wells were loaded with 1 x 10
6 uninfected or scrapie-infected PBMCs as shown.  In lanes 6 - 
10, wells were loaded with 300 µg wet tissue equivalent of uninfected or scrapie-infected sheep 
brain homogenate.  Samples were treated with or without PK as indicated.  All samples were 
NaPTA precipitated.  In lanes 1 and 6, samples were not PK digested, lanes 2 and 7, 50 µg/ml 
PK was used, lanes 3 and 8, 100 µg/ml PK, lanes 4 and 9, 500 µg/ml PK and lanes 5 and 10, 
5000 µg/ml PK.  Blots were probed with BC6 at a concentration of 2 µg/ml and developed 
using standard ECL methods; the exposure time was 20 min.  Molecular masses are shown on 
the left (kDa).   
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High molecular weight bands were still apparent in scrapie-infected and uninfected 
PBMCs, even following digestion with 5000 µg PK (figure 5.8, lane 5).  The signal 
was diminished in the equivalent brain control samples suggesting that PK digestion 
was occurring (figure 5.8, lane 10).  It was surprising to find no difference between 
scrapie and uninfected PBMCs as digestion with such high concentrations of enzyme 
should have degraded the PrP
C and most other proteins in the uninfected blood.  This 
should have left no PrP
C to concentrate, yet following precipitation with NaPTA high 
molecular weight bands were still present.  This strongly suggests that the high 
molecular weight bands do not contain protein.  Alternatively, the protein is in a form 
that is protected from PK digestion. 
 
To further investigate if the high molecular weight bands do or do not contain protein, 
methods that visualise proteins were used. 
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Figure 5.9:  High molecular weight bands were not seen in uninfected PBMCs or CD21 
+ 
B cells following silver staining.  Cells were titrated, PK digested and NaPTA precipitated.   
Gel electrophoresis was performed and proteins visualised using standard silver staining 
techniques.  Lane 1, 1 x 10
6 cells, lane 2, 5 x 10
5, lane 3, 2.5 x 10
5, lane 4, 12 x 10
4, lane 5, 6 x 
10
4, lane 6, 1.5 x 10
4, lane 7, 7 x 10
3, lane 8, 3.5 x 10
3, lane 9, 18 x 10
2, lane 10, 9 x 10
2 and 
lane 11, 4.5 x 10
2 .  The exposure time was 6 min.  M indicates molecular masses (kDa).   
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Figure 5.9 shows that the high molecular weight bands were not visible following 
staining with silver.  It is possible that the high molecular weight bands may be 
glycosylated as glycoproteins do not stain well using silver (Goldberg et al., 1997).   
 
SYPRO
® orange dyes interact with the SDS coat around proteins in gels and give more 
consistent staining between different types of proteins compared to gels stained with 
Coomassie blue.  Unlike silver, SYPRO
® orange dyes also stain glycoproteins well and 
because of this characteristic this dye was used to stain the high molecular weight 
proteins.  
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Figure 5.10:  High molecular weight bands were not seen in uninfected PBMCs, CD21 
+ B 
cells or unbound cells following SYPRO
® orange staining.  Cells were titrated, PK digested 
and NaPTA precipitated.   Gel electrophoresis was performed and proteins visualised using 
standard coomassie blue or SYPRO
® orange techniques.  Lanes 1, 4, and 7, 3.5 x 10
3 PBMCs, 
CD21 
+ B cells or unbound cells respectively
 , lanes 2, 5 and 8, 18 x 10
2 PBMCs, CD21 
+ B cells 
or unbound cells respectively, lanes 3, 6, and 9, 9 x 10
2 PBMCs, CD21 
+ B cells or unbound 
cells respectively. In lanes 10 and 11, wells were loaded with 10 µg and 5 µg wet tissue 
equivalent of PK digested, NaPTA precipitated uninfected sheep brain homogenate 
respectively.  The SYPRO
® orange gel was scanned using a Typhoon Trio imager laser scanner 
(GE Healthcare, UK). M indicates molecular masses (kDa) on the coomassie gel, but these 
were not included for SYPRO
® orange to prevent fluorescence quenching of samples.    158
However, high molecular weight bands were also not visible using SYPRO
® orange 
techniques (figure 5.10).  Although high molecular weight bands were evident on 
Coomassie Blue stained gels, they were not seen with silver (figure 5.9) and SYPRO
® 
orange staining (figure 5.10) which supports the idea that they are not proteinaceous.  
 
Experiments have revealed evidence suggesting NaPTA precipitated high molecular 
weight bands in blood may be protein, possibly PrP.  However this could not be 
confirmed as the high molecular weight bands were not sensitive to high PK amounts, 
and could not be visualised on gels using several methods.  Therefore to conclusively 
demonstrate the identity of these high molecular weight bands, bands were excised 
(figure 5.11) and analysed using mass spectrometry.   
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Figure 5.11:  High molecular weight bands in PK digested, NaPTA precipitated CD21 
+ B 
cells were analysed using mass spectrometry.  The two lanes nearest to the markers were 
loaded with 8 µg of recombinant full length ARR alpha recombinant ovine PrP.  The following 
six lanes were loaded with 1 x 10
6, 5 x 10
5 and 2.5 x 10
5 CD21 
+ B cells from two uninfected 
sheep respectively.  Bands were excised from the gel as indicated.  Band 6 represents a slice of 
blank gel that was excised as an additional control.    
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Mass spectrometry data was obtained from Dr. P. Skipp (Proteomics Manager, 
Southampton University).  Results were entered into MASCOT where peptide 
sequences were searched against sequence databases to identify possible proteins.   
Results initially looked promising as the high molecular weight bands in CD21 
+ B 
cells were identified as PrP.  However, band 1 (recombinant PrP control) contained 
high amounts of protein which was analysed first.  Therefore all bands were re-
analysed in a different order to validate the initial result and to check for possible 
contamination from the recombinant PrP positive control.  Unfortunately, following 
further analysis, contamination was confirmed.  Mass spectrometry for the high 
molecular weight bands gave a negative result for protein.  The control bands were 
identified correctly (Band 1, PrP, band 5, Beta-Galactosidase).  Table 5.1 summarises 
mass spectrometry data.          
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Table 5.1: Summary of mass spectrometry data revealed the high molecular weight bands may not be composed of protein.  Mass 
spectrometry data was obtained from Dr. P. Skipp (Proteomics Manager, Southampton University).  
 
 
Band Mascot 
search ID 
NCBI 
accession 
number 
Matching peptides  Homology 
threshold 
% sequence 
coverage 
1 Prion  protein 
(Ovis aries) 
gi/ 38145699 
 R.ESQAYYQR.G  41  
 
 
 
 
       47 % 
      R.YPGQGSPGGNR.Y 44 
      R.VVEQMCITQYQR.E 33 
      R.YPNQVYYRPVDR.Y 35 
      R.VVEQMCITQYQR.E + Oxidation (M) 35 
      K.GENFTETDIKIMER.V 38 
      K.GENFTETDIKIMER.V + Oxidation (M)  20 
      R.YSNQNNFVHDCVNITVK.Q 32 
      K.QHTVTTTTKGENFTETDIK.I 21 
      K.HVAGAAAAGAVVGGLGGYMLGSAMSRPLIHFGNDYEDR.Y 34 
           
2 No  protein 
hits to report 
None  None  None None 
           
3 No  protein 
hits to report 
None  None  None None 
           
4 No  protein 
hits to report 
None  None  None None 
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Table 5.2: Summary of mass spectrometry data revealed the high molecular weight bands may not be composed of protein.  Mass 
spectrometry data was obtained from Dr. P. Skipp (Proteomics Manager, Southampton University).  
 
 
Band Mascot 
search ID 
NCBI 
accession 
number 
Matching peptides  Homology 
threshold 
% sequence 
coverage 
5 Beta-
Galactosidase 
(E.Coli) 
gi/50513329   R.GDFQFNISR.Y 32  
 
 
        
 
 
 
      19 % 
      R.IDPNAWVER.W 33 
      R.LAAHPPFASWR.N 36 
      K.HQQQFFQFR.L 38 
      R.VDEDQPFPAVPK.W 39 
      K.LWSAEIPNLYR.A 42 
      R.APLDNDIAVSEATR.I 37 
      R.LSGQTIEVTSEYLFR.H 40 
      R.IENGLLLLNGKPLLIR.G 25 
      R.DVSLLHKPTTQISDFHVATR.F 31 
      R.VVQPNATAWSEAGHISAWQQWR.L  25 
      R.VTVSLWQGETQVASGTAPFGGEIIDER.G 35 
           
6  No protein hits 
to report 
None  None None None   162
 
Evidence presented in this chapter indicates that high molecular weight bands are 
present in scrapie-infected and uninfected blood following NaPTA precipitation.  Work 
was carried out to identify these high molecular weight bands which is summarised in 
table 5.2.  Experiments did not conclusively show that the high molecular weight bands 
were PrP although there was some evidence to suggest this.  Additionally there was 
also evidence to indicate use of NaPTA may result in possible artefacts and that the 
high molecular weight bands may not be protein based.  Although this work was not 
continued due to time constraints it raises thought-provoking questions regarding the 
use of NaPTA in a diagnostic capacity.           
 
Evidence high molecular weight bands 
are PrP 
Evidence high molecular weight bands 
are not protein 
High molecular weight bands were 
recognised by several PrP antibodies in 
PBMCs and CD21 
+ B cell subsets 
High molecular weight bands were still 
present in uninfected blood after PK 
digestion prior to NaPTA precipitation  
Secondary and non-PrP antibody blots 
were negative  
High molecular weight bands were not 
sensitive to high amounts of PK 
High molecular weight bands were 
observed using coomassie protein 
staining techniques 
High molecular weight bands were not 
observed using silver or SYPRO orange 
staining techniques 
  Mass spectrometry results suggested 
there was no protein in the high 
molecular weight bands 
 
Table 5.2: Summary table of the results presented in this chapter to identify the high 
molecular weight bands observed in scrapie-infected and uninfected blood. 
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5.3.  Discussion 
 
The strategy of the research presented in this chapter involved characterisation of 
potentially novel high molecular weight bands as markers for TSE disease in blood.  
The starting point for this strategy was to compare high molecular weight band 
expression in blood cell subsets from clinical scrapie-infected, pre-clinical BSE-
infected and uninfected sheep.  Identifying the high molecular weight bands was also 
important and to establish if they represented aggregates of PrP, several PrP antibodies 
(recognising different epitopes on the PrP molecule) were tested with appropriate 
controls.  Although initially promising, further evidence revealed high molecular 
weight bands were not sensitive to enzymatic digestion with PK, prior to NaPTA 
precipitation in uninfected and scrapie-infected samples.  Additionally high molecular 
weight bands were not always visualised using various protein staining techniques and 
mass spectrometry data indicated the high molecular weight bands were not 
proteinaceous.  Therefore, as the high molecular weight bands were not disease-specific 
and had similar characteristics in both scrapie and uninfected blood they could not be 
used as markers for TSE disease.  However bands with molecular weights of 60 kDa, 
112 kDa and 195 kDa have not been described before, and if infectivity is associated 
with a non-conventional form of PrP
Sc it is possible these high molecular weight bands 
may represent where infectivity resides.  Additionally, subtle differences in infected 
blood may be revealed following more detailed examination.  Unfortunately it was not 
possible to conclusively identify the high molecular weight bands although some 
intriguing observations were made, particularly concerning the use of NaPTA in PrP
Sc 
blood detection methods.   
 
NaPTA was used to concentrate PrP in blood and increase the sensitivity of the 
Western blot assay.  NaPTA (Na2H[PW12O40]) features the nearly spherical (termed 
Keggin-type) trianion [PW12O40] which belongs to a broad class of polynuclear 
transition metal-oxo molecules known as polyoxometalates (POM).  POM anions, 
including those with Keggin structures are known to undergo degradation due to 
changes in pH and/or buffer characteristics (Hill et al., 1990).  In many published 
methods that incorporate NaPTA, samples are pre-incubated in buffers containing   164
sarcosyl (Safar et al., 1998; Wadworth et al., 2001).  Initial method development 
experiments within this thesis (chapter 3) also employ sarcosyl.  However in further 
experiments (chapter 4) sarcosyl was omitted and samples (brain and blood) were 
suspended in cell lysis buffer prior to NaPTA precipitation (chapter 2, section 2.2.4).  It 
is possible that a change in buffer may result in a partial breakdown of POM anion 
structure, altering POM size, shape and charge.  Breakdown in POM structure may 
result in size-specific electrostatic interactions between Keggin-type anions and sample 
proteins, causing the presence of high molecular weight bands in blood.  However, this 
requires that the interacting proteins (whether PrP or not) survive digestion after 
digestion with very high levels of PK.  The same effect may not have been observed in 
brain due to the presence of different proteins, differing charges and therefore modified 
electrostatic interactions.  It would be interesting to carry out spectroscopic studies to 
establish the POM structure in solution, such as the cell lysis buffer containing the 
blood and brain proteins.             
 
Evidence suggests that NaPTA and PrP
Sc can form large high molecular weight bands 
which can be identified by electron microscopy, due to the tungsten content (Safar et 
al., 1998).  Additionally the association (and dissociation) of NaPTA with PrP
Sc does 
appear to be dependent on POM size, shape and charge (Lee et al., 2005).  POMs can 
also influence polymerisation of amyloid fibrils in a charge-dependent manner, with 
Keggin-type species, differing in their charge, shifting the equilibrium of PrP 27-30 
polymers between amyloid fibrils and POM crystals, resulting in the growth of lattices 
(personal communication Dr J Safar – manuscript in preparation).  This suggests that 
NaPTA could contribute to the formation of PrP
Sc aggregates in blood although it is 
difficult to conclusively state that the aggregates are abnormal prion protein as they are 
present in uninfected blood samples following PK digestion.  However, these 
aggregates require further investigation.  Conventional PrP
Sc is not detectable by 
anything other than amplification methods in blood, so infectivity may be associated 
with a form of PrP
Sc such as these aggregates which have not been described before.    
 
Conformation–dependent immunoassays (CDI) have been developed that use 
denaturation with guanidinium hydrochloride, rather than PK-resistance to distinguish   165
between cellular and disease associated PrP (Safar et al., 1998).   The basis of the CDI 
is that the detector antibody recognises an epitope that is always exposed in PrP
c, but 
only becomes exposed in PrP
Sc following denaturation. As a result of this PrP
Sc can be 
identified and measured by comparing antibody binding to denatured and native forms 
of the prion protein. Recently a CDI-formatted sandwich immunoassay was described 
for the measurement of PrP
Sc in sheep brain (McCutcheon et al., 2005).  Scrapie-
infected samples showed significant increases in PrP measured in the denatured 
fraction (which represents PrP
Sc) compared to uninfected sheep.  When a NaPTA 
concentration step was incorporated into this method, interestingly results suggested 
that a higher concentration of PrP was also present in the denatured than in the native 
fractions of brain samples from uninfected sheep.  This provides further evidence that 
NaPTA may be able to induce a change in the conformation of PrP (McCutcheon et al., 
2005).  It would be intriguing to test this CDI-based assay on NaPTA precipitated ovine 
blood from scrapie-infected and uninfected animals. 
 
There was evidence suggesting the novel high molecular weight bands observed in 
NaPTA precipitated blood included PrP.  Several PrP monoclonal antibodies were 
tested, all of which cross-reacted with the high molecular weight bands.  When the 
membrane was probed with the secondary antibody only or a monoclonal antibody with 
an irrelevant specificity, there was no signal, indicating that the high molecular weight 
band result from specific binding of anti–PrP primary antibodies.  Interestingly the 
intensity of the Western blot signal varied depending on the PrP antibody used.  All the 
antibodies recognised epitopes within the C terminus of the PrP molecule (residues 90-
233) although the epitope for JB10 was located at the extreme C terminal end.  When 
JB10 was used signal intensity was increased.  All the epitopes are accessible but it 
may be that if NaPTA is inducing a change in conformation, the JB10 epitope becomes 
more accessible in re-folded PrP.   
 
A PrP band of approximately 250 kDa has been described in activated platelets (Jones 
et al., 2005) and carbohydrate-dependent aggregates of PrP-like proteins have been 
described in plasma (Tsukui et al., 2007) although NaPTA precipitation was not used.  
Apart from these reports there is no other published evidence (at the time of writing)   166
suggesting that PrP aggregates are present in blood or that NaPTA precipitation may be 
inducing conformational change in blood-associated PrP.  This made the initial results 
presented in this chapter potentially very interesting.  Studies using brain material have 
shown that TSE infectivity is associated with a wide range of PrP
Sc aggregate states 
(Caughey et al., 1997).  In addition to large amyloid fibrils there are smaller subfibrillar 
oligomers.  Evidence suggests these non-fibrillar particles are more infectious than 
larger aggregates, and are more efficient initiators of TSE disease (Silveira et al., 
2005).  It is conceivable that such aggregates, induced by NaPTA precipitation may be 
present in blood.  High molecular weight bands were not observed in NaPTA 
precipitated brain which suggests that if PrP aggregates were being formed in blood 
then possibly one or more biochemical factors present only in blood were enhancing 
aggregate formation.  High molecular weight bands were observed in CD21 
+ B cell 
subsets in addition to PBMC fractions, also indicating there is a common factor present 
on different blood cells that is involved in aggregate formation.  Due to time constraints 
it was not possible to test plasma or other leukocyte cell subsets such as monocytes, 
which have recently been implicated in the pathogenesis of scrapie infectivity in sheep 
(Andreoletti et al., 2007).  It would have also been interesting to test the effect of other 
concentration methods such as classical salt precipitation or cyclic amplification 
techniques (Soto et al., 2002) to establish if high molecular bands are only apparent 
using NaPTA.    
 
Despite initial findings it was not possible to conclusively show that the high molecular 
weight bands were composed of PrP.  Some evidence suggested the bands were not 
composed of protein.  The characteristics of the high molecular weight bands were 
similar in scrapie-infected and uninfected sheep blood, and even following PK 
digestion (prior to NaPTA treatment) high molecular weight bands remained in 
uninfected samples.  This result was unusual as proteolytic digestion with PK should 
degrade all the PrP
C, leaving none left for the NaPTA to concentrate.  It was possible 
that PK digestion was compromised due to the presence of protease inhibitors in the 
cell lysis buffer (chapter 2, section 2.2.4).  However high molecular weight bands were 
still present (in uninfected and scrapie-infected) even after high concentrations of PK 
were tested.  One interpretation is that the high molecular weight bands are artefacts,   167
and that the presence of NaPTA is causing a cross-reaction that is recognised by the 
PrP antibodies.  However, it is also possible that the NaPTA is causing a complex to 
form, including PrP, but which is physically protected from degradation by the action 
of NaPTA or some other factor. 
 
Various staining techniques for the detection of protein exist such as silver staining 
(Switzer et al., 1979) coomassie blue (Schaffner and Weissmann, 1973) and fluorescent 
dyes (Steinberg et al., 1996; Patton, 2002).  Coomassie blue binds non-specifically to 
virtually all proteins stoichiometerically, and the high molecular weight bands observed 
on blots were seen using this staining method.  Surprisingly when more sensitive 
methods such as silver staining were used, the high molecular bands were no longer 
visible.  Protein detection using silver depends on the binding of silver ions to the 
amino acid side chains, primarily the sulfhydril and carboxyl groups of proteins 
(Switzer et al., 1979; Oakley et al., 1980; Merril et al., 1981; Merril et al., 1990) 
followed by reduction to free metallic silver (Rabilloud, 1990 and 1999).  Lack of 
detection using silver does not necessarily mean that the high molecular weight bands 
are not protein as not all proteins are stained equally using this technique.  For instance, 
several classes of highly negatively charged proteins including proteoglycans, 
glycoproteins and mucins, which contain high levels of sulphated sugar residues, are 
detected poorly by silver staining (Goldberg et al., 1997).   
 
Fluorescent SYPRO
® orange dyes interact with the SDS coat around proteins in the gel 
and give more consistent staining between different types of protein compared to 
coomassie blue.  Unlike silver, these dyes also stain glycoproteins well (Steinberg et 
al., 1996).  It is conceivable that the high molecular weight bands contain large 
amounts of carbohydrates which can not be visualised using silver staining.  However, 
when SYPRO
® orange staining techniques were applied, the high molecular weight 
bands were again not visible.  The exact mechanism of the interaction between proteins 
and SYPRO
® orange dyes has not been fully characterised but the interaction does 
seem dependent upon an initial binding of SDS to the proteins.  Evidence suggests that 
SDS binding is occurring as the high molecular weight bands are being resolved by 
electrophoresis.  It is possible that NaPTA precipitation of samples is effecting   168
SYPRO
® orange stain efficiency, by causing any protein present to become so 
surrounded by glycans that the dye is unable to detect it.  Alternately the high 
molecular weight bands are not composed of protein, which is why no detection was 
observed with SYPRO
® orange of silver staining techniques. 
 
Mass spectrometry was applied to try to identify the high molecular weight bands.  
Results were intriguing as they indicated that the high molecular weight bands did not 
contain any peptides.  Positive control samples (one of the protein molecular weight 
markers and recombinant PrP) were analysed and correctly identified, indicating that 
the mass spectrometer was working optimally.  This data suggests that the high 
molecular weight bands are not protein, or that NaPTA is causing protein to complex 
into a state not compatible with mass spectrometry.  Due to time constraints it was not 
possible to test the effect of NaPTA precipitation on the positive controls although it 
would be interesting to see if NaPTA prevents identification of these samples.  It may 
be that NaPTA is causing resistance to enzymatic digestion prior to mass spectrometry 
and again this could be tested. 
 
High molecular weight bands in scrapie-infected and uninfected blood could not be 
identified.  Initial results indicated that the high molecular weight bands may include 
PrP but additional evidence showed that the bands could be non-protein artefacts 
present due to NaPTA precipitation.  NaPTA may be promoting the association of 
carbohydrate moieties (glycans) with proteins.  Various methods can be used to detect 
glycoproteins on blots although these were not employed due to time constraints.   
Lectins are carbohydrate binding proteins which can be used to discriminate and 
analyse the glycan structure of glycoproteins, and there are various commercial lectin 
stains available.  Additionally proteoglycans can be detected with cationic dyes such as 
alcian blue.  Other glycan detecting methods include periodic acid-Schiff staining, 
digoxigenin or Emerald 300.  Testing such methods may have revealed the presence of 
glycans within the high molecular weight bands. 
 
Novel high molecular weight bands have been characterised in blood.  Although 
evidence suggested the bands were not protein, they were reactive to several PrP   169
antibodies.  It is possible that the high molecular weight bands contain carbohydrate.  
Recently a potential blood test for TSE disease has been described by detecting 
carbohydrate-dependent aggregates of PrP
Sc – like proteins in scrapie-infected hamster 
plasma (Tsukui et al., 2007).  In this study the authors detected PK-resistant 3F4-
reactive protein in scrapie plasma following protein concentration using SDS and acetic 
acid (termed acidic SDS precipitation).  The 3F4-reactive proteins in scrapie-infected 
animals resulted in multiple high molecular weight bands (37, 40 and 50 kDa) on gels.  
Interestingly, pre-treatment with PNGase F (to remove carbohydrate side chains) prior 
to acidic SDS percipitation resulted in the disappearance of these high molecular 
weight bands.  This data indicates that PrP
Sc may aggregate with blood proteins (in this 
case plasma) through carbohydrate side chains. 
 
There were several differences between the study described by Tsukui and colleagues 
and the data presented in this chapter.  Different concentration methods were tested 
(acidic SDS precipitation compared to NaPTA) in addition to different blood 
components from different animal species, infected with different scrapie strains.  The 
size of the high molecular weight bands observed also differed (37, 40 and 50 kDa 
compared to 60, 112 and 195 kDa).  Additionally in this chapter high molecular weight 
bands were not only observed in scrapie-infected blood but also uninfected samples.  It 
is possible that NaPTA causes more aggregation than acidic SDS precipitation, 
resulting in high molecular weight bands in uninfected blood.  It is also conceivable 
that plasma proteins do not promote aggregation in the same way as PBMC subset 
proteins.   
 
The observations from the experiments described in this chapter show that NaPTA 
precipitation of scrapie and uninfected PBMC and CD21 
+ B cell subsets results in the 
presence of high molecular weight bands.  These are only present in blood and were not 
observed in brain.  It was not possible to discriminate between scrapie-infected and 
uninfected sheep blood, which may be an extremely important finding for the 
development of diagnostic TSE blood tests that incorporate PrP concentration using 
NaPTA.  NaPTA precipitation clearly increases the sensitivity of detection of   170
immunoassay methods for PrP
Sc detection in blood, but these results highlight that 
NaPTA precipitation may produce artefacts that could interfere with such tests.             171
 
 
 
 
 
 
 
 
Chapter 6 
 
The Effect Of Scrapie Infection On Protein 
Expression In Sheep Leukocytes    
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6.1. Introduction 
 
PrP
Sc is used as a biochemical marker for the presence of TSE infectivity.  However, 
rodent models exist where TSE disease develops but abnormal PrP is not detectable 
indicating that PrP does not always correlate with infectivity (Manson et al., 1999).  
Detection of conventional PK resistant PrP
Sc in blood was not possible using the 
sensitive Western blot assay described in Chapter 3.  It may be that levels of PrP
Sc are 
too low in blood and/or the assay did not have the required sensitivity for detection.  
PrP
Sc has not yet conclusively been detected in TSE-infected blood (Wadsworth et al., 
2001; Schmerr et al., 1999) although more recently a new technique termed protein 
misfolding cyclic amplification (PMCA) has successfully been applied to TSE infected 
buffy coat samples, where PrP
Sc is amplified to detectable levels (Castilla et al., 2005; 
Saa et al., 2006).  Although there is still considerable research into PrP
Sc based blood 
diagnostic tests, these difficulties have led researchers to look for alternative TSE 
biomarkers which may be indicators of the onset of TSE disease. 
 
It has been shown that TSE infection can effect the expression of other molecules.  Non 
prion protein biomarkers such as 14-3-3 proteins (Green et al., 2002) and the protease 
inhibitor Cystatin C (Sanchez et al., 2004) have been suggested as markers of TSE 
disease, but these are not specific and altered concentrations of both markers are 
observed in other neurological disorders such as Alzheimers disease.  The acidic 
calcium binding protein S100B which is produced by astrocytes, microglial cells and 
oligodendroglial cells is also elevated in TSE as well as Alzheimers disease (Beaudry et 
al., 1999; Cepek et al., 2005).  However, in hamster scrapie models serum levels of 
S100B are elevated only towards the end of scrapie progression (Otto et al., 1998; 
Beekes et al., 1999), suggesting that S100B may not be suitable for use as a  preclinical 
TSE diagnostic marker.   
 
In blood, TSE associated biochemical changes in metabolites and hormones have been 
described.  TSE infected hamsters show elevated levels of plasma noradrenalin after 
comparison with control animals (Pollera et al., 2007).  Moorby and co-workers (2000) 
sampled blood from 47 healthy and BSE-infected dairy cows over a 28 week period, 
and observed increased levels of plasma β-hydroxybutyrate in diseased animals.  In a   173
follow up study, increased concentrations of lactic acid and amino acids were observed 
in pre-clinical and clinical BSE-infected animals (Moorby et al., 2002).  However, 
changes in metabolite concentrations may be attributed to other conditions such as 
ketosis (Lindner, 1959).  Other novel molecular biomarkers in blood have also been 
described.  Miele et al., (2001) found that transcription of the gene encoding erythroid 
differentiation related factor (EDRF), now known as erythroid-associated factor 
(ERAF) was down-regulated in TSE infected mice.  However, ERAF transcription in 
healthy individuals was found to occur with a high degree of variation which questions 
the suitability of using EDRF as a marker for TSE disease.  
 
It is clear that a wide range of approaches have identified potential markers of TSE 
disease other than the prion protein, but it is evident that further work is required before 
routine testing for specific TSE biomarkers in blood can be implemented.  The primary 
objective of this chapter therefore was to investigate changes in protein expression in 
buffy coat samples from sheep clinically affected with scrapie compared with 
uninfected animals.  After observing differences in protein expression using relatively 
insensitive methods such as Coomassie Blue staining of 1D PAGE separated samples, 
clinical scrapie-infected and uninfected buffy coats were analysed further by two-
dimensional gel electrophoresis (2-D PAGE).  The buffy coat proteomes were screened 
using SameSpots PG240 Software to identify any differences between the two samples.  
Any changes of significance were taken forward for identification by mass 
spectrometry.  The ultimate aim was to identify biochemical markers other than PrP
Sc 
that are identifiable during a TSE infection and may therefore have future diagnostic 
value.   
 
This chapter contains preliminary work performed with assistance from Dr S. Banner 
(Roslin Institute).  Preliminary isoelectric focussing (IEF) runs and 2D gels shown in 
sections 6.2.2 and 6.2.3 as well as initial small format 2D Western blots shown in 
Figure 6.8 were performed by Dr S. Banner.  These experiments were carried out by Dr 
S. Banner during the process of demonstrating the 2D PAGE technique which was then 
subsequently used for the remainder of the work presented in this chapter.  
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6.2. Results 
 
6.2.1. Coomassie Blue staining reveals differences in protein expression between 
scrapie-infected and uninfected buffy coats 
 
Conventional PrP
Sc was not detected in buffy coat samples from sheep clinically 
affected with scrapie (chapter 4, section 4.3) when tested by Western blot.  However, 
some unusual PrP-related bands were detected but these proved difficult to identify, 
therefore other protein markers of TSE disease were also sought.  Initially, buffy coat 
samples from two scrapie cases and two uninfected sheep were resolved on a gel and 
stained by Coomassie Blue (chapter 2, section 2.3.5.2) to compare the protein profiles 
of the two samples (figure 6.1). 
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Figure 6.1:  Coomassie staining reveals differences in the protein profiles of scrapie-
infected and uninfected buffy coats (leukocytes and platelets).  Scrapie-infected and 
uninfected buffy coat samples were PK digested and NaPTA precipitated.  The number of 
buffy coat cells loaded per well was 12 x 10
6 cells.  Lanes 1 and 2 represent two different 
scrapie animals, lanes 3 and 4, two different uninfected animals.  Differences in protein 
expression are highlighted by the red (scrapie) and black (uninfected) arrows and brackets.  M 
indicates molecular weight markers.  The gel was stained using standard coomassie staining 
methods.  Molecular masses are shown on the left (kDa).   175
Coomassie staining revealed some differences between the protein profiles of scrapie-
infected and uninfected buffy coat samples (figure 6.1).  A protein of approximately 35 
kDa appeared more highly expressed in scrapie-infected buffy coats (red arrow).   
Additionally, a protein with an approximate molecular mass of 84 kDa was up-
regulated in uninfected buffy coats (black arrow).  The expression of lower molecular 
weight proteins also differed between diseased and healthy animals (black bracket).  
Buffy coat protein profiles from the two uninfected sheep were similar, but     
differences in protein expression were observed among the two scrapie-infected buffy 
coats (red bracket).  This may have been due to natural variation between animals, and 
it is possible that the buffy coat of the second animal may have contained more platelet 
or plasma proteins than the sample from the first animal.  Silver staining confirmed 
these differences in protein expression (data not shown).  These preliminary results 
warranted more detailed investigation to identify the proteins that appear to be up or 
down-regulated in disease. 
 
Due to the number and complexity of proteins present in the buffy coat fraction of 
blood it was considered not sensible to excise single protein bands from one 
dimensional gels for analysis by mass spectrometry.  Mixed protein samples would 
invariably become an issue and proteins would not be easily identifiable.  Therefore, 
the method of 2-D polyacrylamide electrophoresis (2D PAGE) first described by 
O’Farrell (1975) was used as this allows greater separation of proteins, initially by 
isoelectric point (pI) using isoelectric focussing (IEF) and then by mass using standard 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).  Proteomes 
can then be compared and differences identified more easily.  Protein spots in these 
gels are more likely to consist of a single protein and therefore identification by mass 
spectrometry will be more reliable.         
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6.2.2. Buffy coat protein precipitation with NaPTA inhibits isoelectric focussing  
 
Iso-electric focussing is an electrophoretic method that separates proteins according to 
their isoelectric points (pI).  The IEF technique relies on use of a stable pH gradient 
under the influence of an electric field.  Proteins migrate towards the cathode if 
positively charged or the anode if negatively charged until they reach their pI.  At this 
point they have a net charge of zero.  If the protein diffuses away from its pI, its charge 
changes because it enters a different pH and therefore migrates back to its pI.  This is 
termed the focusing effect of IEF.   
 
In previous experiments (described in more detail in Chapter 3) buffy coat proteins 
were concentrated using NaPTA.  For continuity NaPTA precipitation was also 
included in buffy coat sample preparation for 2-D PAGE.  Initially, uninfected buffy 
coat pellets containing 1 x 10
7 cells were incubated in cell lysis buffer before NaPTA 
precipitation (described in Chapter 2, section 2.2.4).  Following protein concentration 
with NaPTA, samples were combined with DeStreak rehydration buffer containing 0.5 
% pH 3-11 immobilised pH gradient (IPG) buffers.  The IPG buffers, developed by 
Gorg and colleagues (1998; 2000) help to define the range and shape of the pH gradient 
produced for IEF as well as retaining protein solubility.  Following sample loading into 
the IPG strips, using passive in-gel rehydration (Chapter 2, section 2.3.6.2) buffy coat 
proteins were subjected to IEF.  The progress of an IEF run with NaPTA precipitated 
samples is shown in Figure 6.2.  
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Figure 6.2: NaPTA precipitation adversely affects isoelectric focussing.  Uninfected buffy 
coats (1 x 10
7 cells) were NaPTA precipitated before IEF.  During the first 2 hours of IEF the 
current stays high and prevents volts reaching the set point.  IEF was stopped periodically to 
replace wicks so that the current could reduce (D).  Panel C shows after several electrode wick 
changes the current begins to drops after approximately 2 hr 40 min.  The lines corresponding 
to the current and voltage are described in the key above.  A description of an expected IEF 
profile is described in the text below and shown in Figure 6.4 later.  
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NaPTA precipitation of buffy coat proteins appears incompatible with separation of 
proteins by IEF.  IPG strips are subjected to IEF for a total of 40 kV hr, which 
ordinarily takes approximately nine hours.  However, when samples were precipitated 
using NaPTA it took 23 hours to accumulate the required kV hr. In a standard IEF run 
the initial high current should fall and remain low until focussing completes.  If the 
samples contain high levels of salts or other interfering components, this will not occur.  
Changing the electrode wicks can be used as a method of “desalting” a sample, and in 
this case replacing electrode wicks on an hourly basis did help to reduce the current, 
but only after approximately 2 hours 40 min (figure 6.2, C).  The binding of NaPTA 
directly to the proteins appears to adversely affect IEF and it was therefore deemed 
incompatible with 2D gel electrophoresis.    
 
6.2.3. NaPTA precipitated buffy coats do not produce satisfactory 2D proteomes  
 
Despite the problems associated with IEF in the presence of NaPTA, the samples did 
reach 40 kV hrs and so were separated by 2D PAGE.  This was carried out as described 
in chapter 2, section 2.3.6 and the resultant silver stained gel shown in figure 6.3. 
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pH 3                   pH 11 pH 3                   pH 11
 
 
Figure 6.3: NaPTA precipitation of uninfected buffy coats results in poor protein 
resolution by 2D PAGE.  NaPTA precipitated protein samples (50 µg) were electrophoresed 
on 12 % homogenous SDS-PAGE gels.  Samples were visualised by silver staining according 
to the Plus One method (GE Healthcare). 
 
NaPTA precipitation of uninfected buffy coats resulted in the apparent uniform loss of 
the majority of the protein spots (figure 6.3).  This was not due to insufficient sample as 
50 µg of protein was loaded.  NaPTA may adversely affect the protein charge such that 
many proteins may take on a very high positive or negative charge.  Proteins could then 
migrate beyond pH3 or pH10 and are excluded from the IPG strips and hence are not 
observed in the 2D gel.   
 
Protein concentration steps are often included during sample preparation prior to 2D 
when the starting tissue proves problematic, for instance there is a low protein 
concentration.  Buffy coat samples are protein rich (approximately 300 µg of protein 
per 1 x 10
7 cells) and so the lack of starting material is not anticipated to be a problem 
here.  NaPTA precipitation was used in buffy coat sample preparation because this step 
had been used in previous experiments outlined in chapter 3.  However, the use of 
NaPTA does not appear compatible with 2D PAGE (figures 6.2 and 6.3) and although   180
other methods could be employed to potentially improve compatibility with NaPTA, 
ultimately the aim of this work was to identify any changes in protein expression 
between scrapie and uninfected buffy coats.  In order to avoid protein losses it is 
important to minimise manipulation of the starting tissue and because of this as well as 
the problems observed with IEF, NaPTA precipitation for 2D-PAGE sample 
preparation was not pursued.          
 
6.2.4. Buffy coat IEF is optimal without a NaPTA concentration step 
 
Buffy coats containing 1 x 10
7 cells from three clinical scrapie–infected and three 
uninfected sheep were prepared without NaPTA.  They were assayed for total protein 
using a non-interfering protein assay (2D quant kit, described in chapter 2, section 
2.3.6.1), and 50 µg of protein was added to each IPG strip by passive in-gel rehydration 
(Chapter 2, section 2.3.6.2).  Following sample rehydration the buffy coat proteins were 
separated by IEF. 
 
KEY:
Blue = Set Volts
Red = Actual Volts
Green = Set mA
Yellow = Actual mA
KEY:
Blue = Set Volts
Red = Actual Volts
Green = Set mA
Yellow = Actual mA
KEY:
Blue = Set Volts
Red = Actual Volts
Green = Set mA
Yellow = Actual mA
 
 
Figure 6.4:  Standard IEF profile of ovine buffy coats.  The traces corresponding to the 
current and voltage are described in the key above.  IPG strips containing scrapie–infected and 
uninfected buffy coat proteins were run together and subjected to IEF for 40 kV hr.    
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Figure 6.4 shows a typical profile observed after scrapie and uninfected buffy coat IEF.  
The required 40 kV hr were accumulated over 9 hours, the initial high current dropped 
after approximately 30 min and then remained below the set limit throughout the 
focussing.  No manual intervention (electrode wick exchange) was required indicating 
samples were appropriately prepared, and contained no interfering components.   
 
6.2.5. Buffy coat proteome analysis from scrapie-infected and uninfected sheep  
 
Buffy coat proteins from the three infected and uninfected animals were then separated 
by 2D PAGE and representative 2D gels from one scrapie and one uninfected animal 
are shown in figure 6.5 
 
 
Scrapie buffy coat                         Uninfected buffy coat
pH 3                                pH 11   pH3                  pH11
Scrapie buffy coat                         Uninfected buffy coat
pH 3                                pH 11   pH3                  pH11
Scrapie buffy coat                         Uninfected buffy coat
pH 3                                pH 11   pH3                  pH11
Scrapie buffy coat                         Uninfected buffy coat
pH 3                                pH 11   pH3                  pH11
 
 
Figure 6.5: Buffy coat proteome analysis from scrapie-infected and uninfected sheep show 
reproducibly similar proteomes.  12 % homogenous SDS PAGE gels were loaded with 50 µg 
of protein from clinical scrapie infected or uninfected buffy coats.  Gel electrophoresis was 
performed at 12 W overnight at 30ºC.  Proteins were visualised using Plus One silver staining 
methods (GE Healthcare). 
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A total of 50 µg of protein appeared optimal as the 2D gels were not overcrowded with 
protein spots, allowing visibility of less abundant proteins and an accurate 
representation of buffy coat proteins.  On visual inspection, the proteomes looked 
generally similar in diseased and uninfected animals (figure 6.5).  This is not surprising 
as disease may only cause subtle differences in protein expression.  However, the slight 
overall variation of staining intensity between these two gels is most likely caused by 
small variations in protein loading and/or silver staining procedures.  These issues are 
counteracted by the software (SameSpots PG240, see section 6.2.6) used for 
subsequent analysis of these gels as it allows for minor variations in staining intensities 
using normalisation algorithms.  Therefore any differences observed are anticipated to 
be real and not due to silver staining variations.      
 
In order to identify any differences in protein expression between healthy and clinical 
scrapie animals, buffy coat samples were taken from three clinical scrapie and three 
uninfected sheep.  After IEF and 2–D PAGE specific protein changes between diseased 
and uninfected blood were analysed using SameSpots PG240 analysis software 
(Nonlinear Dynamics). 
 
6.2.6. SameSpots PG240 software analysis  
 
SameSpots PG240 is a specific 2D analysis tool that has significantly streamlined the 
analysis of sample proteomes.  Analytical gels are aligned perfectly using an automated 
image alignment programme.  Gel images are then analysed rapidly in a single step that 
includes detection of protein spots, background subtraction, normalisation and protein 
spot matching.  Maximum fold change based on the spots normalised volume and one 
way ANOVA p-values are calculated.  Protein spots are then ranked according to their 
p-values and fold change, so that the most significantly different spots can be identified 
quickly.  Protein spots can then be accepted or rejected for further study.   
 
In total, eighteen buffy coat proteomes (three clinical scrapie and three uninfected, with 
three repeats of each) were analysed using SameSpots software.  Collectively six 
protein spots appeared to be significantly up-regulated in scrapie buffy coats and one in   183
uninfected buffy coats.  Figure 6.6 shows an example of a protein spot (spot 33) that 
was significantly up-regulated in scrapie buffy coats. 
 
Protein spot 33 Protein spot 33
 
 
Figure 6.6:  SameSpots analysis revealed subtle differences in protein expression between 
scrapie-infected and uninfected buffy coats.  The maximum fold change based on the spots 
normalised volume is displayed.  Pink shading represents control buffy coat, blue shading 
represents scrapie-infected buffy coat.  Colours have been assigned arbitrarily by SameSpots 
software.    
 
After analysis protein spots of interest were displayed statistically as shown in table 6.1 
 
Protein spot   Fold-difference  ANOVA p-value   Scrapie regulation  
20  2.218598 0.008731 Up-regulated 
32  2.020842 0.015532 Up-regulated 
33  2.000824 0.015562 Up-regulated 
82 1.9161  0.024771  Down-regulated 
52 1.80308  0.039457  Up-regulated 
50  1.776065 0.046021 Up-regulated 
73 1.74703  0.046543  Up-regulated 
 
Table 6.1: Summary of the protein spots that were up and down–regulated in clinically 
infected scrapie buffy coats   184
Table 6.1 shows the fold difference between scrapie-infected and control animals, in 
addition to the calculated analysis of variance (ANOVA) for the selected proteins.  The 
column of interest is the ANOVA which demonstrates that all the proteins have a p-
value less than the critical p-value of 0.05, which is classed as significant.  SameSpots 
analysis revealed seven buffy coat protein spots that were significantly up or down-
regulated following scrapie infection.  The next step was to try and identify these 
proteins.  
 
6.2.7. Mass spectrometry identified lactate dehydrogenase, annexin 1 and 
elongation factor 1 as proteins of interest 
 
Preparative gels were prepared so that proteins of interest could be identified by mass 
spectrometry.  A total of 400 µg of buffy coat protein from either a scrapie–infected or 
an uninfected sheep were separated by IEF and then 2D PAGE as normal.  These gels 
were stained using a modified silver staining protocol as described in chapter 2, section 
2.3.6.5 (Yan et al., 2000).  It was important to resolve more sample than before to 
ensure there was sufficient protein available for mass spectrometry analysis and also to 
allow for the reduction in sensitivity when using a modified silver staining protocol.  
The resultant gels were compared and matched to the analytical gels.  However, due to 
the greater protein load, silver impurities and gel to gel variation it was not possible to 
excise with confidence all seven protein spots.   This could be achieved by repeating 
these experiments with lower protein amounts or using narrower pH ranges and 
different gels to separate proteins over a greater distance.  However, it was possible to 
excise five protein spots for identification (protein spots 32, 82, 52, 73, and 33).   
 
The excised proteins were digested with trypsin by Dr A. Gill (Roslin Institute) and the 
resulting digest mixture analysed by mass spectrometry.  The experimental mass values 
of the resultant peptides were entered into MASCOT where peptide sequences were 
searched against sequence databases to identify possible proteins. This work was 
carried out by Dr D. Kurian (IAH, Compton).  In total, three protein spots were 
identified, spot 82 was recognised as elongation factor 1 (EF-1), spot 52, lactate 
dehydrogenase (LDH) and spot 32, annexin 1 (Table 6.2).181 
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Table 6.2: Summary of mass spectrometry results.  Three potential biomarkers (lactate dehydrogenase B, elongation factor 1 and 
annexin 1) were identified.  
Spot  Mascot search ID  NCBI accession 
number 
Matching peptides  Homology 
threshold 
% sequence 
coverage 
52 Lactate 
dehydrogenase B 
gi/27806561   K.FIIPQIVK.Y     33  
 
 
 
 
         18 % 
      K.SADTLWGIQK.D   36 
      K.MVVESAYEVIK.L    33 
      K.SLTDELALVDVLEDK.L   45 
      K.SLTDELALVDVLEDKLK.G   27 
      K.GEMMDLQHGSLFLQTPK.I   17 
      K.GEMMDLQHGSLFLQTPK.I  
 
26 
      K.LKGEMMDLQHGSLFLQTPK.I   22 
           
82  Elongation factor 1  gi/86827651   R.LPLQDVYK.I    22  
         9 %        K.IGGIGTVPVGR.V   38 
      R.EHALLAYTLGVK.Q   47 
      K.YYVTIIDAPGHR.D    50 
           
32 Annexin  1  Gi/74  K.GVDEATIIEILTK.R   33           
 
         19 % 
      K.GTDVNVFTTILTTR.S   33 
      K.GLGTDEDTLNEILASR.T   49 
      K.GGPGSAVSPYPTFNPSSDVEALHK.A   19 
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Mass spectrometry and subsequent analysis produced a short list of three candidate 
biomarkers, LDH, and annexin 1 which appeared up-regulated in sheep clinically 
affected with scrapie, and EF-1 which appeared down-regulated.  These proteins 
require validation of their changing expression levels in other formats such as 
Western blotting.  However, due to time constraints and antibody availability, it was 
not possible to investigate all three proteins.  Due to the availability of an anti-LDH 
antibody (details described in Appendix 1) and evidence suggesting a possible role for 
LDH elevation in plasma induced by scrapie infection (Adams and Field, 1967) this 
protein was initially selected for further study. 
 
6.2.8.  Localisation and elevation of lactate dehydrogenase in scrapie–infected 
buffy coats 
 
Experiments to localise LDH on small format 2D PAGE were carried out.  Following 
electrophoresis, gels containing scrapie–infected and uninfected buffy coat proteins 
were Western blotted and probed for LDH (as described in chapter 2, section 2.3.5.5). 
Figure 6.7 represents these preliminary results. 
 Mass spectrometry and subsequent analysis produced a short list of three candidate 
biomarkers, LDH, and annexin 1 which appeared up-regulated in sheep clinically 
affected with scrapie, and EF-1 which appeared down-regulated.  These proteins 
require validation of their changing expression levels in other formats such as Western 
blotting.  However, due to time constraints and antibody availability, it was not 
possible to investigate all three proteins.  Due to the availability of an anti-LDH 
antibody (details described in Appendix 1) and evidence suggesting a possible role for 
LDH elevation in plasma induced by scrapie infection (Adams and Field, 1967) this 
protein was initially selected for further study. 
 
6.2.8.  Localisation and elevation of lactate dehydrogenase in scrapie–infected 
buffy coats 
 
Experiments to localise LDH on small format 2D PAGE were carried out.  Following 
electrophoresis, gels containing scrapie–infected and uninfected buffy coat proteins 
were Western blotted and probed for LDH (as described in chapter 2, section 2.3.5.5). 
Figure 6.7 represents these preliminary results. 
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Figure 6.7:  Localisation of LDH in scrapie–infected buffy coats.  In A), the location of spot  
52, corresponding to LDH is highlighted on a silver stained gel (red circle).  In B) 2D Western 
blots are shown.  Each 2D Western blot contains 50 µg of buffy coat protein from uninfected or 
scrapie–infected sheep.  Samples were separated by IEF before second dimension separation.    
1D wells were loaded with 10 µg of buffy coat protein from uninfected or scrapie–infected 
sheep as indicated by ٭.  The blots were probed with anti-LDH at 1:1000 dilution.  The 
secondary antibody, rabbit α-goat HRP was used at a dilution of 1:1000.  The circles indicate 
immunoreactivity to LDH.  Key: The arrows show approximate molecular weights (kDa) for 
each spot.   The blots were developed using standard ECL methods; the exposure time was 2 
min.   188
LDH has a molecular weight of approximately 37 kDa and the protein spot selected 
from the 2D gel for mass spectrometry (figure 6.7, A) was approximately 38 kDa and 
up-regulated in scrapie-infected buffy coats.  The 2D blots (figure 6.7, B) demonstrate  
immunoreactivity to LDH, which appears elevated in scrapie–infected buffy coat (as 
indicated by the black and red circles), but also down-regulated in scrapie-infected 
buffy coat (as indicated by the green and blue circles).  There are two isoenzymes of 
LDH in mammals, LDH–M and LDH–H (Sass et al., 1989).  Each molecule consists of 
four subunits, where each subunit is either H (heart-specific) or M (muscle-specific) so 
the protein spots observed on the 2D blot may represent the H or M tetrameric 
isoenzymes. The pI of the LDH protein spots are approximately pH 4.5 (blue circle) pH 
5 (green circle) pH8 (black circle) and pH 9.5 (red circle).  LDH has an expected pI of 
7.  However, the shift may depend on the isoenzyme of LDH being detected here.  The 
protein spots on the 2D blot may represent different LDH subunit aggregation states.    
 
Although this blot did not contain standard molecular weight markers (a 1D buffy coat 
sample was resolved instead), after comparison with previous 2D blots generated by Dr 
S. Banner (Roslin Institute) it appears that the lowest immunoreactive band present in 
the 1D samples does migrate at approximately 37 kDa (molecular weight of LDH) 
corresponding to the lowest protein spot in the 2D blot (black circle).  Interestingly, this 
band appears more abundant in the scrapie–infected buffy coat when compared to the 
uninfected sample.  Similarly, the immunoreactive bands in the 1D samples that 
migrate at approximately 45 kDa, 58 kDa and 60 kDa all correspond to 2D protein 
spots (red circle, blue circle and green circle respectively) and show up or down-
regulation in the same way.  This result is promising as it begins to validate the 2D 
methodology and SameSpots analysis.     
 
To further characterise the LDH antibody and also quantify the level of change in LDH 
expression in scrapie–infected buffy coat, 1D blots were carried out as shown in figure 
6.8.  These blots are quicker and generally more reproducible than 2D blotting and will 
allow better quantification of LDH levels in scrapie and uninfected buffy coats. 
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Figure 6.8:  LDH and actin expression in 1D blots of scrapie–infected and uninfected 
buffy coats.  Wells were loaded with 10 µg of buffy coat protein from three scrapie–infected 
sheep (lanes 1, 2, 3 and 7), or 10 µg of buffy coat protein from three uninfected sheep (lanes 4, 
5, 6 and 8).  Blots were probed with anti–lactate dehydrogenase at a 1:1000 dilution or anti–
actin at a 1:5000 dilution.  Secondary antibodies used were goat α mouse HRP, 1:2000 (actin) 
and rabbit anti-goat HRP, 1:1000 (lactate dehdrogenase).  Lanes 7 and 8 in each gel were 
probed with the appropriate secondary antibody only.   The blots were developed using 
standard ECL methods; the exposure time was 2 min for anti–lactate dehydrogenase and flash 
for anti–actin.  Differences in LDH expression between scrapie and uninfected animals are 
indicated using arrows.  Molecular weight masses are shown on the left (kDa). 
 
As shown in the 2D blots (figure 6.7), LDH appeared elevated in the scrapie–infected 
buffy coat samples in the 1D blots (figure 6.8).  In particular, a stronger signal was 
present in the lower protein bands (just above 30 kDa and 45 kDa, black and red 
arrows) when compared to the uninfected controls.  Interestingly, protein bands with a 
higher molecular weight (around 58 kDa, blue and green arrows and 111 kDa, orange 
arrow) were elevated in the uninfected buffy coats.  When the membrane was probed 
with secondary antibody only there was no signal, indicating that the immunoreactivity 
observed in lanes 1–6 was due to the anti–lactate dehydrogenase primary antibody.  
Actin was used as a protein loading control.  
   190
The 1D blots (figure 6.8) appear to validate the 2D (figure 6.7) blots.  Therefore, to 
help illustrate this, figure 6.9 shows a comparison of the two, highlighting that changes 
in LDH protein expression between scrapie and uninfected buffy coats in 1D blots are 
the same as shown in 2D blots.  
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Figure 6.9:  LDH protein expression in uninfected and scrapie-infected buffy coats 
appears the same on 1D and 2D blots.  Differences in LDH expression between scrapie and 
uninfected animals are indicated using arrows and circles.  Key: The arrows show approximate 
molecular weights (kDa) for each spot.   
 
Although preliminary, these results are promising as they identify that certain LDH 
isoforms are possibly elevated in the buffy coat fraction of blood after scrapie infection.  
LDH was initially localised in 2D gels because of its relative increase compared to 
uninfected.  Expression levels analysed by 1D PAGE do seem to increase in scrapie-
infected buffy coats.  Further work is required to confirm this result and may reveal 
LDH as a potential biomarker for scrapie infection.    
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6.3. Discussion 
 
The diagnosis of TSE disease remains a fundamental problem for animal health and 
welfare.  Existing methods rely on post-mortem immunohistochemistry or immuno-
detection of PK resistant PrP
Sc in brain and tonsil tissue by Western blotting, but 
obtaining this material involves invasive procedures.  Therefore there is a need for 
validated, non-invasive diagnostic tests and the use of blood as a test material would be 
ideal.  It has been shown that TSE disease can be transmitted between animals via the 
blood system (Houston et al., 2000), but previous studies to detect PrP
Sc in blood 
samples have met with limited success.  Only PMCA technology appears sensitive 
enough for PrP
Sc detection in clinical and pre-clinical TSE infected blood (Castilla et 
al., 2005; Saa et al., 2006).    However, this technique requires highly specialised 
equipment, making automated high throughput diagnosis difficult.  Consequently, there 
is a need for the identification of biomarkers other than PrP
Sc in blood that indicate the 
presence of a TSE infection, and can be used in the development of diagnostic blood-
based tests. 
 
2D gel analysis of buffy coats from clinical scrapie-infected and uninfected sheep 
blood revealed a panel of seven proteins that were significantly up or down-regulated 
after scrapie infection.  Using Q-TOF-MS analysis, three candidate protein biomarkers 
were identified, lactate dehydrogenase (LDH), elongation factor 1 (EF-1) and annexin 1 
(A1).  LDH and A1 were elevated in clinical scrapie-infected sheep while EF-1 was 
down-regulated.  Even though preliminary, these results may have potential diagnostic 
value which could be explored in a follow-up study. 
 
Appropriate sample preparation is essential for good 2D electrophoresis results.  Before 
preparation for 2D PAGE, buffy coat proteins from infected and uninfected animals 
were concentrated using NaPTA precipitation.  However, problems during IEF were 
encountered when this was performed.  IPG strips were subjected to IEF for a total of 
40 k V hr which takes approximately nine hours during a standard IEF run.  However, 
NaPTA precipitated samples required 23 hours to accumulate 40 k V hr.  It is possible 
that in addition to protein, NaPTA was concentrating non-protein components such as   192
salts.  This could leave the sample in a highly conductive state.  Focussing of proteins 
at their pI would not occur until the salt ions had moved out of the strip, prolonging the 
time for complete IEF.  The presence of salts can also result in non-focussing of 
regions at either end of the IPG strip.  This effects second dimension separation of 
proteins and promotes horizontal streaking on the final 2D gel, which was observed 
after 2D electrophoresis. Salts can be removed using gel filtration or precipitation and 
resuspension methods but this was not carried out due to possible protein loss.   
Additionally, dialysis would be time consuming to perform and so was not pursued.   
 
NaPTA-based protein precipitation is not a standard procedure commonly used in 2D 
electrophoresis.  There is evidence to suggest that NaPTA precipitation is specific for 
both protease resistant and sensitive forms of PrP
Sc (Safar et al., 1998; Tremblay et al., 
2004), although the precise molecular mechanism of PrP
Sc interaction with NaPTA is 
largely unknown.  Therefore it is conceivable that poor 2D separations were due to 
NaPTA only precipitated PrP or proteins associated with PrP.   
 
Protein precipitation is an optional step in sample preparation for 2D electrophoresis 
which is often employed to concentrate protein from a dilute source.  Because the buffy 
coat samples were rich in protein and precipitation with NaPTA caused the problems 
outlined above it was not pursued.  It was important to obtain a complete and accurate 
representation of all buffy coat proteins in the scrapie-infected and uninfected samples.  
Therefore for effective proteome analysis, sample preparation was kept as simple as 
possible to avoid protein losses (chapter 2, section 2.3.6.1).      
 
Lactate dehydrogenase (LDH) is an enzyme responsible for converting muscle lactic 
acid into pyruvic acid which is an essential step in producing cellular energy.  LDH 
consists of five tetrameric isoenzymes composed of the random association of two 
subunits (H and M) that are encoded by different genes (Cahn et al., 1962).  LDH was 
found to be up-regulated in the buffy coat blood fraction from sheep clinically infected 
with scrapie.  These results are in agreement with Schmidt and colleagues (2004) who 
saw elevated LDH levels in CJD patients when compared to individuals suffering from 
other dementias (Schmidt et al., 2004).  This study was conducted using cerebrospinal   193
fluid (CSF) samples, but does provide further evidence of elevation of LDH in TSE 
disease.   Additionally, a possible role for LDH elevation induced by scrapie infection 
in mouse plasma has also been described, although this was reported to have been due 
to contamination of the mouse scrapie strain with a LDH elevating virus (Adams and 
Field, 1967).  LDH enzymes are widely distributed throughout the body and studies in 
humans show high levels in the heart, kidney, liver, muscle, brain, red blood cells and 
lungs (Abeloff et al., 2004).  Following cellular damage LDH is released into the blood 
stream.  Therefore it is conceivable that in TSE disease LDH may be elevated in blood 
as a result of tissue damage from PrP
Sc accumulation in the brain and other organs.  If 
tissue damage is required before detection, pre-clinical diagnosis using LDH may not 
be possible, which would rule out this protein as a true diagnostic biomarker     
However, this will be the subject of further studies and ongoing experiments in our 
laboratory.   
 
It was observed that protein bands in 1D Western blots were more intense around 30 
and 45 kDa in scrapie infected buffy coats, whereas in uninfected samples, bands were 
more intense around 58 kDa.  This may represent LDH H and M tetrameric 
isoenzymes.  Because many disease processes cause elevations in total LDH levels (i.e. 
cancer, heart and liver disease) a breakdown of the five different isoenzymes that 
comprise LDH may be helpful for diagnosis.  For example, in humans after myocardial 
infarction LDH-1 rises over LDH-2 which is normally the dominant isoenzyme present 
in blood (Lott and Stang, 1980).  If the levels of individual isoenzymes were measured 
in the blood of sheep this may help to differentiate a diagnosis of scrapie, providing the 
normal limits in healthy animals were also determined.         
 
The annexins are a family of closely related calcium and membrane-binding proteins 
expressed in most eukaryotic cell types.  There are over one hundred and sixty unique 
annexin proteins (Morgan et  al., 1997).  Although structurally and biochemically 
similar annexins have diverse functions that include vesicle trafficking, cell division, 
apoptosis, calcium signalling and growth regulation.  Annexin 1 in particular also has 
an anti-inflammatory role (Ferlazzo et al., 2003).  Annexin 1 was found to be up-  194
regulated in clinical scrapie-infected buffy coats, although this requires further 
experimental confirmation.   
 
To date there appears to be no evidence suggesting a link between annexin 1 expression 
and TSEs.  However, annexin 5 has been shown to be up-regulated in cerebellar brain 
tissue from transgenic mouse models of inherited prion disease (Biasini et al., 2006). 
There is also good evidence to suggest that in other clinical conditions (i.e cancer and 
diabetes) changes in annexin expression levels may contribute to pathological disease 
(Xin et al., 2003; Ghitescu et al., 2001).  Annexins 1, 2, 4 and 6 have been isolated 
from mammalian brain and two patterns of annexin localization are characteristic of 
Alzheimer’s disease.  Annexin 6 appears associated with granulovacuolar bodies in 
degenerating pyramidal neurons, while annexin 2 is expressed in astrocytes associated 
with some β-amyloid plaques (Eberhard et al., 1994).  Annexin 1 is also increased in 
injured brain tissue (Johnson et al., 1989) and it may be that in scrapie-infected sheep 
this protein is released from brain or inflammatory cells.  
 
Elongation-factor-1 (EF-1) is responsible for aminoacyl-tRNA transfer on the ribosome 
in the process of protein synthesis, and is comprised of two components, a G-protein 
named eEF-1A and a nucleotide exchange factor, eEF-1B.  In several cancers EF-1 is 
up-regulated which is thought to be detrimental to cell cycle checkpoint mechanisms 
(Ogawa et al., 2004).  There appears to be no reported evidence suggesting a role for 
EF-1 in TSE disease, but results in this study indicate a possible down-regulation in 
scrapie-infected buffy coats. The precise biological involvement of EF-1 in scrapie 
infection remains to be determined.  
 
Although three potential TSE biomarkers have been described, it is important to note 
that caution is required when comparing protein expression in blood from clinically 
sick animals with healthy animals. Sheep that are suffering from any type of disease 
may exhibit abnormal behaviours (for instance, a reduction in appetite or an increase in 
stress hormone levels) causing changes in blood protein levels that are not specific to 
actual TSE infection.  Therefore, when proteomic studies are carried out, it is important 
that appropriate controls are considered.   195
 
Sheep are susceptible to a wide range of disorders of which bacterial infections are 
common. For example, animals can become infected with Johne’s disease, a contagious 
fatal bacterial infection of the intestinal tract. Also called Paratuberculosis, this disorder 
is caused by the Mycobacterium avium bacteria (Greig. 2000). Sheep are also prone to 
viral infections such as Maedi Visna which is a common disease caused by an ovine 
letivirus. This disorder affects the lungs, causing these organs to fill with fluid and 
imflammatory cells (Stroub. 2004). However, bacterial and viral infections such as 
these will cause increased numbers of leucocytes in the blood and cause an immune 
response. Therefore, these can not really be used as appropriate controls for brain 
degenerative diseases like scrapie which has no classical immune response.     
 
Neurological disorders that are not related to TSE disease would represent suitable 
controls. Polioencephalomalacia (caused by a deficiency in thiamin) occurs 
sporadically in sheep at pasture. This disease causes acute cerebral oedema with 
cerebral necrosis.  There are also other CNS disorders such as plant associated 
toxicoses where animals suffer paralysis and gait disturbances after accidentally 
ingesting toxins from plants (Chattopadhyay et al., 1985). These would be more 
appropriate control sheep diseases although blood samples from such animals may be 
difficult to acquire.  Centres specialising in such disorders may have to be approached.  
However, comparison of blood from animals suffering from non-TSE related 
neurological disorders is required to identify biomarkers specific for TSE disease.   
 
Disease-specific PrP
Sc accumulation represents the only available molecular marker of 
TSE disease.  However, PrP
Sc is not detectable in all TSE-affected animals (Manson et 
al., 1999) and though the detection of PrP
Sc in blood may prove useful, current 
techniques such as PMCA will be technically demanding to perform on a high 
throughput scale (Castilla et al., 2005; Saa et al., 2006).  Although there are other 
potential biomarkers for TSE disease, many have been identified in body fluids such as 
CSF which are difficult to obtain. Currently no reliable biomarkers have been identified 
in sheep blood.  In this study three potential biomarkers were identified.  LDH and 
annexin 1 appeared up-regulated in buffy coat following scrapie infection, while EF-1   196
appeared down-regulated.  Further work is required to determine how valuable these 
markers may be for diagnostic testing of scrapie, but these preliminary findings may be 
of interest in further studies investigating possible surrogate markers for TSE disease.                  
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Chapter 7 
Final Discussion 
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7.1.  TSEs and blood 
 
TSE animal models have provided important information on the presence and 
distribution of infectivity in peripheral blood during the pre-clinical and clinical stages 
of TSE disease.  Preliminary studies in sheep show that TSEs can be transmitted to 
animals following  blood transfusion from donor sheep with natural scrapie or 
experimental BSE (Houston et al., 2000; Hunter et al., 2002).  Recently, the final 
results of this long-term study have shown that whole blood and buffy coat obtained 
during the pre-clinical and clinical phase of disease infection transmitted BSE infection 
to 36 % of transfusion recipients and scrapie to 43 % of recipients (Houston et al., 
2008).  These experiments provide evidence that TSE infectivity is present in the 
peripheral blood of TSE-infected animals.  However, it is unclear exactly where in the 
blood such infectivity resides. 
 
Although it has been shown that TSE disease can spread via blood transfusion it is 
possible that different TSE strains may act in different ways.  There are two groups of 
CJD, classical (which include sporadic CJD (sCJD), inherited, and iatrogenic CJD) and 
variant CJD (vCJD).  In humans there have been four blood transfusion-related vCJD 
infections in individuals who received non-leucodepleted red cells (Peden et al., 2004; 
Llewelyn et al., 2004; Health Protection Agency, 2007).  However, there is no evidence 
to suggest that sCJD can be transmitted via blood.  This may be because like bacterial 
or viral infections, different TSE strains may target different tissues within the body.  
For example, hepatitis B primarily invades the liver (Wu et al., 1991) and HIV attacks 
the immune system (Zheng et al., 2005). In sCJD, the infectivity may target the brain 
and central nervous system (CNS) and may not accumulate in other tissues or within 
the blood system.             
 
In individuals infected with vCJD, however, the infectious agent and/or PrP
Sc is known 
to replicate in the lymphoreticular tissues such as the spleen, tonsil and lymph nodes 
before neuroinvasion (Hill et al., 1999).  Involvement of the lymphoid tissues in sCJD 
cannot completely be ruled out as recently PrP
Sc has been demonstrated in the spleen in 
some cases of sCJD, however the role of the lymphoreticular system is thought to be   199
minimal (Glatzel et al., 2003).  It is known that lymphocytes continually recirculate 
between blood and lymphoreticular tissues, which is why the blood of vCJD patients 
may be more efficient in spreading infection unlike sCJD.  
 
The sheep TSE model may help in the study of the pathogenesis of human TSE disease 
as the distribution of infectivity and/or PrP
Sc is similar in TSE-infected sheep and 
humans infected with vCJD (Hadlow et al., 1982; Van Keulen et al., 2000; Jeffrey et 
al., 2001).  Therefore results presented in this thesis are may reflect the human 
situation.  
 
One characteristic of TSE disease is the accumulation of an abnormal form of the prion 
protein, PrP
Sc, which can form amyloid plaques (Prusiner, 1998).  Detection of 
conventional PK-resistant PrP
Sc is used as a biochemical marker for TSE infection, and 
it is possible that PrP
Sc may exclusively be the causative agent of TSE disease.  This is 
termed the “protein-only” hypothesis and is supported by experiments which show that 
scrapie infectivity is reduced by procedures that hydrolyze or modify proteins (Diener 
et al., 1982).  Additionally, PrP knockout mice (Prnp 
o/o) appear completely protected 
against scrapie disease and fail to propagate infectious agent (Bueler et al., 1993).  If 
murine PrP transgenes are re-introduced into these mice susceptibility is restored 
(Fischer et al., 1996).   
 
Conventional PK-resistant PrP
Sc gives a distinct pattern on Western blots where three 
distinct bands can be identified and resolve between 27-30 kDa (Collinge et al., 1996).  
The original objective of the research presented in this thesis was to use conventional 
PrP
Sc as a marker for TSE disease in blood to investigate which blood components 
carry the abnormal PrP isoform and therefore likely infectivity, which would aid in our 
understanding of disease pathogenesis.  So far, most attempts to detect conventional 
PrP
Sc in blood have been unsuccessful.  This protein may be difficult to detect in blood 
as it may only be present at very low levels and as a consequence detection methods 
require excellent analytical sensitivity.  One major aim of this project was give a 
definitive answer to the question of whether conventional PrP
Sc is present in TSE-
infected sheep blood in sufficient quantities to explain the infectivity levels shown by   200
bioassay.  It was first therefore necessary to develop and optimise a sensitive Western 
blot immunoassay for conventional PK resistant PrP
Sc using scrapie-infected sheep 
brain homogenates. 
 
In some rodent models TSE disease develops but abnormal PrP is not detectable 
indicating that PrP may not always correlate with infectivity (Manson et al., 1999).  
Therefore, another aim of the project was to use a proteomics approach to identify 
biochemical markers other than conventional PrP
Sc to demonstrate TSE infection in 
blood.   
 
7.2.  Conventional PrP
Sc may not correlate with the level of TSE infectivity found 
in sheep blood by bioassay  
 
There are relatively few published records of attempts to detect PrP
Sc in blood samples 
using Western blotting.  Wadsworth and colleagues (2001) increased the sensitivity of a 
Western blot by incorporating a NaPTA concentration step, but when applied to blood, 
they were unable to detect PrP
Sc in the buffy coat fraction of blood from a single vCJD 
case.  However, the starting sample contained only 15 ml of whole blood, and the 
advantage of using scrapie-infected sheep is that the methodology could be applied to 
much larger volumes of blood. 
 
Using scrapie-infected sheep brain homogenates, the overall sensitivity of a Western 
blot immunoassay was increased by incorporating a NaPTA precipitation step to 
concentrate PrP
Sc, and screening a panel of novel monoclonal antibodies raised to 
recombinant sheep PrP (this thesis).  Using the optimised method, PrP
Sc was detected in 
as little as 2 µg wet brain equivalent, although in brain spiking experiments to mimic in 
vivo conditions, the sensitivity was slightly reduced, with consistent recovery of 20 µg 
brain spikes.  This level of sensitivity compared well with the assay developed by 
Wadsworth and co-workers, and was applied to 50 ml of blood and blood cell subsets 
(PBMCs and CD21
+ B cells) from several clinical scrapie-infected sheep.   However 
conventional PrP
Sc was still undetectable. 
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High levels of infectivity are found in the brain of TSE-infected individuals.  In sheep 
and goats clinically affected with natural scrapie, infectivity levels are greater than or 
equal to 10
4 infectious units (IU)/g of brain homogenate (Hadlow et al., 1979, 1980, 
1982; Pattison et al., 1964, 1972; Groschup et al., 1996).  Titres of the CJD infectious 
agent are higher than that of natural scrapie, with levels of 10
8 to 10
8.3 IU/g of brain 
homogenate (Sklaviadis et al., 1989).  Rodents infected with the 263 K scrapie strain 
contain very high levels of infectivity in brain (10
9.6 IU/g of brain homogenate) 
(Kimberlin et al., 1986).  The levels of infectivity clearly differ depending on the TSE 
agent, the bioassay host and the strain of agent.  Levels of infectivity may also vary 
considerably between different individuals of the same species.  Unless the particular 
isolate being used has been titrated and characterised it is difficult to equate infectivity 
per gram in this way.  However, based on titres of natural scrapie infectious agent, it is 
possible to estimate that 2 µg of scrapie-infected brain homogenate contains 
approximately 0.02 infectious units, whereas 20 µg wet brain equivalent contains 
approximately 0.2 infectious units.  It is difficult to estimate the amount of PrP
Sc 
molecules present in these brain amounts as PrP
Sc alone may not cause infection.  An 
infectious unit may comprise PrP
Sc alone, but could also contain a subspecies of PrP
Sc 
or other molecules yet to be identified. 
 
Attempts have been made to physically separate PrP
Sc and TSE infectivity in order to 
establish the nature of the infectious agent and estimate how many PrP
Sc molecules are 
required to cause infection (Sklaviadis et al., 1989; Somerville et al., 1999).  Recent 
experiments to disaggregate purified PrP
Sc from 263 K scrapie-infected hamster brain 
using detergents and sonication have produced a wide range of different sized particles. 
These particles (from very small units up to large amyloid fibrils) can be separated 
using fractionation techniques.  Subsequent bioassay studies indicate that the most 
infectious units of PrP are 17-27 nm particles of 300-600 kDa, and if composed 
completely of PrP, would give an oligomer of 14-28 PrP molecules.  Clusters of less 
than six molecules have virtually no infectivity (Silveira et al., 2005). This data 
suggests that between 14-28 molecules of protein monomers are required in a single 
particle of infectious PrP
Sc.  This may differ depending on the TSE strain and although   202
possible, it is currently unknown if infectious PrP in blood could be in the form of these 
small oligomers. 
 
Because the number of infectious PrP
Sc particles within an infectious unit in each TSE 
strain may differ, it is difficult to estimate exactly how many PrP
Sc molecules are 
present in the scrapie-infected brain homogenate and also in the SMB cells used in this 
study.  Quantification of PrP
Sc in brain to give an idea in absolute terms of how much 
abnormal prion protein in actually detected in wet tissue could be carried out using 
ELISA or Western blotting techniques and then comparing signals with known 
recombinant PrP concentrations.  SMB cells expressing PrP
Sc could be quantified using 
a colony-lift assay, where PrP
Sc-expressing cell colonies can be identified.  
    
Evidence from rodent models show that TSE infected blood contains much lower levels 
of infectivity than brain.  The highest levels of infectivity have been found in the buffy 
coat fraction of blood.  In mice infected with vCJD or a Gerstmann-Straussler-
Scheinker (GSS) disease isolate (Fukuoka-1), there were similar infectivity levels of 
approximately 18-30 IU/ml in buffy coat, but no detectable infectivity in red cells 
(Cervenakova et al., 2003). Infectivity in the blood of clinical mice can rise to 100 
IU/ml in buffy coat, and 20 IU/ml in plasma (Brown et al., 1999).  Whole blood and 
buffy coat obtained from pre-clinical and clinical sheep infected with BSE or scrapie 
has also been transfused (intravenously) into healthy animals (Houston et al., 2000; 
Hunter et al., 2002; Houston et al., 2008).  If titres of infectivity in sheep blood are 
similar to those in rodents (for example, 10 IU/ml) then administration of up to 500 ml 
of blood would deliver a significant dose (approximately 5000 IU).  This suggests there 
could still be a good chance of transmission, even if the titre of infectivity was 
relatively low.   
 
It appears that 500 ml of scrapie infected blood is sufficient to transmit infection via the 
transfusion route in sheep ((Houston et al., 2000; Hunter et al., 2002; Houston et al., 
2008).  However, the number of infectious units present in 500 ml of blood is 
unknown. In theory, titres of infectivity in sheep blood may be similar to those in 
rodents (10 IU/ml) but it is also possible that there is less infectivity (for example 1   203
IU/ml). Infectivity levels of 1 IU/ml would mean that administration of 500 ml of blood 
would deliver approximately 500 IU.  It is difficult to determine the levels of infectivity 
present within the starting volume of 50 ml of blood used in this study and the number 
of cells tested (1 x 10
6 to 1 x 10
8 cells). In addition, regardless of the infectivity levels it 
does not necessarily mean that a large amount of PrP
Sc is present. 
 
In order to establish how the sensitivity limit of the developed Western blot assay 
(optimised using brain) relates to blood volume, a titration of blood in sheep would 
have to be carried out in parallel with titrations of the brain material used in this study.  
This would show if large blood volumes (500 ml) or the 50 ml of blood tested contains 
infectivity and detectable PrP
Sc.  Such experiments are required as blood associated 
PrP
Sc is not well defined and there may be differences in sensitivity limits of detection 
compared to PrP
Sc found in brain. If PrP
Sc is detected (by Western blot in brain) and 
correlates with infectivity in smaller blood volumes, it may then be possible to estimate 
what the concentration of infectivity may be. Presently, this is very difficult to define. 
 
The levels of PrP
Sc present in TSE-infected blood remain unknown.  Soto and 
colleagues (2005) reported that using PMCA technology, PrP
Sc could be detected in 
clinical scrapie hamster buffy coat blood samples.  They found that 7 rounds of 144 
PMCA cycles were optimal for detection of as little as 20 fg/ml or as few as 4 x 10
5 
equivalent molecules of PrP
Sc /ml.  Based on the total buffy coat volume of 20 µl used 
in their experiments it was estimated (by Western blotting and ELISA, comparing 
signals with known recombinant PrP concentrations) that approximately 8,000 
equivalent molecules of PrP
Sc could be detected (Castilla et al., 2005).   The PMCA 
method is extremely sensitive to be able to detect such low PrP
Sc levels.  Therefore, it is 
not surprising that when the optimised Western blot was applied to clinical scrapie-
infected blood and blood cell subsets, conventional PrP
Sc was not detected (this thesis).  
The 263 K scrapie model contains very high levels of infectivity in brain tissue (10
9.6 
IU/g of brain homogenate) and although 8,000 equivalent molecules of PrP
Sc were 
detected in hamster blood by PMCA, it is conceivable that infection with different TSE 
agents (such as natural scrapie with a lower titre of infectivity) may even contain lower 
blood-associated levels of PrP
Sc.  Low levels of PrP
Sc may contribute to transmission of   204
TSE infection via blood with success rates of 36 % (BSE) and 43 % (natural scrapie) in 
sheep when large volumes of blood are used, resulting in a relatively large dose 
(Houston et al, 2008).  However, lower volumes of blood may contain extremely low 
levels of PrP
Sc which may not be present in sufficient quantities to contribute to the 
spread of infectivity. 
 
7.3.  Comparison with virus infectivity in blood. 
 
Viruses  such as HIV and hepatitis also infect the blood system and studying 
mechanisms of virus infection may provide clues as to how TSE infectivity may spread 
within the body.   The HIV virus for example infects the blood by attaching to the 
CD4
+ receptor and co-receptor on the host CD4
+ T helper cell (Berger et al., 1999), 
using the enzyme reverse transcriptase to convert viral RNA to DNA, which is then 
incorporated in to the host cell genes (Zheng et al., 2005).  The cell then begins to 
make the proteins of the HIV virus, using the HIV mRNA as a template.  Viral 
envelope proteins are also produced which come together within the host cell 
membrane to package the viral RNA, enzymes and core proteins.  The virus then 
pinches off the cell, buds and is released into the extracellular environment (Zheng et 
al., 2005).  This mechanism is used by many viruses to infect host cells (i.e. HIV, 
hepatitis B and C).  Interestingly, evidence suggests that during the replication process 
of HIV, defective virus particles are also produced (Bernier and Tremblay, 1995).   
These defective particles possess a genome which contains deletions of the infectious 
virus genome, and they can only infect and replicate in a host cell if fully infectious 
virus is present.  This is also true for hepatitis viruses (Terre et al., 1991).   
 
Following infection, the TSE agent may replicate in the blood using a similar 
mechanism.  Levels of infectivity increase as infection is released from one blood cell 
allowing further blood cells to become infected.  As replication of the TSE agent 
occurs, small numbers of defective particles (as described in HIV and hepatitis 
infection) are also produced.  These particles are not required for infection but instead 
are a by product of the infection process.  Defective particles also become apparent in 
the brain and nervous system as infection spreads and reaches these tissues.  It is   205
possible that the defective particles could be conventional PrP
Sc, and that the molecules 
really responsible for infection consist of a different form of PrP or they may be 
molecules that as yet have not been identified.   
 
Some viruses (for example, Epstein-Barr virus) have the ability to mimic host proteins 
which help protect the infectious viral proteins (preventing detection by the host 
immune system) as they continue to infect the host (Schaadt et al., 2005). These 
protective “mimicked” proteins are not infectious.  Following TSE infection, it is 
possible that the infectious agent may try to mimic host PrP
C.  However, this process 
may be inefficient and the mimic of PrP
C that is produced may not have all the 
characteristics of the host PrP
C.  Instead the infectious agent could produce a protein 
with a different conformation, which represents conventional PrP
Sc.  The real molecules 
causing infection may be buried deep within the protective PrP
Sc coat, which is 
required to enable efficient spread of the infectious agent. 
 
Some viruses have the ability to produce viral proteins which interfere in the normal 
processing of host proteins on the surface of the cell.  Herpes simplex virus for example 
produces viral proteins able to make subtle changes to host major histocompatibility 
complex 1 (MHC) molecules.  MHC class 1 molecules exist on all cells where they 
hold and present foreign antigens to CD8 cytotoxic T lymphocytes if the cell has been 
infected by a virus or other microbe.  Following the alteration of the MHC molecules 
by the virus, the host cell recognises the MHC as defective and ejects it from the cell.  
This process disrupts the normal host immune response allowing the herpes infection to 
spread (Fruh et al., 1995).  Like the herpes virus, the TSE infectious agent may be able 
to make subtle changes to PrP
C processing on the cell membrane, which produces 
conventional PrP
Sc that is not recognised as PrP
C and is therefore ejected by the host 
cell.  The conventional PrP
Sc is not infectious but as a result of it being produced, the 
function of PrP
C is disrupted enough to allow the real infectious agent (which could be 
an unrelated molecule) to spread more efficiently.  This is theoretical as the exact 
function of PrP
C is unknown and there is no evidence to suggest the proposed 
biological roles of PrP
C could be disrupted following TSE infection. However if PrP
C 
for example played a role in efficient immune system function (and there is evidence   206
suggesting PrP
C may help in activation and proliferation of T cells (Bainbridge and 
Walker, 2005), disrupting the host immune system would help promote TSE agent 
infection.   PrP
C may also have several different roles in the central nervous system, 
and PrP knockout mice show defects in synaptic function (Manson et al., 1995), 
increased vulnerability of neurones to oxidative stress (Brown et al., 1999), reduced 
Cu
2+/Zn
2+ dependent superoxide dismutase (SOD) activity (Brown et al., 1999), and 
changes in membrane localisation of nitric oxide synthase (Ovadia et al., 1996).   
Therefore if the infectious agent is able to disrupt this normal function of PrP
C (by 
producing PrP
Sc) the loss of PrP
C may help contribute to neurodegeneration which is 
observed in TSE-infected individuals.   
 
7.4.  Isoforms of PrP, other than PrP
Sc, may be associated with infectivity 
 
The possibility that TSE infectivity is not directly related to PrP
Sc may explain why 
some experimental mouse models (for instance, transgenic mice with a P102L 
mutation) develop TSE disease but have no detectable conventional PrP
Sc (Manson et 
al., 1999; Barron et al., 2001).  Pathology studies of scrapie-infected mouse brain have 
shown damaged brain areas without accumulation of PrP
Sc (Jeffrey et al., 1994; Jeffrey 
et al., 1996) which also indicates that PrP
Sc itself my not constitute the infectious agent.  
TSE infectivity appears to be associated with a wide range of PrP
Sc aggregate states 
(Caughey et al., 1997; Silveira et al., 2005) and it is possible that smaller particles are 
more infectious than larger aggregates or amyloid fibrils. It is possible that smaller 
particles and not aggregated PrP
Sc may be responsible for spread of TSE infection, and 
that these particles may be present in blood.  
 
Attempts have been made to assess if different forms of PrP are associated with 
infectivity.  Recently Piccardo and colleagues (2007) performed bioassay studies using 
human brain from two cases of Gerstmann- Straussler-Scheinker (GSS) with the P102L 
prion protein gene mutation.  The first case showed accumulation of PrP amyloid in the 
brain, whereas the second case showed PrP amyloid accumulation and spongiform 
encephalopathy.  TSE disease was transmitted efficiently to transgenic mice 
(PrP101LL) when brain tissue from the second case was inoculated into the animals.    207
The recipient mice showed PrP amyloid accumulation in the brain and spongiform 
degeneration.  However, there was almost a complete absence of disease transmission 
in transgenic mice inoculated with brain material from the first GSS case.  PrP amyloid 
was still present in the brain but there were no clinical signs of disease (Piccardo et al., 
2007).  This data may suggest that infectivity is not associated with PrP amyloid.   
Alternatively, it is possible that large aggregates of amyloid forming PrP have a 
protective role and sequester smaller infectious particles into inert non-infectious 
aggregates.     
 
These explanations may explain why high titres of TSE infectivity are observed in 
blood, yet conventional PrP
Sc is undetectable unless using ultra-sensitive methods of 
detection (PMCA).  However, it should also be noted that the nature of blood-
associated PrP
Sc is unknown, including sensitivity to digestion with proteinase K.   
Evidence suggests that PK sensitive forms of PrP
Sc exist (Tremblay et al., 2004) and it 
is conceivable that this form of PrP
Sc may be present in blood.  Therefore this would 
not be detected by current methods such as Western blotting which rely on treatment 
with PK to distinguish PrP
C from PrP
Sc, and could explain why high levels of TSE 
infectivity may not correlate with conventional PrP
Sc.  Western blots for blood-
associated PrP were carried out with and without PK.  A signal for conventional PrP 
was observed in scrapie-infected blood without prior PK treatment between 30-35 kDa, 
although it is unclear if this represents PrP
Sc.  However, following PK digestion no 
signal was observed indicating that any PrP
Sc present in the scrapie-infected blood 
sample was undetectable at the level achieved by the immunoassay.  The PrP
Sc may 
also have been PK sensitive and therefore degraded.  PrP
Sc can exist in a number of 
different conformations (Safar et al., 1998) and sensitivity to PK digestion may depend 
on how tightly the PrP
Sc molecule is folded.  Tightly folded aggregated PrP
Sc molecules 
may be less prone to PK degradation, whereas protein monomers and smaller oligomers 
may be more easily degraded.  If blood-associated PrP
Sc in blood is in the form of 
smaller oligomers, high concentrations of PK would degrade the protein very quickly.  
However, it is possible that very low PK concentrations would have less of an effect 
and may produce a signal on a Western blot, although it would still be difficult to   208
conclude if this represents conventional abnormal prion protein as cellular PrP
C may 
still be present.     
 
7.5.  Factors other than conventional PrP
Sc in TSE infected sheep blood. 
 
Although conventional PrP
Sc was not detected in TSE-infected blood, interestingly 
bands with higher molecular weights were detected with anti-PrP antibodies in blood 
samples with prior NaPTA treatment before Western blotting.  Initially these bands 
appeared to be present only in scrapie-infected blood.  However, further investigation 
revealed these bands were also present in uninfected blood.  After sample resolution on 
gels that separate high molecular weight proteins the exact molecular weights were 
determined.  Bands of 60, 112 (a doublet) and 195 kDa were observed.  High molecular 
weight bands in blood have been described previously (Jones et al., 2005; Tsukui et al., 
2007) although the bands described in this thesis are of different molecular weights and 
have not previously been described in blood using NaPTA based Western blot methods.   
 
Although high molecular weight bands were detected in both scrapie-infected and 
uninfected blood, it is still possible that they may have importance in TSE disease.  The 
Western blot method does not have the capabilities to show subtle 
differences/characteristics that may exist in high molecular weight bands from TSE-
infected animals compared to controls.  The biological role of the high molecular bands 
is unclear.  It is possible that the bands may contain carbohydrate.  Following NaPTA 
precipitation, carbohydrates could cause aggregation with proteins or other molecules, 
creating high molecular weight complexes in blood.  The level of carbohydrate or other 
components required for aggregation may be different in TSE-infected blood.  The 
infectivity of the high bands has also yet to be tested and it may be that bands from 
uninfected blood are not infectious but bands from scrapie-infected blood do contain 
levels of TSE infectivity.  PK-resistant PrP molecules have recently been reported in 
uninfected mouse, hamster and human brain (Yuan et al., 2006).  These molecules 
(called “silent prions”) may also exist in blood and could aggregate with themselves, 
with other proteins or non proteinaceous components.  This could explain why high 
molecular weight bands are also observed in uninfected blood and highlights the need   209
for further study to try to discriminate the bands present in blood of diseased and 
healthy animals.  “Silent prions” could be present in uninfected and TSE-infected 
blood, but only contribute to the disease process by interaction with the infectious agent 
in TSE affected animals. 
 
In addition to high molecular weight bands, a preliminary proteomics study to assess 
changes in protein expression in buffy coat samples from sheep clinically affected with 
scrapie against uninfected animals was also carried out.  2D gel and Q-TOF-MS 
analysis identified three candidate protein biomarkers, lactate dehydrogenase (LDH), 
elongation factor 1 (EF-1) and annexin 1 (A1).  LDH and A1 were elevated in clinical 
scrapie-infected sheep while EF-1 was down-regulated.   
 
LDH is an enzyme responsible for converting muscle lactic acid into pyruvic acid 
which is an essential step in producing cellular energy.  LDH consists of five tetrameric 
isoenzymes composed of the random association of two subunits (H and M) that are 
encoded by different genes (Cahn et al., 1962).  LDH was found to be up-regulated in 
the buffy coat blood fraction from sheep clinically infected with scrapie.  These results 
are in agreement with Schmidt and colleagues (2004) who saw elevated LDH levels in 
CJD patients when compared to individuals suffering from other dementias (Schmidt et 
al., 2004).  Further evidence supporting a role for LDH elevation in TSE-infected 
plasma is also described (Adams and Field, 1967).  LDH enzymes are widely 
distributed throughout the body and following cellular damage LDH is released into the 
blood stream.  Therefore it is conceivable that in TSE disease LDH may be elevated in 
blood as a result of tissue damage from PrP
Sc accumulation in the brain and other 
organs. 
 
The annexins are a family of closely related calcium and membrane-binding proteins 
expressed in most eukaryotic cell types (Morgan et al., 1997).  Although structurally 
and biochemically similar annexins have diverse functions that include vesicle 
trafficking, cell division, apoptosis, calcium signalling and growth regulation.  Annexin 
1 (A1) in particular also has an anti-inflammatory role (Ferlazzo et al., 2003).  A1 was 
found to be up-regulated in clinical scrapie-infected buffy coats.  To date there appears   210
to be no evidence suggesting a link between annexin 1 expression and TSEs.     
However, A1 appears to increase in injured brain tissue (Johnson et al., 1989) and it 
may be that in scrapie-infected sheep this protein is released from brain or 
inflammatory cells.  
  
Elongation-factor-1 (EF-1) is responsible for aminoacyl-tRNA transfer on the ribosome 
in the process of protein synthesis, and is comprised of two components, a G-protein 
named eEF-1A and a nucleotide exchange factor, eEF-1B.  Results indicate a possible 
down-regulation in scrapie-infected buffy coats. The precise biological involvement of 
EF-1 in TSE infection remains to be determined.  
  
The detection of markers for TSE infection (such as LDH, A1, EF-1 or the high 
molecular weight bands for example) allows interesting pathogenesis studies to be 
carried out.  In the case of the high molecular weight bands, initially, it would need to 
be shown that these are significantly different in uninfected and scrapie-infected blood, 
and then they would have to be identified.  If the high molecular weight bands or LDH, 
A1 or EF-1 genuinely proved to be blood biomarkers of TSE infectivity, it would be 
interesting to challenge transgenic mice deficient in the biomarker with infectious TSE 
agent. This may result in a longer incubation period before onset of disease or 
alternatively, animals may not succumb to disease.  This would highlight that the 
biomarker is essential for pathogenesis.  It should be noted though that not all 
biomarkers may have the same effect on disease.  Although PrP
Sc has a direct effect on 
disease (PrP null mice are resistant to scrapie) other proteins or molecules may just be 
up-regulated and play less of a role in the disease progress (for instance 14-3-3 proteins 
are up-regulated in neurological disorders but do not have a direct effect on TSE 
infection (Green et al., 2002).     
 
To assess which blood cells might carry the biomarker, blood could be separated into 
components and blood cell subsets and a proteomics study (similar to the one described 
in this thesis) could be carried out and validated by Western blotting. This would show 
which blood cells are important in spreading the infection.  Subsequent bioassay studies 
may establish whether TSE infectivity correlates with accumulation of the marker.    211
 
 
 
7.6.  Summary 
 
This study has demonstrated that conventional PrP
Sc may not present in TSE-infected 
sheep blood in sufficient quantities to explain the infectivity levels observed in TSE-
infected sheep blood.  An optimised sensitive Western blot, incorporating a NaPTA 
concentration step was tested on large sheep blood volumes.  The pattern of protein 
detected with novel anti-PrP monoclonal antibodies on Western blots, was very 
different from the conventional triple banded pattern of PrP
Sc.  High molecular weight 
bands of 60, 112 (doublet) and 195 kDa  reactive with a number of PrP-specific 
monoclonal antibodies were apparent in Western blots of NaPTA precipitated scrapie-
infected and uninfected blood samples, both before and after PK digestion.  These 
bands were not present in equivalent brain homogenate samples.  Such bands have not 
been reported before using NaPTA based Western blot methods, and may represent a 
novel form of blood-specific PrP.  It is possible that TSE infectivity may be associated 
with a non-conventional form of PrP although further analysis and identification of the 
high molecular weight bands is required to conclusively show this.  Proteins other than 
PrP
Sc could also be used as markers of TSE infection, and using a proteomics approach 
three candidate biomarkers, lactate dehydrogenase (LDH), elongation factor 1 (EF-1) 
and annexin 1 (A1) were identified.  
 
The results presented in this thesis may explain the difficulties found in many labs in 
developing sensitive detection methods for conventional PrP
Sc in blood.  TSE 
infectivity in sheep blood is considerable (Houston et al., 2008) but using a very 
sensitive Western blot immunoassay conventional PrP
Sc was not detected.  The nature 
of PrP
Sc in blood is unknown, and identification of a non-conventional form would 
enable some advances within the TSE field.  For instance levels of various forms of PrP 
could be established on various blood cells to gain insights into which cells contribute 
to TSE pathogenesis.  Additionally, such findings would aid in the development of ante   212
mortem blood diagnostic tests.  The effectiveness of control measures currently used by 
the National Blood Service to safeguard the UK blood supply could also be assessed. 
 
 
7.7.  Future plans 
 
From this study it has become apparent that sheep blood may contain a non-
conventional form of PrP.  Sensitive western blot analysis using anti-PrP antibodies 
revealed the presence of high molecular weight bands in scrapie-infected and 
uninfected sheep blood.  The conventional triple protein pattern of PrP
C and/or PrP
Sc 
was not observed.  However, further investigations are required to conclusively show 
that the nature of PrP
Sc in blood is different to the form associated with brain and 
lymphoid tissue.  Therefore aims for future research include the following: 
 
1.  Studies to conclusively identify the PrP-related high molecular weight bands.  
Initially, mass spectrometry experiments would be carried out on known 
proteins with or without NaPTA precipitation to establish if NaPTA is causing 
protein to complex into a state that is not compatible with mass spectrometry.  If 
positive control samples are not identified with NaPTA, it may be that the 
concentration step is causing possible resistance to enzymatic digestion prior to 
mass spectrometry so this would also be tested. 
 
2.  If non conventional PrP is identified by mass spectrometry techniques, plasma 
and leukocyte subsets will be examined for the presence of non-conventional 
forms of PrP.  Such subsets would include monocytes as these may be 
associated with TSE infectivity (Andreoletti et al., 2007). 
 
3.  Perform a titration of scrapie infected blood in a sheep model testing a range of 
blood volumes alongside a parallel study of titrated scrapie brain using the 
blood Western blot method developed in this thesis. Parallel titrations are 
required because the nature of PrP
Sc in blood is not well defined and there may 
be differences in the sensitivity of detection compared to brain associated PrP
Sc.   213
 
4.  Carry out bioassay studies on blood cell subsets simultaneously with 
amplification of conventional PrP
Sc by PMCA and subsequent Western blotting.  
This would also help to establish if conventional PrP
Sc correlates with TSE 
infectivity.  Additionally, the infectivity of the high molecular weight bands 
could be tested, and PMCA carried out to establish if this material can be 
amplified alongside bioassay experiments.  
 
5.  If PrP
Sc is not identified in the high molecular weight bands by mass 
spectrometry, test for the presence of non-protein components such as 
carbohydrates.  Experiments could include lectin staining, alcin blue staining, 
periodic acid-Schiff staining, digoxigenin or Emerald 300.  Such experiments 
may reveal the presence of glycans within the high molecular weight bands.  By 
investigating the characteristics of the high molecular weight bands, disease-
related differences may be identified. 
 
6.  Establish other protein markers for TSE disease.  Preliminary proteomic studies 
indicate three potential TSE candidate biomarkers; LDH and A1 appeared up-
regulated in buffy coat following scrapie infection, while EF-1 appeared down-
regulated.  It is important to repeat these preliminary studies, establish normal 
levels of these proteins in a range of healthy animals.  If levels appear similar in 
uninfected sheep, it would then be interesting to see the effect of scrapie 
incubation periods on knock out mice.  Additionally, it would be intriguing to 
establish if LDH and A1 are up-regulated on leukocyte subsets during scrapie 
infection and if EF-1 is down-regulated.  The TSE infection process may be 
responsible for up or down-regulation of these proteins, as apposed to these 
proteins influencing infection.  It is possible though that these candidate 
biomarkers may correlate with TSE infectivity.  By measuring the levels of 
blood-associated LDH, A1 and EF-1 it may be possible to establish where the 
infection travels in the body and which tissues/blood cells become infected.  
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Appendix 1: Antibodies  
Antibodies used in this study are tabulated below 
Name Subclass  Antigen  Supplier  Reference  Use 
CC15  IgG2a  γ/δ T cells  IAH, Compton  Clevers et al., 1990  Flow Cytometry 
1:400 
CC21  IgG1  CD21 (B cells)  IAH, Compton  Sopp (1996)  Flow Cytometry 1:10 
MACS 1:10 
CC63  IgG2a  CD8 (T cell subset)  IAH, Compton  MacHugh  et al., 
1991 
Flow Cytometry 1:10 
MACS 1:10 
CC-G33  IgG1  CD14 (monocytes)  IAH, Compton  Sopp et al., 1996  Flow Cytometry 1:10 
 
DU2-104   IgM  CD72 (B cells)  Dr W. Hein, Basel 
Institute for 
Immunology, 
Switzerland 
Young et al., 1997  Flow Cytometry 1:10
36F  IgG1 CD2  (α/β T cell 
receptor) 
Dr W. Hein, Basel 
Institute for 
Immunology, 
Switzerland 
Mackay et al., 1988  Flow Cytometry 1:10 
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Appendix 1: Antibodies 
Name Subclass  Antigen  Supplier  Reference  Use 
44-97  IgG1  CD4 (T cell subset)  Dr E. Meeusen, 
University of 
Melbourne, Australia 
Maddox et al., 1985  Flow  Cytometry 
1:10 
TRT 1  IgG1 Turkey 
rhinotracheitis 
IAH, Compton  Cook et al., 1993  Flow  Cytometry  
1:10 
Western Blotting 
1:200 
TRT 3  IgG2a Turkey 
rhinotracheitis 
IAH, Compton  Cook et al., 1993  Flow  Cytometry 
1:10 
Monoclonal  antibody 
             AE11 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon, 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:200 
1:500  
1:1000 
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Appendix 1: Antibodies 
 
Name Subclass  Antigen  Supplier  Reference  Use 
Monoclonal antibody 
              BC6 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:200 
1:500  
1:1000 
1:2000 
1:5000 
Monoclonal antibody 
              BD12 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
BF5 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation) 
Western Blotting 
1:1000 
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Appendix 1: Antibodies 
Name Subclass  Antigen  Supplier  Reference  Use 
Monoclonal antibody 
BH1 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:200 
1:500 
1:1000 
1:2000 
1:5000 
 
Monoclonal antibody 
CF5 
IgG2a Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
DB12 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
DC12 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
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Appendix 1: Antibodies 
Name Subclass  Antigen  Supplier  Reference  Use 
Monoclonal antibody 
DE3 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
EA6 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
EC9 
IgG2a Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
EG6 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
FD1 
 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
FD12 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000   220
Appendix 1: Antibodies 
Name Subclass  Antigen  Supplier  Reference  Use 
Monoclonal antibody 
FH6 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
FH10 
IgG2a Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:500 
1:1000 
Monoclonal antibody 
HB4 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
HC2 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
HC7 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:500  
1:1000 
Monoclonal antibody 
IF1 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000   221
Appendix 1: Antibodies 
Name Subclass  Antigen  Supplier  Reference  Use 
Monoclonal antibody 
IH9 
IgG2b Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:200 
1:500  
1:1000 
Monoclonal antibody 
IH11 
 
IgG2a Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Monoclonal antibody 
JB10 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:500  
1:1000 
Monoclonal antibody 
JC4 
IgG1 Recombinant  sheep 
PrP (residues 90-
233) 
Dr S McCutcheon 
IAH, Compton 
Dr S McCutcheon 
(manuscript in 
preparation)  
Western Blotting 
1:1000 
Polyclonal antibody    
Anti-Lactate             
Dehydrogenase 
IgG Lactate 
Dehydrogenase 
Rockland 
Immunochemicals, 
USA 
Sass et al., 1989  Western Blotting 
1:1000 
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Appendix 1: Antibodies 
Name Subclass  Antigen  Supplier  Reference  Use 
Monoclonal 
antibody 
Anti β-actin clone 
AC15 
IgG1 Actin Sigma  Aldrich,  UK  North  et al., 1994 
 
Western Blotting 
1:5000 
Goat anti-mouse 
HRP 
IgG Mouse  IgG  F(ab’)2  Sigma Aldrich ,UK  Sigma Aldrich, UK 
 
Western Blotting 
1:2000 
1:2500 
1:5000 
1:7000 
1:10,000 
1:100,000 
1:200,000 
1:500,000 
Rabbit anti-goat  
HRP 
IgG  Goat IgG F (ab’)2  Sigma Aldrich, UK  Sigma Aldrich, UK  Western Blotting 
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Appendix 1: Antibodies 
Name Subclass  Antigen  Supplier  Reference  Use 
Goat anti-mouse   
FITC 
IgG1 
IgM 
Mouse IgG1  
Mouse IgM  
 
Southern 
Biotechnology, USA 
The et al., 1970  Flow Cytometry 
1:200 
Goat anti-mouse   
PE 
IgG Mouse  IgG    Southern 
Biotechnology, USA 
Southern Biotech  Flow Cytometry 
1:400 
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Appendix 2: Serial dilutions of PK-resistant PrP
Sc from scrapie-infected  
sheep brains 
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Appendix 2:  Western blot analysis of serial dilutions of NaPTA precipitated PK-resistant 
PrP
Sc from scrapie-infected sheep brains.  Wells were loaded with serial dilutions of the PK 
digestion products from natural scrapie infected sheep brains.  In lane 1 the equivalent of  2500 
µg wet tissue was loaded, in lane 2, 1250 µg, in lane 3, 625 µg, lane 4, 313 µg,  lane 5, 156  µg, 
lane  6, 78 µg, lane 7, 19 µg, lane 8, 9 µg, and lane 9, 5 µg.  The blot was probed with the mAb 
IH9, and was developed using standard ECL methods; the exposure time was 10 sec.   
Molecular masses are shown on the left (kDa). 
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Appendix 3. Detection of PK-resistant PrP
Sc is not affected by sample storage 
Conditions 
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Appendix 3:  Detection of NaPTA precipitated PK-resistant PrP
Sc is not affected by 
sample storage conditions (lanes 1-3). Wells were loaded with the PK digestion products 
from scrapie infected sheep brains.  2.1 mg wet tissue equivalent was loaded in each well.  
Fresh samples were loaded into lane 1, samples stored at -20 ºC in lane 2, and samples stored at 
-80 ºC in lane 3.  The blot was probed with the mAb IH9 at a concentration of 1 µg/ml.  In lane 
4 the sample was not NaPTA precipitated.  The blot was developed using standard ECL 
methods; the exposure time 2 sec.  Molecular masses are shown on the left (kDa).   
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Appendix 4. Buffy coat IEF template 
 
 
 
 
Key: Blue = set volts, Green = set mA Key: Blue = set volts, Green = set mA
 
 
Appendix 4: Buffy coat IEF template.  The traces corresponding to the current and 
voltage are described in the key above.  IPG strips containing scrapie-infected and uninfected 
buffy coat proteins are subjected to IEF for 40 k V hr using this template. 
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Appendix 5. Application of the blood Western blot to buffy coat and PBMC 
samples from seven scrapie infected sheep. 
 
The blood Western blot method was applied to frozen buffy coat and PBMCs from a 
starting volume of 50 ml obtained from ten sheep clinically affected with scrapie. The 
number of buffy coat or PBMC cells obtained from 50 ml of blood ranged from 
between 1 x 10
6 to 1 x 10
8 cells. The cell numbers analysed in each blot are detailed in 
each figure legend. Each experiment was repeated three times.  
 
In chapter 4, representative blots from three animals clinically affected with scrapie are 
shown. Representative blots where blood from the remaining seven sheep clinically 
affected with scrapie was tested are shown below. 
 
 
 
Appendix 5.1:  Western blot analysis of  a PK digested, NaPTA precipitated buffy coat 
sample from one clinical scrapie infected sheep.  Key: Panel 1, Western blot: panel 2, 
Ponceau S stained membrane .  Lane 1, 1 x 10
8  buffy coat cells: lane 2, freezing media: lane 3, 
5 x 10
5 SMB cells: lane 4, 500 µg wet tissue equivalent of normal brain homogenate: lane 5, 
500 µg wet tissue equivalent of scrapie infected brain homogenate: lane 6 & 7, 300µl of wash 
buffer (PBS).  The blot was probed with the mAb BC6 at a concentration of 2 µg/ml and 
developed using standard ECL methods; the exposure time was 1 hr.  Molecular masses are 
shown on the left (kDa).  
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Appendix 5.2:  Western blot analysis of  PK digested, NaPTA precipitated titrated buffy 
coat cells from one clinical scrapie infected sheep.   Key : lane 1, 5 x 10
7 buffy coat cells: 
lane 2,  1 x 10
7 , lane 3, 5 x 10
6  : lane 4, 1 x 10
 6 : lane 5, 5 x 10
5: lane 6, 1 x 10
5:  in lane 7, 5 x 
10
4 :  lane 8, 1 x 10
4  : lane 9, 200 µg wet tissue equivalent of scrapie infected brain 
homogenate.  The blot was probed with the mAb BC6 at a concentration of 2 µg/ml and 
developed using standard ECL methods; the exposure time was 30 min.  Molecular masses are 
shown on the left (kDa).    
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Appendix 5.3: High molecular weight bands are PK resistant in PBMCs from scrapie-
infected sheep.  Key: In lanes 1, 2 and 3, approx 1 x 10
6 scrapie infected PBMCs from one 
scrapie infected sheep. In lanes 4 & 5 wells were loaded with 300 µg wet tissue equivalent of 
uninfected sheep brain homogenate.  In lanes 6 & 7 wells were loaded with 300 µg wet tissue 
equivalent of sheep scrapie brain homogenate.  Samples were PK digested and NaPTA 
precipitated as indicated. The blot was probed with the mAb BC6 at a concentration of 2 µg/ml 
and developed using standard ECL methods; the exposure time was 5 min.  Molecular masses 
are shown on the left (kDa).     
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Appendix 5.4: High molecular weight bands are PK resistant in PBMCs from scrapie-
infected sheep.  Key: In lanes 1 & 2, approx 1 x 10
6 scrapie infected PBMCs from one scrapie 
infected sheep. In lanes 3 & 4, approx 1 x 10
6 scrapie infected PBMCs from a second scrapie 
infected animal. Lanes 13 & 14 and 15 & 16 represent approx 1 x 10
6 scrapie infected PBMCs 
from a third and fourth scrapie infected sheep respectively.  In lanes 5 – 12, wells were loaded 
with 300 µg wet tissue equivalent of sheep scrapie brain homogenate.  Samples were PK 
digested and NaPTA precipitated as indicated. The blot was probed with the mAb BC6 at a 
concentration of 2 µg/ml and developed using standard ECL methods; the exposure time was 5 
min.  Molecular masses are shown on the left (kDa).     
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